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1. Allogeneic hematopoietic stem cell transplantation
RANSPLANTATION OF ALLOGENEIC HEMATOPOIETIC STEM CELLS (SCT) following
high-dose systemic chemotherapy or chemoradiotherapy is the most effective
curative treatment for patients with leukemia or other hematological malignancies.
The pre-transplant conditioning regimen induces a major cytoreduction of malignant
hematopoietic cells. However, it also results in the destruction of the bone marrow
and normal hematopoietic cells. The recipient’s hematopoietic system is restored by
infusion of hematopoietic stem cells from a donor, which are capable of reconstituting
sustained hematologic and immunologic function. Most hematological malignancies
exhibit a steep dose-response reaction to chemoradiotherapy. However, not every
malignant cell may be killed, even when the conditioning regimen has been
intensified to levels at which serious organ toxicities are encountered1,2.
T
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It is now clear that an additional component contributes to the antileukemic properties
of allogeneic SCT. This component is associated with immunocompetent cells
transplanted with, or arising from, the donor graft, and is termed graft-versus-
leukemia (GVL) reactivity.
1.1. GVL reactivity and graft-versus-host-disease
The earliest evidence that a potent GVL reactivity is associated with allogeneic SCT
was found in murine transplant experiments. Leukemic mice treated with radiation
therapy died of recurrent leukemia if transplanted with syngeneic marrow, whereas
mice transplanted with allogeneic marrow did not relapse3. The recipients of
allogeneic marrow, however, died of graft-versus-host disease (GVHD), an
immunological response directed towards antigens expressed by normal host tissues,
demonstrating that GVL reactivity and the development of GVHD are intimately
associated processes.
Most evidence for GVL reactivity is based on several indirect clinical observations.
Recipients of marrow grafts from identical twins, and recipients of autologous grafts,
are more likely to develop a relapse than recipients of matched sibling grafts4.
Furthermore, the occurrence of GVHD after allogeneic BMT is associated with a
lower risk of relapse5-7. Moreover, some recipients of allogeneic SCT achieved
complete remissions of relapsed leukemia or leukemia refractory for conventional
chemotherapy, after a flare of GVHD, or following withdrawal of immunosuppressive
therapy, suggesting that immunocompetent cells are involved8-10.
1.2. Donor-derived T cells mediate anti-host reactivity
The development of GVHD is a major complication of allogeneic SCT. The incidence
and severity of GVHD can be reduced by depletion of T lymphocytes from the stem
cell graft. T cell depletion, however, is associated with an increased risk of leukemia
recurrence5,11. Furthermore, in vivo primed anti-host donor-derived cytotoxic T
lymphocytes (CTL) can be readily obtained from the peripheral blood of recipients of
allogeneic BMT12-18. Some of these CTLs effectively lyse leukemic cell precursors
and circulating myeloid and lymphoid leukemia cells, but not cells derived from
GVHD target organs such as skin fibroblasts, keratinocytes, or liver cells16,18-22. Direct
clinical evidence for T cell-mediated GVL reactivity has been provided by the transfer
of donor peripheral blood mononuclear cells (PBMC), containing large numbers of T
cells, to treat patients with relapsed leukemia23-27. These T cell infusions induced both
complete cytogenetic remissions and the development of GVHD. These observations
re-affirm the intimate association of GVHD with GVL reactivity and demonstrate that
donor-derived T cells play a key role in mediating anti-host immune reactivity.
Clinically significant acute GVHD develops in 9-50% of patients who receive a
human leukocyte antigen (HLA)-identical graft2 8 , 2 9 . This suggests that
incompatibilities for non-major histocompatibility complex (MHC)-encoded minor
histocompatibility antigens (mHags) play an important role in the induction of T cell
mediated alloimmune responses.
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1.3. Minor histocompatibility antigen incompatibilities induce T cell responses
after HLA-matched allogeneic SCT
Minor Hags are peptides that are derived from proteins that differ between the
recipient and donor due to polymorphisms in the genome. The polymorphisms that
give rise to mHags encode changes in amino acid sequence that result in altered
binding of peptides to the MHC, or altered contact between the MHC/peptide-
complex and the T cell receptor (TcR), or differential processing of the polymorphic
cellular protein30 (Table 1). For example, the change in amino acid sequence of mHag
HA-1 causes the non-immunogenic allelic peptide not to be expressed at the cell
surface by HLA-A*0201 molecules31. A proline to arginine substitution in the HA-8
mHag causes differential processing of the polymorphic peptide, which facilitates the
transport of the immunogenic allelic variant of the HA-8 peptide into the
endoplasmatic reticulum by TAP (transporter associated with antigen processing)32.
Another example of differential processing of polymorphic peptides is the differential
cleavage of allelic variant peptides of mHag H-Y by the proteosome, resulting in
premature destruction of the CTL epitope. In summary, due to genetic differences
outside the MHC complex, the repertoire of endogenous peptides displayed in the
peptide-binding groove of HLA-matched siblings may differ substantially. These
incompatibilities in displayed peptide repertoire may constitute immunogenetic
differences that induce (reciprocal) allogeneic T cell responses.
Most mHags have a broad tissue expression. Therefore, mHags expressed by both
hematopoietic cells as well as by epithelial cells present in skin, liver, and gut, will
induce GVHD, including GVL reactivity. Minor Hag expressed exclusively by
hematopoietic or leukemic cells are of particular interest, since they may elicit a
selective GVL-response, and could be used as target antigens for specific
immunotherapy without causing GVHD.
Several mHags have been characterized at the molecular level, with different
expression patterns (i.e. ubiquitously, tissue restricted, or leukemia-associated), HLA-
restriction, and phenotype frequency (Table 1).
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1.4. Mechanism of the alloimmune response after HLA-matched hematopoietic
SCT
The generation of alloimmune responses after hematopoietic SCT is a multistep
process, mediated by T lymphocytes, involving different effector cells and
inflammatory cytokines (Figure 1). Primary allogeneic responses are initiated when
immunogenetic mHag disparities and possibly leukemia-associated antigens are
presented to naïve donor T cells by activated host antigen-presenting cells (APCs)41,42.
Host dendritic cells (DCs) play a pivotal role as professional antigen presenting
cells43.
The conditioning regimen before allogeneic SCT damages host tissues (including
DCs), resulting in the release of inflammatory cytokines (e.g. IL-1, TNF-α, GM-CSF,
and IFN-γ)44-46. These inflammatory cytokines upregulate adhesion molecules and
MHC antigens47,48, which may enhance the recognition of host-tissue antigens by
donor-derived T cells after transplantation. In addition, the damage caused by
extensive conditioning causes breakdown of mucosal barriers, such as the
gastrointestinal tract, resulting in increased bacterial lypopolysaccharide (LPS)
translocation49. This bacterial product serves as a ‘danger signal’ that can trigger the
activation of DCs.
Activation of APCs results in an increased surface expression of MHC, co-stimulatory
(CD80 (B7.1), CD86 (B7.2)) and adhesion molecules (e.g. CD54 (ICAM), CD11a
(LFA-1)). This makes the APC ideally suited for recognition by T cells. CD4+ T cells
are activated after specific binding of their TcR to a MHC class II/peptide-complex on
the activated APCs (signal 1: antigen-specific stimulation) in combination with an
interaction of co-stimulatory molecules and their ligands on the T cell (signal 2: co-
stimulation). This physical APC-T cell interaction, referred to as the ‘immunological
synapse’50, results in the production of activating (Th1) or inhibitory (Th2) cytokines
by the CD4+ T cell that regulate the immune response. Furthermore, coupling of the
CD40 ligand (CD40L), which is expressed on activated CD4+ T cells, to the CD40-
receptor on the APC, upregulates the expression of MHC class I and co-stimulatory
molecules on the APC, and the secretion of cytokines by the APC. This stimulation
increases the ability of APCs to activate naïve CD8+ T cells, initiating the effector
arm of the immune response. Thereafter, T cells clonally expand, while other cell
types are recruited, such as macrophages, granulocytes, natural killer cells, large
granular lymphocytes. The T cells and other cell types are responsible for the
execution of the alloresponses associated with GVHD and GVL.
T cell effector responses are further regulated in the periphery by recently described
novel members of the B7-family of costimulatory ligands, such as B7h, PD-L1, PD-
L2, and B7-H3, reviewed in51. Unlike CD80 and CD86 that are involved in the
initiation of adaptive immune responses, these ligands are also expressed on non-
lymphoid tissues at sites of inflammation. Their receptors are induced on activated T
cells, while CD28, the activating receptor for CD80 and CD86, is expressed on both
activated and naïve T cells.
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Figure 1. Generation of an immune response after HLA-matched allogeneic HSCT. LGL, large
granular lymphocyte; PMN, polymorphonuclear leukocyte.
1.5. Variables influencing the development and intensity of an alloimmune
response after SCT
Several variables associated with allogeneic SCT influence the development and
intensity of an alloimmune response after SCT. These variables, the way their
influence is mediated, and selected published findings, are summarized in Table 1.
The immunogenicity of the leukemic cells influences the ability of donor-derived T
cells to generate a GVL response. Leukemic cells generally lack expression of co-
stimulatory molecules, although leukemic-cell-derived APC have been identified and
generated52-54. The conditioning regimen contributes to the pathogenesis of GVHD, as
described above. Furthermore, it ablates host APCs, and exerts host
immunosuppresion, contributing to the extent of engraftment and outgrowth of donor
hematopoietic cells. The graft provides the T cells that mediate anti-host responses.
Depletion of T cells from the graft and the immunogenetic features of the graft,
contribute to the intensity of (reciprocal) alloresponsiveness. GVHD prophylaxis after
SCT may reduce and even abrogate anti-host alloresponses. The genetic origin of the
cells that constitute the hematopoietic compartment is of particular interest for this
thesis, since the genetic origin of these cells, and in particular those that exert
immunological function, may influence the response to immunotherapy given after
allogeneic SCT (Table 1.).
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1.5.1. Definition and development of hematopoietic chimerism after allogeneic SCT
The term hematopoietic chimerism refers to the presence of hematopoietic cells of
non-host origin. This exceptional immunogenetic state can develop after allogeneic
hematopoietic SCT. The conditioning treatment allows the engraftment and outgrowth
of hematopoietic cell populations of donor origin. A mixture of donor and host
hematopoietic cells is called mixed chimerism. Full or complete chimerism refers to
complete replacement of host by donor hematopoiesis.
Most patients undergoing unmanipulated allogeneic hematopoietic SCT will become
full hematopoietic chimeras. Presumably, T cells in the graft contribute to the
establishment of full chimerism by a graft-versus-recipient-hematopoiesis response.
In contrast, if the graft is T cell depleted68-72, or if the conditioning regimen is reduced
in intensity73-79, development of mixed chimerism in patients is observed more
frequently.
1.5.2. Detection of chimerism
Differences between donor and recipient in polymorphic genetic markers or their
products have been used for the detection of chimerism by employing a variety of
molecular methods with various sensitivities80-89. The most generally applied method
to evaluate chimerism is restriction fragment length polymorphism (RFLP) analysis.
The introduction of polymerase chain reaction (PCR) as a method for rapid
amplification of minisatellite (variable number of tandem repeats; VNTR) and
microsatellite (short tandem repeats; STR) sequences, has significantly enhanced the
sensitivity of detection of chimerism. The fluorescent in situ hybridisation (FISH)
technique is also widely applied for the detection of chimerism, but is restricted to
sex-mismatched donor-recipient couples90. The value of chimerism analysis is
increasingly appreciated in understanding the development of allogeneic immune
responses and monitoring imminent leukemic relapse91-93. The success of adoptive
immunotherapy may be enhanced with frequent analysis of chimerism, using sensitive
and accurate quantification methods for optimal diagnosis94-96. Therefore, we have
developed a real-time PCR-based method using single nucleotide polymorphisms
(SNP) as discriminative markers (Chapter 5; this thesis)97.
1.5.3. T cell chimerism status in regard to the development of alloimmune responses
after SCT
Several clinical studies have indicated a correlation between mixed hematopoietic
chimerism and a reduced incidence of acute GVHD, compared to full chimerism, after
myeloablative allogeneic SCT69,98-101. In two of these studies, however, a significant
number of patients received a T cell depleted graft69,98, which in itself is associated
with a reduced incidence of GVHD and a more common development of mixed
chimerism. Furthermore, patients were given GVHD prophylaxis when deemed
necessary. Mattsson et al. have lineage-specified the correlation between mixed
hematopoietic chimerism and a reduced incidence of GVHD to mixed chimerism in
the T cell population102. They argued that the failure of some other studies103-105 to
show this relationship could be due to low T cell numbers during the first months
after SCT, and the unavailability of sensitive methods for chimerism analysis.
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Few have studied the effect of T cell chimerism on the development of
immunoresponses after non-myeloablative allogeneic SCT106,107. Conflicting results
have been described. Childs et al. showed that acute GVHD only occurred in patients
who achieved full donor T cell chimerism, while in the study of Mattsson et al. mixed
T cell chimerism did not protect against acute GVHD. It was unclear, in the latter
study, why patients with a high degree of remaining recipient T cells may still
develop acute GVHD. The lack of accordance between the findings of these studies
may be accounted for by the use of different conditioning and immunosuppressive
regimens.
The correlation between mixed hematopoietic chimerism and relapse is extensively
studied. Several studies have suggested an increased occurrence of relapse of CML in
patients with mixed hematopoietic chimerism, compared to patients that have
developed full hematopoietic chimerism70. However, other studies have failed to show
the correlation between mixed chimerism and an increased risk of relapse, or failed to
show this correlation for relapse of acute leukemias69,105,108,109. Residual recipient
hematopoietic cells at best may reflect healthy hematopoiesis or residual lymphocytes
that survived chemotherapy, or at worst cells derived from the malignant clone.
Furthermore, mixed hematopoietic chimerism may reflect a state of immunotolerance
between donor and recipient, allowing more host-type cells to survive. Mackinnon et
al., however, have shown a correlation between mixed T cell chimerism and an
increased relapse for CML, suggesting a correlation with GVL reactivity70. This
correlation between mixed hematopoietic chimerism and reduced GVL reactivity was
also suggested for other diseases, such as lymphoma110.
Taken together, these studies show that mixed hematopoietic chimerism, and more
importantly T cell chimerism (being the prime cell population modulating allo
immune responses after SCT), is correlated to a reduction in the development of
donor immune reactivity towards the recipient (i.e. GVHD and possibly GVL
reactivity), compared to full chimerism. Still, GVHD can develop and disease
response can occur. Furthermore, these studies show the role of multiple variables in
the development of immune responses after SCT, and demonstrate how these
variables influence each other (Figure 2).
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Figure 2. Interaction of variables associated with SCT that influence the development and
intensity of anti-host immune responses after allogeneic SCT. Increased magnitude of
respective variables either increase (⊕) or reduce () T cell chimerism or anti-host cellular
immunity. The latter variables interact with each other.
2. Adoptive immunotherapy after allogeneic SCT
Clear clinical evidence shows that immune-mediated elimination of leukemia
contributes to the success of hematopoietic SCT. Immune-based therapies such as
antibody and cytokine therapy have already been successfully developed and
incorporated into standard treatment regimens for some human malignancies. Cellular
immunotherapy is an attractive approach to augment GVL reactivity after allogeneic
SCT to prevent or treat relapse. However, alloresponses of adoptively transferred
unselected leukocytes are initiated towards a wide range of alloantigens. The
development of methods to activate and expand effector cells with defined specificity
and function should improve the effectiveness and safety of this form of therapy.
2.1. Donor leukocyte infusions to treat relapse after allogeneic SCT.
The infusion of leukocytes from the original donor, administered separately from the
initial transplant, to treat relapsed CML was first described a decade ago23,24. These
donor leukocyte infusions (DLI), containing large amounts of T cells, induced
complete cytogenetic remissions and provided the first direct clinical evidence for
GVL reactivity.
DLI have been especially successful in the treatment of relapsed CML in chronic
phase, where complete remissions have been reported in about 80% of patients.
Patients in more advanced stages of CML, and with acute leukemia, obtain a lower
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percentage of response (i.e. 12-28% for advanced phase CML, 22% for AML and 8%
for ALL)25-27.
Acute and chronic GVHD develops in approximately 60% of patients after DLI, and
has contributed to death in almost 10% of patients who develop GVHD25. Several
approaches have been developed to reduce GVHD after DLI. In small studies, the
infusion of escalating doses of T cells111,112, the introduction of suicide genes into
transferred cells113-117, or the administration of T cells after the selective depletion of
CD8+-subsets118,119, resulted in a reduced incidence and/or severity of GVHD. These
approaches may be beneficial for patients with CML.
To control GVHD after T cell depleted allogeneic SCT DLI has been successfully
applied as a delayed add-back of T cells120-126. Several mechanisms may contribute to
a decrease in the development of GVHD after delayed infusion of donor lymphocytes,
including the avoidance of the ‘cytokine storm’ induced by pretransplant
conditioning46,127,128, the presence of fewer host-type APCs43, and the development of
immunosuppresive regulatory cells57,129. In addition, T cell depletion itself reduces
GVHD. GVL reactivity was preserved as shown by salvage of 72-89% of relapses120-
123
 and favourable relapse-rates in patients who are at high risk for relapse126. Caution
should be taken, however, since T cell depletion increases the risk of fatal graft
rejection, and even if recovery of autologous hematopoiesis ensues, the patient has
been sensitized to the donor and may reject subsequent DLI.
DLI-induced pancytopenia is somewhat less common than GVHD after DLI, occuring
in 18-50% of patients130,131. Aplasia resulting from DLI to treat patients that developed
a full clinical relapse, in general, is mild and transient132.
2.2. DLI after non-myeloablative allogeneic stem cell therapy
High-dose chemoradiotherapy may not completely eradicate all host normal and
malignant hematopoietic cells, even after intensification of the pretransplant therapy
to a point where non-marrow organ toxicities become limiting1,2. DLI can induce
complete remissions in patients who relapsed with leukemia after hematopoietic SCT,
even when the leukemic cells are resistent to chemoradiotherapy. This has led in
recent years to a conceptual shift in allogeneic hematopoietic SCT from trying to
eradicate malignant cells through maximally tolerated doses of toxic therapy, towards
using allogeneic leukocytes to eliminate the malignancy. Alternative conditioning
regimens with reduced toxicity are being developed, which allow initial engraftment
of donor effector cells (i.e. induce HVG tolerance), with these cells being the primary
therapeutic modality73-78. DLI in this setting is intended to effect a powerful
lymphohematopoietic GVH-reaction to consolidate donor engraftment and enhance
GVL reactivity. However, the optimal usage has yet to be determined.
Major responses have been seen in a variety of hematologic malignancies, primarily
including patients with highly chemorefractory disease73-78. GVHD remains a major
clinical concern and treatment challenge. Follow-up data are limited and additional
time is needed to determine the efficacy and toxicities of this form of immunotherapy.
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2.3. T cell chimerism status in regard to the development of DLI-induced
alloimmune responses
The mixed T cell chimeric state represents a co-existence between immune effector
cells that may exert potential reciprocal reactivity. Following non-myeloablative
conditioning and in situations in which host hematopoiesis has returned with relapse
of hemological malignancy, host T cells can be present in substantial numbers, and
consequently influence the development of DLI-induced alloimmune responses.
Several groups have described the role of regulatory cells in the development of
immune tolerance after BMT57,133,134. Johnson et al. identified a donor-derived
immunoregulatory CD4+/CD25+ T cell population that suppresses GVH reactivity in
a MHC-mismatched murine model for DLI57,129. A clinical study by Schattenberg et
al. showed that the percentage of donor-derived T cells at the time of DLI
significantly correlated with the occurrence of GVHD and induction of remission55.
Patients treated with DLI have immunocompetent T cells. If these cells are of
recipient origin they may exert an alloresponse towards infused donor lymphocytes
and subsequently cause rejection. Blazar et al. showed that host T cells are capable of
generating anti-donor CTL reactivity that results in an impaired ability of DLI to
induce GVHD in murine models56. We have shown that a predominance of recipient T
cells at the time of DLI significantly reduces the survival time of infused donor T
cells in a rat model (Chapter 4; this thesis). This fast disappearance suggests that this
elimination of donor T cells is an active process possibly mediated by alloreactive
sensitized recipient T cells. Moreover, Spitzer et al. found that donor T cell levels
≤20% were associated with graft loss after non-myeloablative allogeneic SCT, despite
subsequent DLI, suggesting a strong HVG response73. Keil et al., however, described
a patient who had full recipient hematopoiesis at the time of DLI to develop aplasia,
resulting from a DLI-induced T cell response towards the hematopoietic
compartment132.
2.4. In vitro generated antigen-specific donor-derived T cell clones
The adoptive transfer of T cells that are selected for specific recognition of mHags
exclusively expressed by recipient leukemic cells or recipient hematopoietic cells
represents a potential approach for eradicating leukemic cells without inducing
GVHD. Furthermore, in this way a more potent antitumor effect can be achieved
compared to unselected polyclonal donor lymphocytes used for DLI. Falkenburg et al.
have treated a patient in accelerated phase of CML with leukemia-reactive CTL,
resulting in complete molecular remission135. No GVHD was observed in this study.
An increasing number of mHags is being characterized at the molecular level, which
may broaden the application of mHag-antigen specific T cells for adoptive
immunotherapy136.
Potential targets for immunotherapy that would not require allogeneic SCT are being
evaluated. These proteins include leukemia-specific proteins (e.g. Bcr-Abl fusion
protein, PML/RARα fusion protein, and ETV6-AML1)137-139 and leukemia-associated
normal proteins (e.g. proteinase-3, WT-1, hdm2, and hTERT)96,140-142. Epstein Barr
virus (EBV)-specific donor-derived T cell lines have been generated and infused to
successfully treat EBV-induced post-transplant lymphoma and relapsed Hodgkin’s
disease143,144. Complete eradication of EBV-induced lymphoproliferative disease after
DLI had been described previously145.
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Taken together, these studies have demonstrated that it is feasible to generate T cells
of desired specificity in vitro that retain function and the ability to persist and migrate
in vivo after infusion into patients.
3. Monitoring T cells after adoptive therapy
The ability to study the fate of infused cells used for adoptive immunotherapy can
provide valuable biological information about the mechanisms involved in the
development of immunological responses. Better understanding of these mechanisms
may lead to the development of methods to improve the outcome of this form of
therapy.
3.1. T cell marking
The addition of a marker enables to monitor and quantify the survival of infused T
cells. In this way infused cells can be distinguished from pre-existing cells in the
recipient. Marked T cells can be tracked to learn if they can home to specific sites and
if they are involved in GVHD and GVL reactivity.
3.2. Use of retroviral vector for gene-marking of adoptively transferred T cells
Gene-marking provides a tool to mark cells not only for their entire lifespan, but also
for the life span of their progeny. The majority of marker studies performed have used
murine retroviral vectors to introduce foreign DNA (i.e. viral and transgene)
sequences into a host cell. The stable introduction of a marker provides a strong
advantage over the use of radioisotopes or fluorescent dyes in labeling procedures of
cells. Isotope half-life, leakage of dye out of cells, and reduction of label in dividing
cells will hamper accurate quantification and significantly decrease the follow-up time
after transfer. Several marking studies have been performed. Table 2 summarizes the
results on persistence and homing of retrovirally transduced T cells used in clinical
studies. These studies show the feasibility of follow-up of infused cells, and provide
valuable information about homing and accumulation of T cells at target sites.
Furthermore, information on T cell persistence and dynamics, such as expansion upon
Ag-encounter, and T cell eradication upon suicide induction, can be obtained.
Marked T cells can be identified and quantified via PCR of transduced DNA
sequences, or via flow cytometric analysis after antibody staining of expressed
retroviral transgene products.
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3.3. Method of retroviral T cell marking
Currently, mammalian C-type retroviral murine leukemia virus (i.e. Moloney murine
leukemia virus (MoMLV)) based vectors are the predominant vehicles for gene gene-
delivery systems, especially in gene-marking studies. Retroviruses are RNA viruses
that replicate via DNA proviral intermediates that can stably integrate into host DNA.
Retroviral genomes are composed of cis elements, which are non-coding areas of the
genome necessary for replication, and trans elements, which are coding elements that
give rise to proteins (Figure 3A).
Retroviral vectors are plasmids containing recombinant proviral DNA molecules in
which the packaging signal and long terminal repeat are retained (cis-elements), and
the structural and replicative genes (gag, pol, and env; trans-elements) of a murine
retrovirus are replaced by one or more genes of interest, driven by either the retroviral
promoter in the 5’ LTR, or by an added internal promoter (e.g. SV40) (Figure 3B).
These plasmids are transfected or transduced into a packaging cell-line.
Figure 3. Schematic map of (A) a MoMLV retroviral RNA strand (with the genome
being ‘diploid’), and (B) the retroviral DNA sequence of the retroviral vector. R, direct
repeat; U5, unique non-coding region forming the 3’ end of the provirus genome; PB,
primer binding site; L, leader sequence; ψ, packaging signal; SD, splice donor site;
MA, encodes matrix protein; CA, encodes capsid protein; NC, encodes nucleocapsid
protein; PR, encodes protease protein; RT, encodes reverse transcriptase protein; IN,
encodes integrase protein; SA, splice acceptor site; SU, encodes surface glycoprotein;
TM, encodes transmembrane protein; PP, polypurine tract; U3, unique non-coding
region forming the 5’ end of the provirus genome.
A packaging cell-line contains helper retrovirus that supplies proteins encoded by the
deleted trans-elements, but generates no functional/infectious virus particles by itself
(Figure 4). Transcripts from the retroviral vector, however, can be packaged by the
helper virus proteins to form infectious virus. These viruses are helper free and
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therefore replication-defective. They can only undergo the first stages of the virus life
cycle, i.e. binding to the target cell, cell entry, reverse transcription into proviral
DNA, and stable integration into the host genome. In general, a type C retrovirus
cannot cross an intact nuclear membrane. During mitosis the nuclear membrane
breaks down, allowing the reverse transcribed provirus to stably integrate into the host
genome. Therefore, cells must divide to allow retroviral integration into the genome.
Figure 4. Packaging cell line. Generation of replication deficient virus particles.
The fact that T cells have to divide presents a potential drawback of this approach. In
vitro stimulation induces phenotypic changes that may influence the survival and
trafficking patterns of T cells after infusion. The potential induction of immune
responses towards transduced cells is another drawback in the use of the retroviral
vector system. Immunogenicity of the transduced cells is associated with the
transgene products transcribed from the retroviral vector. For some gene products,
such as the hygromycin-thymidine kinase fusion protein, this has resulted in rapid
elimination of large numbers of transduced cells in fewer than 48 hours154. In contrast,
neo-positive cells e.g. can be detected for up to 9 years after infusion. Moreover, neo-
marked T cells can be readily expanded in vivo by appropriate antigenic
stimulation143,153. To prevent immunoreactivity towards gene-marked cells a non-
expressed sequence is the most ideal marker. However, this excludes the posibility to
select and purify transduced cells via antibody selection or drug-resistence.
The advantages and disadvantages of the use of the retroviral vector system for T cell
marking studies are summarized in Table 3.
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Advantages:
- Stable integration into the host genome.
- Minimal/controllable immunogenicity.
- Stable packaging system.
- Broad host range155.
- Extensively used156.
Disadvantages:
- Integration restricted to dividing cells157.
- Safety issues (i.e. insertional mutagenesis, replication-competent retrovirus, contaminants in
retroviral vector)158.
- Sometimes limited transduction efficiencies.
4. Scope of this thesis
The scope of this thesis encompasses the role of T cell genotype (dynamics) in the
development of alloreactive immune responses and the means to investigate these
processes.
Chapter 2 describes a sensitive method for the in vivo detection and quantification of
infused T cells. Genetic marking of these cells allows them to be discerned from pre-
existing cells in the recipient. The method allows accurate quantification of marked
cells and enables long-term in vivo detection of labeled cells and their progeny in
peripheral blood and tissues. In vitro stimulation of T cells is a prerequisite for
retroviral T cell marking. Also, many adoptive cellular (immuno)therapeutical
approaches involve the use of in vitro manipulated (T) cells. We studied the potential
consequences of prolonged in vitro culturing of T cells before infusion on the in vivo
distribution and retention of these cells in a mouse model.
In Chapter 3 we established the specific strenghts of the real-time quantitative PCR
methodology for studying the biodistribution and retention time of
cultured/retrovirally labeled cells in vivo, in comparison to other quantitative
methodologies. Furthermore, we extended its applicability, when we used it in a rat
BMT model. We studied the involvement of HSV-Tk transduced T cells in the
development of GVHD-induced lesions and provided a platform to monitor their
persistence after ganciclovir induced suicide.
Following non-myeloablative conditioning and in situations in which host
hematopoiesis has returned with relapse of a hematological malignancy, host T cells
can be present in substantial numbers. We hypothesized that T cells of recipient
origin, present at the time of DLI, may inhibit alloreactivity of infused donor
Table 3. Advantages and disadvantages of the murine retroviral vector system for T cell marking
studies
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lymphocytes, and that this inhibition possibly is induced via elimination of infused
donor cells. This might seem predictable. However, host T cells that have co-existed
with donor BM-derived cells could have become tolerant to donor alloantigens56. In
Chapter 4 we studied the in vivo survival of infused donor T cells in a rat model, using
the method described in Chapters 2 and 3. Rats were given different treatments before
DLI, thus influencing the dynamics of immunogenetic reconstitution. Consequently
the survival of infused donor T lymphocytes was affected.
Several methods for the detection of chimerism have been published80-88. Each
technique has advantages and disadvantages demonstrated by the great diversity of
assays and constant development of new detection methods. The majority of these
assays allow only qualitative or semi-quantitative information on the degree of
chimerism. Highly sensitive and quantitative detection methods are of special
importance102,159. The introduction of real-time PCR allows for greater sensitivity and
more accurate quantitation. Chapter 5 describes the introduction of a real-time PCR to
monitor the genetic origin of hematopoietic cells, including immune effector cells and
leukemic cells. In a retrospective detailed analysis of the genetic origin of
lymphocytes and myeloid cells of a patient with CML who relapsed after allogeneic
SCT and was given subsequent DLI, the feasibility of this powerful technique was
demonstrated.
In Chapter 6, we show that the addition of idarubicine, a chemotherapeutical drug, in
the conditioning regimen of patients with CML (CP1), who are transplanted with
partially T cell depleted stem cell grafts from HLA-identical siblings, resulted in a
significantly lower 5-year probability of relapse. Furthermore, the addition of
idarubicine correlated with a significant increase in the development of clinically mild
acute GVHD. Using the technique described in Chapter 5, we investigated the
dynamics of immunogenetic reconstitution of highly purified leukocyte subsets. Here,
we demonstrated a correlation between T cell genotype and the development of
alloimmune responses.
Finally, Chapter 7 summarizes the thesis and provides general conclusions.
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SUMMARY
T lymphocytes used for adoptive immunotherapy are often cultured before transfer to
generate sufficient amounts of effector cells with desired specificity. In vitro activation
and expansion may modify lymphocytes and consequently alter their survival and
trafficking patterns after transfer and influence their potential effector capacity. In this
report, the authors show that the culture period of T cells after ConA/IL-2 stimulation
strongly influences the retention and tissue distribution of these cells after infusion into
syngeneic C57BL/6 mice. Infused labeled cells that have been cultured for 3 days
remained in the peripheral blood and organs in at least a tenfold higher number than
cells cultured for 8 days. In addition, cells cultured for 3 days preferentially migrate to
lungs and liver shortly after infusion, and subsequently to lymph nodes and spleen. Cells
cultured for 8 days preferentially migrate to liver and can be hardly detected in lymph
nodes. In contrast, labeled cells cultured for 3 days are predominantly present in lymph
nodes starting from day 8 until day 28. We showed that accurate monitoring of
transferred cells is feasible, which may contribute to understanding response to adoptive
immunotherapy.
INTRODUCTION
LLOGENEIC STEM CELL TRANSPLANTATION (SCT) is a frequently used form of
immunotherapy for the treatment of patients with leukemia and lymphoma.
Infusion of donor lymphocytes (DLI) induces clinical remission in about 80% of
patients with chronic myeloid leukemia (CML) and in about 15-30% of patients with
acute leukemia who relapse after SCT1-3. In addition, SCT in combination with DLI
has shown promising potential to cure some metastatic solid tumors4,5. Beside
treatment with alloreactive effector cells derived directly from blood and bone
marrow, adoptive immunotherapy with in vitro generated tumor-reactive effector cells
is explored. Falkenburg et al.6 have treated a patient in accelerated phase of CML
with leukemia-reactive cytotoxic T lymphocytes (CTL), resulting in complete
molecular remission without any signs of graft-versus-host disease (GVHD). EBV-
induced lymphoproliferative disease and cytomegalovirus reactivation post SCT have
been frequently treated by infusion of donor-derived virus-specific CTL7-10. Moreover,
CTL specific for hemopoietic cell-restricted minor histocompatibility antigens have
been generated in vitro, which can be used to treat patients with leukemia who relapse
after SCT11-13.
A
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Alloreactive effector cells given by SCT and DLI are directly transferred from donors
to patients. In contrast, tumor-reactive and virus-specific CTL have been cultured to
induce desired specificity and to generate sufficient amounts for effective treatment.
Donor lymphocytes have been transduced ex vivo with the herpes simplex virus
thymidine kinase (HSV-tk) suicide gene to efficiently control DLI-associated
GVHD14-16. However, survival and trafficking patterns of T cells after infusion may be
influenced by phenotypic changes of these lymphocytes induced by in vitro
stimulation and expansion. T cells may become more susceptible to apoptosis that
may influence their survival and preference of tissue distribution. Furthermore,
expression of adhesion molecules and chemokine receptors on the cell surface and
their activation status may increase or decrease upon activation and prolonged
culturing of T cells17. These alterations may strongly influence the effector potential
of cells infused for adoptive immunotherapy.
Here, we studied the effect of the culture period of T cells before adoptive transfer on
their survival and tissue distribution. We cultured splenocytes for 3 and 8 days after
ConA/IL-2 stimulation. Cells were labeled via retroviral transduction with a Moloney
Murine Leukemia virus (MoMLV)-based vector to track T cells in vivo. We
determined the percentage of infused T cells in blood and several tissues after
injection into the tail vein of syngeneic mice. A sensitive real-time PCR was
developed for detection and quantification of the labeled cells, which enables us to
monitor very low percentages of infused cells, and the persistence of these cells in
various organs.
We observed a remarkable quantitative difference of labeled T cells retrieved from
blood and organs after infusion related to culture period. After transfer, cells exposed
to a shorter culture period ex vivo survive in higher amount than T cells cultured for 8
days. Moreover, T cells cultured for different periods showed distinct patterns of
tissue distribution. T cells cultured for 3 days showed a relative preferential migration
to lungs within 4 hours and a subsequent homing and migration to lymph nodes and
spleen. In contrast, cells cultured for 8 days showed a relative preferential migration
to the liver and lungs and disappearance from all organs within 28 days. These clear
differences in survival and tissue distribution between short period cultured cells (3
days) and longer period cultured cells (8 days) suggest that the ex vivo culture period
before infusion may affect the potential number of cells that can exert effector
function in vivo.
MATERIALS AND METHODS
Mice
Eight-week-old male C57BL/6 mice were purchased from Charles River Wiga
(Sulzfeld, Germany). Mice were kept under specific pathogen-free conditions in
positive pressure cabinets at the animal facilities of the University of Nijmegen and
fed irradiated food and acidified drinking water.
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Production of retroviral vector
The replication deficient amphotropic vector SFCM-2-producing cell line (PA317)
was kindly provided by Dr. C. Bonini (Istituto Scientifico H. S. Raffaelle, Milan,
Italy). This MoMLV-based vector contains the truncated form of the human low-
affinity nerve growth factor receptor (∆LNGFR) as marker gene. The virus-producing
PA317 cell line was cultured in Dulbecco’s modified Eagle’s medium (DMEM;
Gibco BRL, Gaithersburg, MD) supplemented with 10% FCS, 50 U/mL penicillin,
and 50 µg/mL streptomycin. When cells reached subconfluency the medium was
changed for IMDM (Gibco BRL) supplemented with 10% FCS, 5 × 10-5 mmol/mL 2-
mercapthoethanol, 50 U/mL penicillin, and 50 µg/mL streptomycin. Virus containing
supernatant was collected after 24 hours of culturing. The supernatant was filtered
(0.45 µm), snap-frozen in liquid nitrogen, and stored at -80°C. Presence of
amphotropic helper virus in the supernatant was excluded by a negative result of PCR
specific for 4070A amphotropic murine leukemia virus envelope sequence
(Accession: M33469) in DNA of transduced splenic T lymphoblasts.
Retroviral transduction of cells
Spleens were homogenized in a filter chamber and subsequently lymphocytes were
isolated by density gradient separation using Lympholyte-M (Cedarlane Laboratories
Ltd., Hornby, Canada). Splenocytes (106/mL) were activated for 24 hours with 5
µg/mL concanavaline A (ConA; Boehringer Mannheim, Mannheim, Germany) and
300 IU/mL recombinant human IL-2 (Glaxo, Geneva, Switserland) in IMDM
supplemented with 10% FCS, 5 × 10-5 mmol/mL 2-mercapthoethanol, 50 U/mL
penicillin, and 50 µg/mL streptomycin. After 24 hours, activated splenocytes were
incubated overnight with retrovirus containing medium in 35 mm diameter wells or
T25 flasks (Becton Dickinson Labware, NJ, U.S.A.) coated with recombinant human
fibronectin fragment CH-29618,19 (RetroNectin; Takara Shuzo Co. Ltd., Otsu, Japan).
After retroviral exposure, cells were washed and further cultured in IMDM/10% FCS
supplemented with 300 IU/mL IL-2. On day 3, cells were either harvested and infused
into syngeneic mice, or further cultured until day 8 with addition of fresh IL-2 (300
IU/mL) on days 3 and 6. The murine P815 mastocytoma cell line was grown in
IMDM supplemented with 10% FCS, 50 U/mL penicillin, and 50 µg/mL
streptomycin. P815 cells and were incubated overnight with retrovirus containing
medium in CH-296 coated 35 mm diameter wells. Transduced P815 cells were sorted
by flow cytometry to obtain a > 98% ∆LNGFR positive cell line.
Flow cytometric measurements
Cell surface expression of the ∆LNGFR on transduced cells was analyzed by flow
cytometry using the murine anti human LNGFR monoclonal antibody (mAb) 20.4
(ATCC) with an indirect fluorescence labeling method. FITC-conjugated goat F(ab’)2
anti-mouse IgG and IgM (Tago Immunologics, Camarillo, CA, U.S.A.) was used for
staining. CD3, CD4 and CD8 expression was analyzed using R-phycoerythrin (R-
PE)-conjugated hamster anti-mouse CD3-ε (PharMingen, San Diego, CA, U.S.A.),
FITC-conjugated rat anti-mouse CD4 (L3T4; PharMingen) and FITC-conjugated rat
anti-mouse CD8a (Ly-2; Pharmingen) mAb, respectively. Analysis was performed on
an Epics XL flow cytometer (Coulter Electronics, Hialeah, FL, U.S.A.).
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T cell transfer to syngeneic mice
Fifteen million splenocytes, cultured for 3 or 8 days after ConA/IL-2 stimulation,
were injected into the tail vein of C57BL/6 mice in 150 µL Hank’s balanced saline
solution (HBSS).
DNA isolation
DNA was isolated from whole blood, (transduced) ConA/IL-2 activated splenocytes
and (transduced) P815 cells, using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany). Whole blood samples were pretreated with dextran to remove
erythrocytes. Briefly, whole blood was diluted with 3 volumes PBS and incubated
with one volume 5% dextran solution (Sigma, St. Louis, MO, U.S.A.). After 30
minutes the upper phase was collected, centrifuged, and the pellet was resuspended in
200 µL PBS. Bone marrow was collected by flushing of the femoral shaft. Organs
were resected and representative specimens were taken. DNA was isolated from
tissues using the QIAamp DNA Mini Kit (Qiagen).
Real-time quantitative PCR
Cells carrying the provirus were quantified by a real-time PCR analysis20,21 using the
5’ nuclease assay (Taqman)22 and the ABI/PRISM 7700 sequence detector (Perkin-
Elmer Applied Biosystems, Fostercity, CA, U.S.A.)23,24. Real-time PCR was
performed in a total volume of 50 µL with 1× buffer A, 1.25 U of DNA polymerase
(AmpliTaq Gold), 250 µmol/L dNTPs, primers at 300 nmol/L, and dual labeled
fluorogenic internal probes at 100 nmol/L. Samples were heated for 10 minutes at
95°C and amplified for 45 cycles of 15 seconds at 95°C and 60 seconds at 60°C.
Proviral primers and probe sequences were chosen to specifically amplify a part of the
U3 region of any MoMLV-based vector. Provirus primer and probe sequences were
as follows: forward; 5’-AAA GAC CCC ACC TGT AGG TTT G-3’; reverse; 5’-TTC
CTG ACC TTG ATC TGA ACT TCT CT-3’; probe; 5’-TET (tetrachloro-6-carboxy-
fluorescin)-TTA AGT AAC GCC ATT TTG CAA GGC ATG-TAMRA (6-carboxy-
tetramethyl-rhodamine)-3’. Mouse serum albumin (Accession: X13060) primer and
probe sequences were as follows: forward; 5’-CAA TCC TGA ACC GTG TGT GTC
T-3’; reverse; 5’-TTC ATC AAC TGT CAG AGC AGA GAA G-3’; probe; 5’-TET-
CCA AGT GCT GTA GTG GAT CCC TGG TGG-TAMRA-3’.
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RESULTS
Retroviral transduction of mouse splenocytes with MoMLV-based vector
To analyze T cell survival and migration after infusion into syngeneic recipients, we
labeled C57BL/6 splenocytes via retroviral transduction with the MoMLV-based
vector SFCM-2 that contains the truncated human LNGFR gene. Splenocytes were
activated with ConA and IL-2, retrovirally transduced and subsequently cultured until
day 8. To determine transduction efficiency, the percentage of ∆LNGFR positive cells
was determined by flow cytometry. We consistently obtained transduction efficiencies
between 40-65% (data not shown). These results demonstrate that mouse T cells can
be efficiently labeled by retroviral transduction with the MoMLV-based vector
SFCM-2 after activation with ConA/IL-2.
Real-time PCR to quantify cells labeled by retroviral transduction
To accurately quantify labeled cells in peripheral blood and tissues, a real-time
quantitative PCR detection assay was developed. For this, primers and probe were
chosen that specifically amplify a part of the U3 region of the long terminal repeats
(LTRs) of the integrated proviral DNA (Fig. 1).
Figure 1. Position of primers and probe on MoMLV-specific sequence of the proviral DNA.
(A) Schematic map of the integrated SFCM-2 proviral genome. ∆LNGFR, human low affinity
nerve growth factor receptor cDNA deleted of the intracellular domain; SV40, SV40 early
promoter. (B) Position of primers and probe on the U3 sequence of the 5’ and 3’ long
terminal repeat (LTR). The 3’ U3 sequence of the SFCM-2 vector acts as a template for both
proviral U3 DNA sequences. This results in duplication of the MoMLV-specific target
sequence for real-time PCR after integration. IR, inverted repeat; R, direct repeat.
Amplification of this specific retroviral sequence enables the detection and
quantification of cells transduced with any MoMLV-based vector. To determine the
amount of input DNA isolated from cell samples collected after infusion, primers and
probe were chosen to specifically amplify a part of the mouse albumin gene.
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The efficiency of the U3 PCR and mouse albumin PCR was determined by specific
amplification of genomic DNA isolated from retrovirally transduced T cells. For this,
DNA was serially diluted in water from 750 ng to 7.5 pg. After real-time PCR
analysis, initial template concentration was plotted against the cycle threshold
(Ct)(Fig. 2).
Figure 2. Amplification efficiencies of mouse albumin PCR and proviral U3 region
real-time PCR. The threshold cycles (Ct) after amplification of serial diluted
template DNA (i.e. closed squares for U3 region PCR, and closed circles for the
mouse albumin gene PCR) are plotted. Regression lines for U3 and mouse albumin
are -3.3097 (R2=0.9968) and -3.2866 (R2=0.9991), respectively, indicating that both
reactions have equal amplification efficiencies.
The difference in Ct between U3 and albumin DNA amplification (i.e. ∆Ct) for each
dilution was constant over a dynamic template concentration range of 5 logs. This
demonstrates that amplification efficiencies of both real-time PCRs are equal, and,
therefore allows normalization of U3 DNA to albumin DNA. The amount of
normalized viral DNA in all cell samples was related to a normalized DNA sample
obtained from P815 cells expressing ∆LNGFR after retroviral transduction. Using this
real-time PCR method, we determined that serially diluted labeled P815 cells in non-
transduced cells could be quantified up to at least 0.01% (data not shown). The
threshold of detection of labeled cells is up to 0.001% with 750 ng input DNA, as
estimated from the data shown in figure 2, assuming that one cell corresponds with 7
pg of genomic DNA. The percentage of labeled P815 cells within serial dilutions of
labeled cells in non-transduced cells, as determined by real-time PCR analysis,
correlated with the percentage determined by flow cytometry (data not shown).
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These results demonstrate that using the developed PCR for specific amplification of
the U3 region of MoMLV-based vectors, the percentage of retrovirally labeled cells in
blood and tissue samples can be accurately calculated.
Influence of culture period on persistence of infused T cells in peripheral blood
The influence of in vitro culture and expansion on the persistence of infused T cells in
peripheral blood was investigated by determining the number and retention time of
cells cultured 8 days after ConA/IL-2 activation. Therefore, syngeneic C57BL/6 mice
(n = 7) were injected with 15 × 106 splenic T lymphoblasts of which 60% were
transduced. We found that the amount of labeled cells in blood rapidly decreased to
very low frequencies (< 0.2%) within 1 day after infusion (data not shown). In
subsequent experiments, we compared the number and retention time of cells cultured
8 days versus cells cultured for only 3 days (Fig. 3). Peripheral blood samples were
collected sequentially at 4 hours up to 28 days after adoptive transfer. DNA of white
blood cells was isolated and the percentage of labeled cells in these samples was
determined by real-time PCR analysis. No significant difference in the amount of
labeled cells cultured for 3 days and 8 days was found in peripheral blood 4 hours
after infusion (Fig. 3). The amount of labeled cells cultured for 8 days decreased
rapidly, as found in the previous experiment. Within one day post infusion the amount
of labeled cells was extremely low (< 0.2%) and reached thereafter a steady state level
(± 0.05%). In contrast, the number of labeled cells cultured for 3 days increased after
infusion and reached a peak level between day 2 and 5 after infusion. Thereafter, the
amount of labeled cells decreased to below 0.2% at day 28, but remained significantly
higher than the amount of labeled cells cultured for 8 days. These data show that the
duration of the culture period of activated T lymphocytes before adoptive transfer has
a dramatic effect on the number of T cells that circulate in blood after infusion.
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Figure 3. Percentage of labeled cells in peripheral blood determined by real-time
PCR analysis. Before infusion, cells were either cultured for 3 days (open symbols)
or 8 days (closed symbols) after ConA/IL-2 stimulation. Mice were infused with 15
× 106 splenic T cells of which 50-55% were transduced. Data are means ± SEM.
Open and closed squares represent data from 2 mice per time point from; 14 mice
were injected with splenocytes cultured for 3 days or 8 days, respectively. Open
circles represent data from 4 mice per time point (n = 4) injected with splenocytes
cultured for 3 days.
Influence of culture period of infused T cells on distribution in lymphoid organs
Mature T cells migrate from the bone marrow to lymphoid organs where they become
educated and activated. The spleen acts as a reservoir for lymphocytes and the lymph
nodes are involved in induction of antigen-specific T cell functions. To investigate the
migration to, and persistence of, infused cells in these organs, we determined the
percentage of labeled cells in spleen and pooled lymph nodes up to 28 days after
infusion (Figs. 4A and B). Four hours after infusion, a higher percentage of labeled
cells cultured for 3 days after ConA/IL-2 stimulation could be found in lymphoid
organs, compared to labeled cells cultured for 8 days. Thereafter, the percentage of
labeled cells cultured for 8 days further decreased to extremely low levels (< 0.1%),
whereas the percentage of labeled cells cultured for 3 days increased 4-fold in spleen
at day 2, and 70-fold in lymph nodes at day 5. Thereafter, the percentage of labeled
cells decreased, but was still detectable in both spleen and lymph nodes 28 days after
infusion (0.32 ± 0.02% and 0.84 ± 0.32%, respectively). These results show that a
significant percentage of ex vivo activated T cells migrate to, and accumulate in,
spleen and lymph nodes after infusion in syngeneic mice. Furthermore, these data
again demonstrate that the culture period of activated T cells before infusion
substantially influences their migration and retention.
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Figure 4. Percentage of labeled cells in (A) spleen and (B) pooled lymph
nodes. Before infusion cells were cultured for 3 days (open squares) or 8
days (closed squares) after ConA/IL-2 stimulation. Data are means ± SEM
from 2 mice per time point.
Influence of culture period of infused T cells on distribution in liver and lungs
In general, activated T cells are preferentially trapped in liver and lungs after infusion,
probably due to an increased expression of adhesion molecules in combination with a
large amount of capillaries in these organs25. Four hours after infusion, a clear
quantitative difference of labeled cells was found between cells cultured for 3 and 8
days after ConA/IL-2 stimulation (Figs. 5A and B). This is consistent with our
findings in peripheral blood and lymphoid organs. Thereafter, the percentage of
labeled cells cultured for 8 days decreased to extremely low levels (< 0.05%). In
contrast to the kinetics observed in peripheral blood and secondary lymphoid organs,
the percentage of labeled cells cultured for 3 days in both liver and lungs decreased
after infusion (Figs. 5A and B).
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Figure 5. Percentage of labeled cells in (A) liver and (B) lungs. Before
infusion cells were cultured for 3 days (open squares) or 8 days (closed
squares) after ConA/IL-2 stimulation. Data are means ± SEM from 2 mice
per time point.
These data show a consistent quantitative effect on the retrieval of infused cells as a
result of culture period before infusion. The difference in kinetics of in vivo
persistence of labeled cells in liver and lungs compared to the kinetics found in
peripheral blood and lymphoid organs suggests entrapment of activated T cells rather
than migration.
Estimated amount of remaining cells in organs after infusion
To compare the quantitative distribution of labeled cells between different tissues, we
determined the amount of labeled cells per tissue. All organs were weighed, except
lymph nodes, and the total amount of cells per tissue was estimated by assuming 1 g
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of tissue corresponds with 109 cells. The total amount of cells in pooled lymph nodes
was estimated by the assumption that the total weight of lymph nodes per mouse is
0.08 g26. The number of white blood cells per mouse was calculated from the WBC
count and the assumption that mice contain 2 mL of blood.
Mice were infused with 15.106 splenic T cells of which 50-55% were transduced, so
7.5-8.25 × 106 labeled cells were transferred. Four hours after infusion the total
amount of retrieved labeled cells that were cultured for 3 days in all tissues analyzed,
was approximately 10 × 106. In contrast, only a total number 0.70 × 106 labeled cells
in all tissues analyzed could be detected when cells were cultured for 8 days. These
estimations of the number of labeled cells present in mice shortly after infusion
suggest that cells cultured for 3 days can survive and expand in vivo.
Figures 6A and B show the estimated total amount of labeled cells per tissue (i.e.
blood, spleen, lymph nodes, liver and lung). In mice injected with labeled cells
cultured for 3 days, the total number of retrieved cells in all organs was at least a 5- to
10-fold higher than in mice injected with labeled cells cultured for 8 days. Four hours
after infusion, the total amount of labeled cells that were cultured for 3 or 8 days in
liver and lungs was approximately 8.4 × 106 (84% of total retrieved labeled cells) and
0.57 × 106 (81% of total retrieved labeled cells), respectively. However, the liver to
lung ratio after transfer of cells cultured for 8 days was 1.8 and 5 for 4 hours and 1
day, respectively, whereas the liver to lung ratio for cells cultured for 3 days was 0.9
and 1.0 after 4 hours and 1 day after transfer. This indicates that cells cultured for 8
days preferentially accumulate in liver compared to cells cultured for 3 days. From
day 1 to day 28 there was a remarkably strong preferential accumulation of labeled
cells cultured for 3 days in lymph nodes, whereas there was hardly any accumulation
in lymph nodes of labeled cells cultured for 8 days.
These data show a substantial difference in the number of labeled cells that
accumulate and migrate to different organs due to culture period before infusion.
CHAPTER 2
                                                                                                                                                      
49
Figure 6. Estimated amount of labeled cells in (A) peripheral blood, spleen and pooled lymph
nodes, and (B) liver and lungs, 4 hours (black bars), 1 day (dark gray bars), 8 days (light gray
bars) and 28 days (white bars) after infusion. Left panels show the number of retrieved labeled
cells stimulated with ConA/IL-2 for 3 days before infusion, and right panels show the number
of retrieved labeled cells stimulated with ConA/IL-2 for 8 days before infusion.
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DISCUSSION
Survival and migration of effector T cells in adoptive immunotherapy are important
parameters influencing treatment results. Alterations in phenotype due to activation
and culture period before transfer might change these parameters and therefore
influence the effector potential of these cells. Tumor-reactive and virus-specific T
cells used in adoptive cellular immunotherapy need to be activated and cultured for
several days to weeks to induce the required specificity and yield sufficient amounts
of effector cells8-10,27. Furthermore, genetically engineered T lymphocytes, which have
been activated and cultured ex vivo to retrovirally transduce them with the HSV-Tk
suicide gene, have been used to induce graft-versus-leukemia activity with control of
GVHD28. In the present report, we studied the persistence and distribution of
retrovirally labeled and cultured cells in blood and organs after infusion using a
sensitive real-time PCR method.
We have demonstrated a dramatic effect of the period of in vitro culture before
infusion on the survival time of lymphocytes in syngeneic mice. Cells that were
exposed to a 3-day culture period before infusion show a significantly higher
persistence in all tissues tested than cells exposed to a 8-day culture period. We are
aware that even a short period of in vitro activation will influence biodistribution and
retention time. However, activation of cells is a prerequisite for retroviral labeling and
to ensure a stable integration of provirus in the cells we did not reduce the culture
period after retroviral exposure below 3 days, to rule out discrepancies in viral DNA
content per cell29-31.
It has been shown that ex vivo activation reduces alloreactive potential of lymphocytes
in vivo32. The reduced reactivity of infused donor lymphocytes is not caused by
retroviral transduction per se but is a result of cell expansion in vitro32. Donor
lymphocytes transduced with HSV-Tk gene to control the occurrence of GVHD after
infusion also show a reduced alloreactive potential in comparison with lymphocytes
transferred directly from leukapheresis products. This was demonstrated both in
human and animal studies33,34. In addition, Contassot et al.35 showed that lymphocytes
propagated in vitro have to administered at least in a 10-times higher amount to
achieve a comparable level of alloreactivity in mice than that observed after infusion
of non-cultured lymphocytes. We can extend these observations, showing that the
period that lymphocytes have been cultured before infusion strongly influences the
persistence and distribution after infusion, which may explain reduced alloreactive
potential by cultured cells.
The mechanism by which cells cultured for 8 days are more rapidly cleared from the
body remains to be elucidated. It has been shown that clearance of HIV-specific CTL
occurs shortly after adoptive transfer36,37. This rapid clearance of CTL was suggested
to depend on increased vulnerability for apoptosis of these cells after in vitro
culture36,37. We analyzed expression of adhesion molecules on retroviral transduced
cells cultured for 3 and 8 days. We only found a slight increase of LFA-1 and CD2
expression on T cells cultured for 8 days, suggesting that the expression level of
adhesion molecules does not dominantly contribute to the observed differences in in
vivo persistence and distribution (data not shown). In addition, we studied cell
proliferation by measurement of DNA contents of cells after a 3- and 8-day culture
period. Cells cultured for 8 days showed fewer proliferating cells (± 52% and ± 37%
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of cells in S/G2M-phase, respectively). This decreased cell cycling activity might
influence long term persistence of infused cells but might have limited effect on cell
numbers retrieved from the mice shortly after infusion.
The liver seems the site at which apototic cells accumulate38,39, whereas retention in
lungs represents an intrinsic component of normal lymphocyte circulation40. We
analyzed the relative distribution and retention of labeled cells in several organs after
infusion and showed that the highest number of labeled cells was found in liver and
lung. Moreover, we found that cells cultured for 8 days after ConA/IL-2 stimulation
preferentially accumulate in liver compared to cells cultured for 3 days. This
difference was already significant 4 hours after infusion, further increased 1 day after
of infusion, and remained significant up to 28 days after infusion. These data suggest
that cells cultured for 8 days are more vulnerable for apoptosis and, therefore, are
trapped in the liver shortly after infusion for clearance. The relatively high percentage
of labeled cells cultured for 3 days in lungs, shortly after infusion, may indicate that a
higher percentage of these cells still circulate in the body.
The most dramatic difference on the in vivo retention of infused cells caused by the
culture period was found in the lymph nodes. We found a 70-fold higher amount of
cells cultured for 3 days than cells cultured for 8 days. The highest amount of labeled
cells in lymph nodes was found at day 5. Interestingly, we observed a similar
accumulation pattern of labeled cells in lymph nodes and peripheral blood. This
confirms the observation of Vasseur et al.41, who found that quantitative changes of in
vivo activated T cells in blood reflect data obtained from lymph nodes, and, therefore,
suggest that peripheral blood samples are useful to monitor immune responses in
human studies.
Several groups have stressed the importance of using the means to quantify survival
of transferred effector cells in vivo27,36,42,43. For the detection of retrovirally marked
cells, we designed primers and probes for MoMLV-specific DNA sequences. This
enables detection of cells marked with any MoMLV-derived retroviral vector, in
contrast to the use of markergene-specific sequences to detect and quantify labeled
cells44-46. Retroviral labeling enables monitoring of infused cells in vivo for a long
period due to stable integration of the proviral DNA. All daughter cells of transduced
cells will contain proviral DNA, as a result, even after proliferation and division cells
can be detected. These characteristics of retroviral labeling provide a strong advantage
over the use of radioisotopes or fluorescent dyes in labeling procedures of cells.
Isotope half-life, leakage of dye out of cells and reduction of label in dividing cells
will influence quantification and significantly decrease the follow-up time after
transfer.
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ABSTRACT
Introduction of the HSV-Tk suicide gene in allogeneic T cells offers the possibility to
control developing host-reactive cells within the context of allogeneic bone marrow
transplantation (BMT). Sensitive quantitative detection methods are a prerequisite to
follow genetically modified T cells both in peripheral blood as well as in tissues to study
their involvement in graft-versus-host disease (GVHD)-induced lesions as well as their
disappearance or persistence after ganciclovir (GCV)-induced suicide. We monitored
the alloreactivity of HSV-Tk-transduced T cells after BMT by studying their in vivo
distribution and quantity in peripheral blood and in tissues in a WAG/Rij into Brown
Norway fully mismatched rat allogeneic BMT model. Genetically modified T cells were
quantified in blood and tissues by fluorescence-activated cell sorting,
immunohistochemical, and real-time quantitative polymerase chain reaction (PCR)
analysis. A significant increase in the number of allogeneic HSV-Tk+ T cells was found
in particular in spleen and lymph nodes and large numbers were found in tongue, skin
and intestines. In blood, an increase of HSV-Tk+ T cells closely preceded clinical
symptoms of GVHD. Real-time quantitative PCR proved to be a fast and accurate tool
by which to quantify transduced T cells both in blood and tissues. This enables the study
of the in vivo alloreactivity of retrovirus-transduced cells and the response of HSV-Tk-
expressing T cells to GCV-induced suicide therapy. Furthermore, we showed the
potential use to study specific cause-effect relationships in a broad range of animal and
clinical studies involving genetically engineered cells.
OVERVIEW SUMMARY
We monitored the alloreactivity of retrovirally transduced T cells after BMT in an
allogeneic rat transplantation model. Genetically modified T cells were quantified in
blood and tissues using fluorescence-activated cell sorting, immunohistochemical
analysis, and real-time quantitative PCR analyses. We found an increased infiltration of
HSV-Tk T cells in GHVD target organs in allogeneic transplanted rats compared with
syngeneic transplanted rats. In blood, an increase of allogeneic HSV-Tk+ cells closely
preceded clinical symptoms of GVHD. Immunohistochemical analysis revealed active
involvement of HSV-Tk+ cells in developing GVHD lesions in a variety of tissues.
Comparison of detection methods showed that real-time PCR analysis enabled fast and
accurate quantification of transduced cells both in blood and tissues.
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INTRODUCTION
LLOGENEIC BONE MARROW TRANSPLANTATION (BMT) is a frequently used
treatment modality to cure patients with leukemia. Despite matching for major
histocompatibility antigens there is a substantial risk for serious morbidity and
mortality caused by graft-versus-host disease (GVHD)1. T cells present in the donor
stem cell graft are responsible for this complication2-4. A number of techniques exist
for removing T cells before BMT, most of which use antibodies (complement-
mediated lysis, immunotoxins, and immunomagnetic beads) or physical methods
(soybean lectin agglutination, counterflow elutriation and albumin gradient
fractionation). Clinical studies using these approaches have unambiguously shown
that T cell depletion markedly reduces the incidence and severity of GVHD.
However, T cell depletion is associated with an increased rate of severe and often
fatal infections, a higher incidence of graft rejection, and an increased risk of
leukemia recurrence. Thus, alloreactive T cells in the graft can have not only a
negative effect, that is, induction of GVHD, but also a positive effect, that is, graft-
versus-leukemia (GVL) activity. An alternative approach to maximize the beneficial
effects of GVL activity, while minimizing the risk of severe GVHD, is the genetic
modification of donor T cells by introduction of the herpes simplex virus thymidine
kinase (HSV-Tk) suicide gene through retroviral transduction5. T cells expressing
HSV-Tk are approximately 10,000-fold more sensitive to the prodrug ganciclovir
(GCV) than are normal cells6. Ex vivo engineered T cells expressing HSV-Tk thus can
selectively be eliminated after administration of ganciclovir in case life-threatening
GVHD develops. A number of phase I/II trials with HSV-Tk suicide gene-transduced
T cells in order to modulate GVHD have been carried out7-10. In these trials all
patients that developed GVHD showed improvement of clinical signs after GCV
administration. Still, basic questions regarding the involvement of genetically
modified T cells in the development of GVHD-induced lesions, as well as their
disappearance or persistence after GCV-induced suicide, remain unsolved.
We address these questions using an MHC-mismatched allogeneic rat transplantation
model originally described by Kloosterman et al.11,12, in which the WAG/Rij rat serves
as allogeneic BM donor for the Brown Norway (BN) rat. Lethally irradiated BN rats
were given suicide gene-transduced T cells of WAG/Rij origin simultaneously with
BMT. In these allogeneic recipients severe GVHD developed. As a syngeneic control
WAG/Rij rats received the same treatment. Genetically modified T cells were
quantified in blood and tissues of allogeneic and syngeneic recipients. In blood,
quantification was performed by fluorescence-activated cell sorting (FACS) and real-
time polymerase chain reaction (PCR). In tissues, quantification was performed by
real-time PCR and after immunohistochemical staining.
We show the involvement of retrovirally transduced T cells in the development of
GVHD. This was demonstrated by a rapid increase in the number of allogeneic HSV-
Tk-transduced T cells that closely preceded clinical signs of GVHD. Furthermore, we
found increased numbers of allogeneic HSV-Tk-labeled T cells, compared with
syngeneic HSV-Tk+ T cells, in all tissues. In GVHD target organs, almost all T cells
were HSV-Tk positive. Real-time PCR proved to be the fastest and most sensitive
tool for the quantification of retrovirally transduced T cells in both peripheral blood
and tissues. Thus, this method provided an accurate tool to study the involvement of
transduced T cells during induction and perpetuation/progression of an alloresponse.
A
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Furthermore, its high sensitivity will enable us to monitor the disappearance or
persistence of HSV-Tk-transduced T cells after GCV-induced suicide.
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MATERIALS AND METHODS
Animals
Experiments were carried out with Brown Norway (BN)/RijHsd (RT-1An) and
WAG/RijHsd (RT-1Au) rats. Animals were kept in filter top cages and received
sterilized food and acidified water ad libitum.
Bone marrow transplantation
Bone marrow cells were collected by flushing of the cavity of WAG/Rij rat tibiae and
femora with RPMI (GIBCO-BRL, Bethesda, MD). A single-cell suspension was
obtained by filtering the bone marrow through a cell strainer (Falcon; BD Biosciences
Discovery Labware, Bedford, MA). BMT recipients received an equivalent dose of
7.2 Gy of γ rays in total body irradiation (TBI), using a linear accelerator
approximately 6 hr before BMT. TBI-conditioned BN and WAG/Rij rats received a
BM transplant of 5 × 107 bone marrow cells. The BM was not T cell depleted and
contained 3% R73-positive cells, which amounted to 1.5 × 105 T cells. The BM
transplant was supplemented with 2 × 107 genetically modified T cells. The BM and
the genetically modified T cells were both of WAG origin.
Animal handling
Body weights of the animals were recorded at regular intervals as a relevant
parameter by which to monitor the onset and further course of GVHD12. At various
time points after the BMT blood samples were taken from the tail vein for flow
cytometric staining and isolation of genomic DNA. Animals were killed at day 18,
before the allogeneic transplanted animals became moribund, and a variety of tissues
were collected for isolation of genomic DNA and for immunohistochemical staining.
Cell culture
WAG/Rij rat spleen cell suspensions were made by gently pressing spleens through
sterile filter chambers (NPBI, Emmer-Compascuum, The Netherlands). Lymphocytes
were isolated from the single-cell suspension by centrifugation on a Ficoll density
gradient (d = 1.077 g/cm3) (Amersham Pharmacia, Uppsala, Sweden). Subsequently,
T cells were activated with concanavaline A (ConA, 5 µg/ml; Boehringer Mannheim,
Mannheim, Germany) in Iscove’s modified Dulbecco’s medium (IMDM; GIBCO-
BRL) supplemented with human recombinant interleukin-2 (rIL-2, 300 IU/ml;
Chiron, Amsterdam, The Netherlands), 10 % fetal calf serum (FCS; Integro,
Zaandam, The Netherlands), penicillin (100 U/ml), streptomycin (100 µg/ml), 2 mM
L-glutamine (GIBCO-BRL) and 5 × 10-5 M  2-mercaptoethanol (Merck, Darmstadt,
Germany) and incubated at 37ºC in a 5% CO2 atmosphere. After 24 hr ConA was
washed away and activated splenocytes were cultured in IMDM medium
supplemented as mentioned above.
The ecotropic packaging cell line Phoenix13 was cultured in Dulbecco’s modified
Eagle’s medium (DMEM; GIBCO-BRL) supplemented with 10 % FCS, penicillin
(100 U/ml), streptomycin (100 µg/ml), and 2 mM L-glutamine.
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Retroviral gene transduction
LZRS-TN is a for Moloney Murine Leukemia Virus (MoMLV)-based ecotropic
retroviral vector comprising the HSV-1 Tk gene, the simian virus 40 (SV40)
promoter, and the truncated human nerve growth factor receptor (NGFR) in the LZRS
vector13. The HSV-1 Tk gene, the SV40 promoter and truncated NGFR were isolated
from SFCMM-3 retroviral vector 5
Retroviral particles were generated after CaPO4 transfection of the ecotropic
packaging cell line Phoenix with 20 µg of LZRS-TN (GIBCO-BRL). Twenty-four
hours after transfection, medium was replaced by 10 ml of fresh medium. The
following day, the retroviral supernatant was harvested, filtered through a 0.45-µm
pore size filter (Millipore, Bedford, MA), and frozen. Fresh medium was added to the
cells for repeated harvesting of viral supernatant. After two or three rounds of
supernatant harvesting, Phoenix cells were cultured for 3 days in the presence of
puromycin (1 µg/ml; Sigma, St. Louis, MO) followed by 2 days in medium without
puromycin before final harvesting of retroviral supernatant.
Before transduction, non-tissue culture-treated flasks (Falcon) were coated with
RetroNectin (12,5 µg/ml; Takara Shuzo, Otsu, Shiga, Japan) for 2 hr, blocked with
2% bovine serum albumin (BSA) in phosphate-buffered saline (PBS) for 30 min, and
washed three times with PBS. Retroviral supernatant containing the LZRS-TN
retroviral vector was added to RetroNectin-coated flasks and preincubated for 1 hr.
Subsequently, ConA-activated WAG/Rij T cells were added at a concentration of 2 ×
106 cells/ml and incubated overnight. T cells were then harvested and transferred into
fresh medium. Fresh retroviral supernatant was added to flasks and preincubated for 1
hr. Harvested WAG/Rij T cells were readded to the flasks with retroviral supernatant.
After 6-12 hr this was repeated. After retroviral exposure cells were washed and
cultured in supplemented IMDM.
Flow cytometry
T cell receptor and NGFR membrane expression on WAG/Rij T cells was analysed
with the monoclonal antibodies R73 (Instruchemie, Hilversum, The Netherlands) and
20.4 (culture supernatant, a gift of MolMed, Milan, Italy), respectively. Cells were
washed in PBS containing 1% FCS. Subsequently, 20 µl of diluted monoclonal
antibody (mAb) was added to the cell pellet and cells were incubated for 30 min at
4°C. Cells were washed in PBS-1% FCS. Phycoerythrin (PE)- or fluorescin
isothiocyanate (FITC)-conjugated goat anti-mouse (GAM) IgG was added for
detection by indirect fluorescence and cells were incubated for 30 min at 4 °C. After
incubation cells were washed in PBS-1% FCS and resuspended in 0.5 ml of PBS for
analysis on a FACSCalibur flow cytometer (BD Biosciences Immunocytometry
Systems, San Jose, CA).
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Immunomagnetic purification of gene-transduced WAG/Rij T cells
The truncated NGFR gene carried by LZRS-TN encodes a nonfunctional form of the
human low-affinity receptor for nerve growth factor. NGFR is located on the cell
surface and allows selection of gene-transduced cells. Retrovirally transduced cells
were harvested on day 5, washed in PBS-1% FCS-1 mM EDTA, and labeled in with
anti-NGFR mAb 20.4 (20 µl/106 cells) for 15 minutes on ice.
Cells were washed in PBS-1% FCS-1 mM EDTA and GAM IgG microbeads (20
µl/107 cells, Miltenyi Biotec, Bergisch Gladbach, Germany) were added for 10 min at
4°C. Cells were washed in PBS -1% FCS-1 mM EDTA and NGFR-positive cells were
separated on a magnetic activated cell-sorting (MACS) column according to the
manufacturer protocol (Miltenyi Biotec). The purity of the selected population was
determined by flow cytometry after incubation with PE-conjugated GAM Ig. The total
duration of the transduction and selection procedure was 5 days and resulted on
average in 45% of the T cells expressing NGFR. The purity of the MACS-selected
population, measured by FACS, was 95%, implying that from the infused number of
2 × 107 T cells, 1 × 106 cells are HSV-Tk/NGFR negative. HSV-Tk+ T cells that are
produced according to this protocol retain their full potential to induce a lethal GVHD
in the allogeneic transplantation setting that was used6.
Immunohistochemistry
Rats were killed on day 18 after BMT, using Euthesate (CEVA Santé Animale,
Maassluis, The Netherlands). Small blocks of tissues were collected and frozen in
liquid nitrogen. Tissues were bedded into Tissue-tek (Sakura Finetek, Torrance, CA)
and slices of 6 µm were cut on a cryostat, air-dried, and fixed in acetone. Staining was
performed with a DAKO animal research kit (ARK/horseradish peroxidase [HRP])
(Dako Corporation, Carpinteria, CA, USA) with extra avidin and biotin blocking
steps, each for 15 minutes (avidin/biotin blocking kit; Vector Laboratories,
Burlingame, CA). The following antibodies were used: anti-NGFR, (20.4; 1.5 µg/ml)
and anti-T cell receptor (R73; ascites, diluted 1:60,000). Immunostaining was
followed by hematoxylin staining. Positive cells are recognized on the basis of a
brown discoloration. The percentage of positive cells was determined by estimating
the frequency of brown cells in five or six representative microscopic fields.
DNA isolation
DNA was isolated from whole blood and (transduced) ConA/IL-2 activated
splenocytes, using the QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany).
Whole blood was collected from the tail vein into sodium citrate (3.8%; 10:1[v/v])
and samples were pretreated with dextran to remove erythrocytes. Briefly, whole
blood was diluted with 3 volumes of PBS and incubated with 1 volume of 5% dextran
solution (Sigma) at room temperature. After 30 minutes the upper phase was collected
and centrifuged, and the pellet was resuspended in 200 µl of PBS.
Organs were dissected from the animals and representative specimens were taken.
Bone marrow was collected by flushing the femoral shaft with medium. DNA was
isolated from tissue and bone marrow, using the QIAamp DNA Mini Kit (Qiagen).
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Real-time quantitative PCR
The number of HSV-Tk/NGFR-transduced lymphocytes in the peripheral blood and
in various organs were quantified by a real-time PCR analysis14,15 using the 5’
nuclease assay (TaqMan; Applied Biosystems, Fostercity, CA)16 and the ABI/PRISM
7700 sequence detector (Applied Biosystems)17.
Real-time PCR was performed in a total volume of 50 µl with 1 × buffer A, 1.25 U of
DNA polymerase (AmpliTaq Gold; Applied Biosytems), 250 µM dNTPs, primers at
300 nM and dual-labeled fluorogenic internal probes at 100 nM. Samples were heated
for 10 min at 95°C and amplified for 45 cycles of 15 seconds at 95°C and 60 seconds
at 60°C. The proviral primers and probe sequences chosen specifically amplify a part
of the U3 region of the long terminal repeat (LTR) of the integrated proviral DNA.
Provirus primer and probe sequences were as follows: forward, 5’-AAA GAC CCC
ACC TGT AGG TTT G-3’; reverse, 5’-TTC CTG ACC TTG ATC TGA ACT TCT
CT-3’; probe, 5’-TET (tetrachloro-6-carboxy-fluorescin)-TTA AGT AAC GCC ATT
TTG CAA GGC ATG-TAMRA (6-carboxy-tetramethyl-rhodamine)-3’. Rat
preproalbumin (derived from the messenger RNA sequence for rat preproalbumin18,
GenBank accession number V01222) primer and probe sequences were as follows:
forward, 5’-AGT GAG CGA GAA GGT CAC CAA-3’; reverse, 5’-CGT CAA CTG
TCA GAG CAG AGA AA; probe, 5’-TET-CCG TCT TTC CAC CAA GGA CCC
ACT ACA-TAMRA-3’. Amplification efficiencies were determined by specific
amplification of the proviral amplicon as well as the rat preproalbumin locus, using a
serial dilution of transduced T cell DNA in distilled H2O, ranging from 500 ng to 5 pg
of genomic DNA. Initial template concentrations were related to cycle threshold (Ct).
The difference in Ct values (∆Ct) for each dilution was constant over a dynamic
template concentration range of 5 logs, demonstrating that the amplification
efficiencies in both reactions were equal. Because the Ct is proportional to the initial
template concentration, the ∆Ct relates the amount of transduced cells (Ct of proviral
DNA) to the total amount of cells used in the amplification reaction (Ct of rat
preproalbumin). This normalized ∆C t value was used for accurate relative
quantification of Tk-transduced cells using the comparative Ct method (ABI PRISM
7700 Sequence Detection System: User Bulletin #2; Applied Biosystems). The
percentage of Tk-transduced cells was determined by reference to a calibrator DNA
sample of purified HSV-Tk/NGFR-transduced T cells (purity ≥ 95%). For peripheral
blood absolute numbers of HSV-Tk/NGFR-positive T cells per milliliter were
calculated by correction for white blood cell (WBC) counts. The sensitivity of the
PCR assay was between 10-4 and 10-5.
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RESULTS
Induction of GVH reactivity
To study the role of HSV-Tk-transduced T cells in GVHD after allogeneic BMT, we
induced alloreactivity in BN rats by injection of HSV-TK/NGFR-transduced
WAG/Rij T cells simultaneously with WAG/Rij BM after lethal irradiation.
Syngeneic WAG/Rij rats received the same treatment to study dissemination of HSV-
Tk+ T cells in peripheral blood and tissues in the absence of allostimulation. Body
weights of the transplanted rats were measured at regular time intervals after BMT as
a parameter to determine the onset and progression of GVH reactivity (Fig. 1).
Figure 1. Relative body weights of allogeneic and syngeneic transplanted
rats after BMT. Body weights of allogeneic (filled squares) versus
syngeneic (open squares) transplanted rats were measured and plotted as
percentage of body weight at day 0. Data repesents mean of four animals
per group ± SE.
Allogeneic as well as syngeneic recipients showed an initial drop in body weight due
to the BMT procedure. The body weights of the allogeneic recipients decreased from
day 7 onward, which continued until day 18, when animals were killed for analysis of
tissue architecture and T cell infiltration. In contrast, syngeneic recipients regained
normal weight and recovered without complications. From day 12 onward, allogeneic
recipients developed clinical symptoms of GVHD, such as rash on paws and snout,
hunched posture, ruffled fur, hair loss, and diarrhea, which gradually increased in
severity. Furthermore, resection of tissues showed macroscopic reduction in liver and
spleen size. The alloreactive responses that occur in this model enable us to monitor
the amount of HSV-Tk-transduced T cells and their in vivo distribution during GVHD
development.
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Quantification of HSV-Tk/NGFR-transduced T cells in the peripheral blood
We determined the percentage and absolute numbers of HSV-Tk/NGFR-transduced T
cells in peripheral blood of rats after allogeneic and syngeneic BMT. Blood samples
were taken at regular time intervals for flow cytometric and real-time PCR analysis.
FACS analysis showed that the majority of T cells in the circulation were HSV-Tk
positive, that is, on days 7, 10, and 14 these values were, 63, 69, and 44% for the
allogeneic transplanted group versus 70, 79, and 56% for the syngeneic group.
Analysis of the absolute number of HSV-Tk/NGFR T cells in the peripheral blood of
allogeneic and syngeneic recipients by either FACS or real-time PCR revealed that
there was no difference through day 10 (Fig. 2A and B).
Figure 2. Absolute number of HSV-Tk/NGFR T cells (× 106/ml) in peripheral blood of allogeneic
and syngeneic transplanted rats after BMT, measured by real-time PCR (A) and flow cytometry
(B). Data represents average values of four animals per group ± SEM.
Thereafter, the number of HSV-Tk/NGFR T cells in rats that had received an
allogeneic BMT increased, whereas the number of HSV- Tk+ T cells in syngeneic
recipients remained at a continuous level. The increase of HSV-Tk+ T cells from day
10 after allogeneic BMT correlates with the decrease in body weight, which is
considered to be an early sign of GVHD (Fig. 1). In addition, Fig. 2 shows that
quantification of HSV-Tk/NGFR T cells in peripheral blood by real-time PCR agreed
well with flow cytometric analysis. However, shortly after BMT flow cytometric
analysis could not be performed because of the low WBC numbers due to a
transplantation-related aplastic phase (Fig. 2B). In conclusion, these data show that
GVH reactivity in allogeneic recipients is, at least in part, exerted by HSV-Tk-
transduced T cells, and that this alloreactivity is reflected by an increase in these cells
in the peripheral blood.
Involvement of HSV-Tk/NGFR-transduced T cells in GVH-induced lesions:
Infiltration of T cells and HSV-Tk/NGFR+ T cells in tissues
To examine the involvement of HSV-Tk/NGFR-transduced T cells in GVH-induced
lesions, we examined the localization of T cells and HSV-Tk/NGFR-transduced T
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cells in frozen tissue sections of a representative allogeneic transplanted rat, 18 days
after BMT, by immunohistochemical staining. T cell localization in the allogeneic
transplanted rat was compared with that in a syngeneic transplanted WAG/Rij and
untransplanted BN rat. From each rat, eight different tissues were investigated, that is,
spleen, lymph node, tongue, skin, intestine, liver, lung, and kidney. In allogeneic
transplanted rats, normal tissue architecture was severely damaged, whereas tissue
architecture in syngeneic transplanted rats was intact and showed post-BMT
histological recovery of lymphoid tissues. An example of the latter is found in the
spleen of the syngeneic transplanted rat in which a follicle structure is recognizable
which contains transduced as well as nontransduced T cells (Fig. 3). In the allogeneic
transplanted rat there was a clear infiltration of both transduced and nontransduced
allogeneic T cells in the various tissues, particularly in tongue, skin, intestine, lymph
node, and spleen. In tongue and skin, we observed a predominant T cell localization
in the subepithelial regions. Notably, in GVHD target tissues the majority of the T
cells were HSV-Tk/NGFR positive. In lung, and kidney T cells were present at lower
frequencies, and HSV-Tk/NGFR-positive cells were rarely found (data not shown).
These results show that tissue damage in allogeneic transplanted rats coincides with a
clear T cell infiltration, including HSV-Tk/NGFR-transduced cells, illustrating the
involvement of transduced T cells at the site of GVHD-induced lesions.
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Figure 3. Immunohistochemical analysis of the infiltration of T cells and HSV-Tk/NGFR-
transduced T cells in spleen, lymph node, and tongue (A ), and skin and intestine (B ), of
allogeneic and syngeneic transplanted rat 18 days after BMT. T cells were stained with R73 mAb,
and NGFR-expressing cells were stained with 20.4 mAb. Positive cells show a brown color.
Involvement of HSV-Tk/NGFR-transduced T cells in GVH-induced lesions:
Quantification of HSV-Tk/NGFR+ T cells in the tissues
To estimate the amount of T cell infiltration in GVH-induced lesions, we determined
the percentage of R73-positive cells (total T cells) as well as the number of 20.4-
positive cells (HSV-Tk-transduced T cells) after immunohistochemical staining.
However, exact quantification was complicated by the fact that GVH-induced cell
damage leads to aspecific background staining that is particularly disturbing at low
levels of T cell infiltration (i.e., less than 1-2%). To accurately quantify the amount of
HSV-Tk/NGFR T cells in the various organs, we performed real-time PCR analysis
on genomic DNA of representative samples. Beside the aforementioned tissues, brain
and bone marrow were also included. Figure 4 shows that in all organs examined the
percentage of HSV-Tk/NGFR-transduced T cells was higher in the allogeneic
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transplanted animals compared with syngeneic transplanted rats. High percentages of
HSV-Tk/NGFR T cells were found in tongue, skin, intestine, spleen and lymph node.
Percentages below 5% were found in kidney, liver, brain and BM. The high ratio of
allogeneic over syngeneic HSV-Tk/NGFR T cells in liver and bone marrow was
suggestive of alloreactivity of these cells in these tissues.
Figure 4. Percentage of HSV-Tk/NGFR T cells in various tissues of allogeneic (gray columns)
and syngeneic (open columns) transplanted rats 18 days after BMT, measured by real-time
PCR. Data represent average values of four animals per group ± SEM.
Figure 5 shows a comparison of data obtained through immunohistochemical and
real-time PCR analysis for the same allogeneic and syngeneic transplanted
representative rats. BN and WAG/Rij untransplanted rats were included as controls.
In the syngeneic transplanted rat there was no discrepancy in the low levels of HSV-
Tk+ T cells found by immunohistochemical and real-time PCR analysis. In the
allogeneic transplanted rat a higher percentage of HSV-Tk positive T cells was found
by real-time PCR analysis in spleen, tongue, kidney and lung. The percentage of
HSV-Tk-positive T cells determined by real-time PCR did not exceed the percentage
of total T cells as determined by immunohistochemical staining, except in lung.
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Figure 5. Percentage of T cells and HSV-Tk/NGFR T cells in various tissues of allogeneic and
syngeneic transplanted rats 18 days after BMT, and untransplanted BN and WAG/Rij rats.
Immunohistochemical data for T cells (gray bars) and HSV-Tk/NGFR T cells (open bars) and
real-time PCR data for HSV-Tk/NGFR T cells (solid circles) are given. Immunohistochemical
data are given for one representative rat per group; real-time PCR data represents percentages
of the same rats as used for immunohistochemical staining ± SD. Dotted line delineates 1%
positivity.
Low percentages of (HSV-Tk+) T cells could not be quantified accurately by
immunohistochemical analysis. Notably, immunohistochemical data showed that T
cells in the allogeneic transplanted group predominantly were HSV-Tk/NGFR-
transduced T cells. Only in typical lymphoid organs, for example, spleen, lymph
IN VIVO ALLOREACTIVITY OF RETROVIRUS-TRANSDUCED T CELLS
                                                                                                                                                      
70
nodes and in mucosa-associated lymphoid tissue (MALT; intestine) a concomitant
high percentage of nontransduced T cells was found.
Taken together, these data show that in allogeneic transplanted rats there was an
increased infiltration of HSV-Tk+ T cells in all tissues examined, especially in spleen,
lymph node, tongue, skin, and intestine. Furthermore, in these rats there is a
concurrent increase of non-transduced T cells in lymphoid and ‘lymphoid associated’
tissues. Finally, we show that real-time PCR analysis provides additional information
in terms of accurate quantification, especially of low percentages, of transduced cells
in tissues.
DISCUSSION
In the present report we monitored the involvement of HSV-Tk-transduced cells in the
development of GVHD. Extensive manipulation of cells that have undergone ex vivo
gene transfer by retroviral transduction could potentially modify their immune
repertoire and their activation status, thus affecting their in vivo survival and
function6,19. We have shown that HSV-Tk-transduced T cells are capable of exerting
alloreactive responses in a rat model in which T cell alloresponses were induced after
allogeneic BMT. HSV-Tk alloreactivity was demonstrated in peripheral blood, where
a sudden increase in the amount of allogeneic HSV-Tk+ T cells, that was not observed
in syngeneic HSV-Tk+ T cells, coincided with the onset of progressive weight loss
and closely preceded the development of clinical symptoms of GVHD. Furthermore,
in all tissues examined higher percentages of allogeneic HSV-Tk+ T cells were found
in allogeneic animals than in syngeneic controls. This increase is likely to be the
result of alloreactivity-induced proliferation, which is much more rapid than the
increase seen in the syngeneic animals. In the latter situation the increase is probably
a normal response to homeostatic signals and is in agreement with earlier observations
by Maury et al., who used carboxyfluorescein diacetate succinimidyl ester (CFSE)-
labeled T cells in a semi-allogeneic/syngeneic transgenic mouse model20. Notably, in
GVHD target organs most T cells were HSV-Tk positive. In skin and tongue
alloreactive T cells showed specific localization patterns in subepithelial regions,
indicating specific homing to target sites.
Genetically modified T cells were quantified in blood and tissues by FACS, and by
immunohistochemical and quantitative PCR analyses. This enabled a comparison of
the utility of these techniques for monitoring alloreactivity of transduced cells in vivo.
In general, the data obtained by these techniques correlated, and confirmed their
validity. The use of immunohistochemical staining of tissues for quantification is in
general difficult and could be done with an accuracy interval of only 1 to 20%. In
contrast, genomic DNA samples for rapid real-time PCR analysis could easily be
obtained, and quantification could be performed accurately, especially in samples
with low percentages of HSV-Tk+ T cells. Immunohistochemical staining, however,
provided direct evidence of concentrated localization of alloreactive HSV-Tk+ T cells
in tissues undergoing a GVH reaction, that is, tongue, intestines, and skin. Also, the
typical GVH-induced loss of tissue architecture was evident. This implies that HSV-
Tk-transduced T cells indeed have retained their potential to induce a GVH reaction
and presumably also a GVL reaction. However, quantification of low percentages of
transduced T cells was complicated by low levels of false positive staining cells
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among the controls (Fig. 5). FACS analysis was performed on peripheral blood, BM,
and tissues from which suspensions could be made (lymph node and spleen). Notably,
with FACS analysis of cell suspensions, as with immunohistochemical quantification,
problems were encountered concerning GVH-induced damage of cells. Furthermore,
FACS analysis required the coexpression of an additional target protein sequence,
preferably on the cell surface. Paquin et al. 21 have described the use of a chimeric
green fluoresecent protein (GFP)-HSV-Tk transgene that can serve as a bifunctional
suicide and reporter transgene, circumventing the need for a specific mAb and
concomittant coexpression.
Finally, detection and quantification of less than 1% transduced cells by either flow
cytometry or by histochemical analysis is problematic. Maddens et al. 22 have
described the use of a competitive PCR method for the quantification of HSV-Tk- and
neomycin resistance gene-expressing cells. However, with this approach transduced
target cells are required to contain either of the genes, whereas we designed primers
and probes for Moloney murine leukemia virus (MoMLV)-specific DNA sequences.
This enables the detection of cells marked with any MoMLV-derived retroviral
vector, in contrast to the use of marker gene-specific sequences to detect and quantify
labeled cells23-26. Furthermore, competitive PCR requires total DNA quantification by
UV spectrophotometry, and is not totally accurate. Taken together, we have shown
that real-time PCR enables fast, accurate, sensitive, and specific quantification of
HSV-Tk-transduced T cells in both blood and tissues.
Our data show that the involvement (quantity and biodistribution) of HSV-Tk+ T cells
in in vivo alloreactivity can thus accurately be monitored. Animal models provide the
means for extensive monitoring of in vivo survival and dissemination of adoptively
transferred genetically engineered cells and to ascertain cause-effect relationships. In
a currently ongoing study, using the same allogeneic rat transplantation model
described here, we are monitoring the fate of HSV-Tk-transduced T cells while a
developing GVHD is being controlled by treatment with ganciclovir. In human
clinical studies HSV-Tk-transduced T cells have been used in the treatment of
GVHD/modulation of GVH alloresponses. Bonini et al. showed that GVH reactivity
could develop in patients who received a donor lymphocyte infusion (DLI) for the
treatment of relapse after a previous bone marrow transplant8. They showed that
GVHD could effectively be controlled by GCV treatment. However, there is no direct
proof that the GVH reactivity was predominantly caused by the transduced T cells
and that the GCV was responsible for the GVHD control. Tiberghien et al. applied
suicide gene therapy using low numbers of HSV-Tk-expressing T cells soon after
HLA-identical BMT. They found no acute toxicity, the gene-transduced cells
persisted in circulation, and they observed GCV-sensitive T cell alloreactivity27. Our
approach enables a more detailed insight in the fate and behaviour of infused labeled
T cells, using peripheral blood samples and (small) tissue biopsies28.
Beside genetic engineering of allogeneic lymphocytes, there is an increased focus on
the modification of autologous lymphocytes and (other) immune-competent cells in
the treatment of, for example, autoimmunity29,30, acquired immune deficiency
syndrome (AIDS)31,32, and cancer33,34. Although a variety of transgenes are used in
these studies, most of the vectors used for transduction contain a MoMLV backbone.
This makes our PCR procedure widely applicable for the detection and quantification
of transduced cells.
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In summary, we show that the amount of genetically engineered cells and their
distribution can be monitored by a variety of methods, each with its own specific
advantages and disadvantages. The PCR-based method is most sensitive and specific
and also most widely applicable. This enables study of the involvement of labeled
cells in in vivo alloreactivity, the response of HSV-Tk-transduced T cells to GCV-
induced suicide therapy, and specific dose-effect relationships of genetically
engineered lymphocytes in a broad range of preclinical and clinical studies.
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ABSTRACT
Donor lymphocyte infusion (DLI) can induce complete remission in patients with
leukemia who relapsed after allogeneic stem cell transplantation (SCT). Lymphocyte
chimerism of patients at the time of infusion might be related to response to this form of
immunotherapy. Here, we studied clearance of donor T cells that were infused after
SCT, using a well-established rat bone marrow transplantation (BMT) model. Rats
receiving reduced intensity conditioning (RIC) transiently repopulated with donor
hematopoietic cells after BMT. Thereafter, hematopoiesis reverted to full host origin
within seven weeks. Survival time of retrovirally marked donor T cells after infusion in
these rats was compared to survival time of infused T cells in recipients that showed
stable donor hematopoiesis after standard intensity conditioning (SIC). Infused donor T
cells were completely cleared in rats engrafted with host-derived hematopoietic cells
after transient engraftment with donor cells. In contrast, significant numbers of infused
donor T cells survived in rats that developed durable donor hematopoiesis. The rapid
elimination of transferred donor T cells in rats repopulated with hematopoietic cells of
host origin suggests that this clearance is an active process mediated by recipient T cells,
likely sensitized in vivo. Furthermore, this study clarifies a mechanism that may
contribute to unresponsiveness to DLI in relapsed patients with hematopoiesis that
reverted to host origin after SCT.
INTRODUCTION
LLOGENEIC STEM CELL TRANSPLANTATION (SCT) can efficiently cure leukemia
patients. However, the number of patients who relapse after SCT is significant.
Relapsed patients can be successfully treated by donor lymphocyte infusions (DLI)1-3.
However, a significant percentage of patients fail to respond to this therapy. Recently,
it has been shown that conversion to complete donor chimerism by DLI diminish the
relapse rate4-6. Childs et al., described that patients treated for solid tumors with SCT
after a non-myeloablative conditioning or reduced intensity conditioning (RIC) only
show tumor remission after hematopoietic conversion to full donor chimerism7.
Previously, we observed that a high percentage of T cells of host origin in the
peripheral blood of relapsed patients at the time of DLI significantly correlates with
non-responsiveness8. Absence of graft-versus-host disease (GVHD) in these patients
suggests that infused donor lymphocytes were reactive neither to leukemia cells nor to
normal tissues. Recently, Blazar et al. showed that host T cells inhibit the
development of GVHD induced by DLI using a murine bone marrow transplantation
(BMT) model9. However, donor-derived regulatory T cells developing post-BMT may
A
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also be involved in suppression of GVHD after DLI, probably by induction of
tolerance10. The mechanisms by which either donor-derived or recipient-derived T
cells contribute to tolerance or non-responsiveness of infused donor lymphocytes are
not clearly demonstrated yet. We hypothesized that recurrent T cells of recipient
origin, present at the time of DLI, inhibit alloreactivity of infused donor lymphocytes
by eliminating these cells11. To study this hypothesis we used an allogeneic BMT
model in rats. BN rats received bone marrow of WAG/Rij rats together with a RIC
regimen. BMT recipients initially engrafted with considerable numbers of donor-
derived white blood cells (WBC) followed by engraftment with host WBC.
Engraftment was accompanied with severe GVHD resulting in survival of
approximately 30% of the rats. Host WBC recurred in surviving rats followed by
complete host hematopoiesis.
In this study, we questioned the potential of infused donor T cells to achieve an
immune response in rats with recurrent host hematopoiesis after BMT. Therefore, we
infused retrovirally marked donor T cells and compared the percentage of donor T
cells that survive in blood and tissues after infusion in rats repopulated with either
recurrent host or persistent donor WBC. The results show that within 3 days, infused
T cells are rejected in rats with recurrent host hematopoiesis after BMT. In contrast,
significant numbers of retrovirally marked donor T cells persist after infusion in
recipients that developed stable donor hematopoiesis after BMT.
MATERIALS AND METHODS
BMT and DLI
BN rats (BN/RijHsd, RT-1An) and WAG/Rij rats (WAG/RijHsd, RT-1Au) were
transplanted with bone marrow cells of WAG/Rij rats. Rats were obtained from
Harlan (Horst, The Netherlands) and kept in filter top cages and given sterilized food
and acidified water. The RIC or non-myeloablative conditioned group (n=17)
received an intra peritoneal injection of 1 ml rabbit anti-rat lymphocyte serum (Sanbio
BV, Uden, The Netherlands) 5 days before BMT. In addition, tacrolimus (FK506, 1
mg/kg, Fujisawa GmbH, München, Germany) was intramuscular injected daily, from
day –1 until day +10 of BMT, and total body irradiation (TBI) with low dose (4.3 Gy)
was given 6 hours before BMT. SIC or myeloablative conditioned rats received high
dose TBI (7.2 Gy) without further treatment before allogeneic (n=5) or syngeneic
(n=5) transplantation. Marrow cells of WAG/Rij donors were collected by flushing
femurs and tibiae with RPMI (Gibco BRL). All rats received 5×107 WAG/Rij bone
marrow cells via injection into the tail vein.
RIC treated BN rats received DLI after they recovered from GVHD and developed
full host hematopoiesis (day 49 post BMT). SIC treated BN and WAG/Rij rats
repopulated with WAG/Rij blood cells were infused 21 days after BMT. All
transplanted rats and 4 untreated BN rats received DLI with 2×107 retrovirally marked
WAG/Rij T cells via injection into the tail vein.
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Retroviral transduction of WAG/Rij splenic lymphocytes
LZRS-TN, a MoMLV-based retroviral vector comprising the SFCMM-3-derived
Herpes Simplex Virus (HSV)-1 thymidine kinase (Tk) gene, the SV40 promoter and
the truncated human nerve growth factor receptor (NGFR)12, cloned into the LZRS
vector13, was used to transduce WAG/Rij splenic T cells as described previously14.
Cells expressing NGFR were purified (purity >95%) 4 days after ConA (5 mg/ml)
activation as described14, and infused 1 day later.
Flow cytometry
Rat MHC haplotype of peripheral WBC was analyzed by flow cytometry (Epics XL,
Beckman Coulter, Fullerton, CA, U.S.A.) using U9F4 and OX27-FITC mAb to
determine WAG/Rij and BN origin, respectively. RPE-conjugated F(ab’)2 fragments
of goat anti-mouse IgM (DAKO, Glostrup, Denmark) were added for detection of
U9F4-positive cells. The percentage transduced cells was determined by flow
cytometry after staining with NGFR specific mAb 20.4. T cells were measured by
flow cytometry using fluorescent conjugated mAb directed against αβ-TCR, CD4 and
CD8 (R73, W3/25 and OX-8, respectively; Immunotech, Marseille, France).
DNA isolation and real-time quantitative PCR
Whole blood was collected from the tail vein into sodium citrate (3.8%; v/v 10:1).
Cell samples were pre-treated with dextran to remove erythrocytes. DNA from WBC
and transduced T cells was isolated using the QIAamp DNA Blood Mini Kit (Qiagen,
Hilden, Germany). DNA was isolated from representative specimens of spleen, liver
and lungs, and from cell suspensions of pooled lymph nodes, using the QIAamp DNA
Mini Kit (Qiagen). The number of transduced T cells in peripheral blood and various
organs after DLI was quantified by real-time PCR analysis using the 5’ nuclease assay
(Taqman) and the ABI/PRISM 7700 sequence detector (Perkin-Elmer Applied
Biosystems, Fostercity, CA, U.S.A.) as described previously15. DNA of purified
transduced T cells (95% pure) was used to determine amplification efficiencies.
Genomic DNA was serially diluted in dH2O, ranging from 750 ng to 75 pg. The
proviral amplicon as well as the rat preproalbumin locus were amplified. Initial
template concentrations were related to cycle threshold (Ct). The difference in Ct
(∆Ct) for each dilution was constant over a dynamic template concentration range of 5
logs, demonstrating that amplification is equally efficient in both reactions, resulting
in detection threshold of 0.01% labeled cells.
RESULTS
Analysis of GVHD and WBC chimerism after allogeneic BMT
Body weight (BW) of the animals was recorded after BMT as parameter to measure
the onset and progression of GVH reactivity. BN rats that received the RIC regimen
recovered from the BMT procedure from day 5 onward, as shown by increase of BW.
At day 23 after BMT, BW of all rats decreased rapidly, which coincided with other
symptoms of severe GVHD. Sequentially, the majority of rats died of GVHD or
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became moribund and therefore killed (< 34 days after BMT). Thereafter, surviving
rats showed rapid increase of BW after day 34, which indicated recovery from
GVHD. Figure 1 shows BW of surviving rats. BW of rats that did not survive was
within the range of BW of surviving rats (data not shown). In contrast, BN rats that
received standard conditioning regained normal BW within 21 days after BMT after
transient weight loss due to the transplantation procedure (data not shown).
Figure 1. BW and WBC chimerism after BMT with RIC regime. BW () of animals that
received BMT with a RIC regimen dropped between day 23-26 demonstrating
development of severe GVHD. Percentage of donor WBC WAG/Rij () increased after
BMT and peaked at day 26. Thereafter, all rats reverted to autologous hematopoiesis
Severity of GVHD showed coincidence with peak levels of donor WBC. Reversion to
host hematopoiesis in surviving rats was followed by recovery of GVHD, shown by
increase of BW. Data represents mean values for surviving rats (n=5) ± SEM.
The genetic origin of WBC repopulated in rats that received allogeneic BMT was
analyzed. Rats treated with the RIC regimen prior BMT showed an increase of the
percentage of donor WBC until day 26 after BMT (Figure 1). Thereafter,
hematopoiesis of all surviving rats reverted to host origin (complete at day 49). WBC
of BN rats that received the standard conditioning regimen converted to donor origin,
ranging from 94% to 97%, within 16 days (data not shown).
These data demonstrate that allogeneic BMT with RIC results in development of
severe GVHD. Rats show reversion of donor hematopoiesis to host hematopoiesis
concurrent with GVHD. In contrast, SIC before BMT results in stable donor
hematopoietic reconstitution without symptoms of GVHD. These observations
suggest that host hematopoietic cells that survived the conditioning regime can
enhance the occurrence and severity of GVHD. Disappearance of donor-derived
alloreactive cells seems required to overcome GVHD resulting in survival of the rats.
Recurrent host-derived WBC are probably responsibly for disappearance of these
alloreactive donor WBC.
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Analysis of T cell numbers in peripheral blood after DLI.
Rats received DLI after transplantation with WAG/Rij bone marrow cells. DLI was
given to rats at the time that BW reached pre BMT levels. Therefore, BN rats treated
with RIC and BMT received DLI at day 47, i.e. at the time they recovered from
GVHD. BN rats and WAG/Rij rats treated with SIC and BMT, and untreated BN
received DLI at day 21. All rats were infused with 2×107 marked WAG/Rij T cells. At
the time of DLI, the number of T cells in BN rats that reverted to host origin after
allogeneic BMT with RIC was hardly lower than T cell numbers in untreated BN rats
(2.2×106/ml, versus 4.2×106/ml). Allogeneic transplanted BN rats repopulated with
WAG/Rij T cells, showed numbers of T cells than syngeneic transplanted WAG/Rij at
the time of DLI (0.6×106/ml versus 0.7×106/ml). T cell numbers in rats with WAG/Rij
hematopoiesis was lower than in rats with BN hematopoiesis. However, T cell
numbers reflected the amount of T cells in untreated WAG/Rij and BN rats.
After DLI the total amount of T cells in the peripheral blood of rats was monitored. T
numbers cells slightly increased after DLI in rats that reverted to host origin after
allogeneic BMT (Figure 2A). T cell numbers in rats treated with allogeneic BMT and
SIC did not change after DLI (Figure 2A). In addition, syngeneic transplanted rats and
rats untreated before DLI showed stable T cell numbers after DLI (Figure 2B).
These data show that at the time of DLI, T cell restitution in rats that recovered from
severe GVHD after BMT with RIC is comparable with that in rats that did not
develop GVHD after BMT with SIC. Furthermore, the data show that DLI results in a
slight and transient increase of T cell numbers in BN rats with WBC that reverted to
autologous hematopoiesis after BMT, and do not affect T cell numbers in other
groups of rats treated with DLI.
Figure 2. T cell counts after DLI. The percentage of TCR positive cells was measured by flow
cytometry. Numbers of T cells per ml blood were calculated from WBC numbers. (A), BN rats
that reverted to autologous hematopoiesis after transient mixed chimerism () showed a slight
increase of T cells after DLI. T cell numbers in BN rats with stable donor hematopoiesis did not
change after DLI (). (B) T cell numbers in syngeneic WAG/Rij transplanted rats (), and BN
rats that received no treatment for DLI () are stable after infusion. All rats received 2×107
marked WAG/Rij T cells. Data represents mean values ± SEM of 5 rats except the BN
nontransplanted rats (n=4).
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In vivo survival of infused T cells in peripheral blood
Retrovirally labeled WAG/Rij T cells (2×107) were infused to determine in vivo
survival after injection. BN rats that reverted to autologous hematopoiesis (BN)
showed rapid clearance of infused labeled WAG/Rij T cells in blood (Figure 3A).
Within 24 hours, the amount of infused T cells declined from 60×103/ml (4 hours post
DLI) to 20×103/ml and reached limit of detection (<100 cells/ml) within 2 days. In
contrast, BN rats with stable WAG/Rij hematopoiesis after BMT tolerated infused
labeled donor T cells (Figure 3A). WAG/Rij T cells persisted during the follow up
period (20 days). Comparable amounts of labeled T cells were found in blood of
syngeneic transplanted WAG/Rij rats after infusion (Figure 3B). Untreated BN rats
rapidly rejected labeled WAG/Rij T cells after infusion (Figure 3B). The kinetics of
WAG/Rij cell clearance in allogeneic transplanted BN rats that reverted to recipient
WBC origin showed similar kinetics than that observed in non-transplanted BN rats.
This suggests that clearance of infused WAG/Rij T cells is an active process in both
untreated BN rats and BN rats with recurrent autologous hematopoiesis after BMT.
Figure 3. Survival of infused T cells in peripheral blood. The amount of retrovirally labeled
WAG/Rij T cells was measured at regular intervals after infusion. (A) Marked WAG/Rij T cells
rapidly decline after infusion in BN rats that reverted to autologous hematopoiesis after transient
mixed chimerism () in contrast to marked T cells in BN rats that had developed stable donor
hematopoiesis (); (B) Marked WAG/Rij T cells survive partially in syngeneic transplanted
WAG/Rij rats () and disappeared rapidly in BN rats that received no previous treatment ().
All rats received 2×107 marked WAG/Rij T cells. Numbers of labeled T cells per ml blood were
calculated from WBC numbers. Data represents mean values ± SEM of 5 rats except the BN non-
transplanted rats (n=4).
In vivo survival of infused T cells in tissues
Rats were killed 20 days after DLI to study the persistence of donor T cells after
infused in a number of organs. DNA was isolated from representative specimens of
spleen, liver and lung, and cell suspensions of pooled lymph nodes. Figure 4 shows
that all examined organs of allogeneic transplanted BN rats with hematopoiesis that
reverted from donor to host after BMT did not contain labeled T cells above detection
limit (< 0.01%). In contrast, significant percentages of labeled donor T cells were
present in the organs of BN rats that repopulated with donor-derived hematopoietic
cells after BMT (Figure 4). The percentages labeled cells measured in the organs of
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these animals were comparable or even higher than found in the organs of syngeneic
transplanted WAG/Rij rats (Figure 4). Labeled WAG/Rij T cells were not detectable
in untreated BN rats 20 days after infusion (Figure 4).
Figure 4. Survival of infused T cells in tissues. The percentage of labeled cells in spleen,
lymph nodes, liver and lungs at day 20 post DLI was determined. Infused marked WAG/Rij
T cells could not be detected in tissues of BN rats that reverted to autologous
hematopoiesis () and in nontransplanted BN rats () (threshold of detection = 0.01%).
Significant percentages infused marked WAG/Rij T cells survive in rats that repopulated
with WAG/Rij hematopoietic cells after BMT () and syngeneic transplanted rats (). All
rats received 2×107 marked WAG/Rij T cells. Data represents mean values ± SEM of 5 rats
except the BN untransplanted rats (n=4). All groups consisted of 5 rats, except the BN non-
transplanted rats (n=4). The percentage of LZRS-TN transduced cells was determined by
reference to a calibrator DNA sample of purified HSV-Tk/NGFR transduced T cells (purity
≥ 95%) after a real-time PCR analysis, using the 5’ nuclease assay (Taqman) and the
ABI/PRISM 7700 sequence detector. Numbers of labeled T cells per ml blood were
calculated from WBC numbers. Data represents mean values ± SEM.
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These observations show that labeled donor T cells infused after BMT migrate to
tissues. Moreover, we observed a remarkable difference in the number of T cells
surviving in the tissues of DLI recipients with either BN or WAG/Rij hematopoiesis.
The absence of marked donor lymphocytes in transplanted rats with hematopoietic
cells that reverted to recipient 20 days after infusion suggests an active elimination of
these cells, likely exerted by in vivo primed recipient-derived T cells.
DISCUSSION
In this study we show that infused donor T cells are rapidly removed in rats that
regain host hematopoiesis after a transient engraftment with donor cells. The fast
kinetics of disappearance in rats repopulated with host WBC and the much slower
disappearance in rats repopulated with donor WBC suggest that alloreactive host T
cells reject infused donor cells. Recently, Blazar et al. have demonstrated in a mouse
model that host T cells can suppress alloreactivity induced by DLI. They suggest that
host T cells are capable of generating anti donor cytotoxic activity resulting in an
impaired ability of DLI to induce GVHD, likely due to elimination of infused donor
cells9. Strong alloreactivity resulting in rapid elimination of allogeneic lymphoid cells
after infusion in untreated mice has been previously described16,17 and is confirmed by
our findings in untreated BN rats that received lymphocytes of WAG/Rij rats.
Rejection of infused donor T cells in rats engrafted with host T cells, as we have
clearly shown here, may reveal one of the mechanisms that limit the efficacy of DLI
in cancer therapy.
We observed in our rat model that recurrence of host hematopoiesis after BMT
coincide with the onset of severe GVHD. In contrast, no sign of GVHD was observed
in rats that developed full donor hematopoiesis after BMT with SIC. These
observations suggest that recurrent host hematopoietic cells may activate donor T
cells and thereby induce severe GVHD. A prominent role of host antigen presenting
cells (APC) in inducing GVHD has been demonstrated previously18. Mapara et al.
showed that host APC can enhance alloreactivity directed against leukemia cells19.
Moreover, Shlomchik et al. showed that inactive host APC (MHC class I negative)
present after BMT prevent development of GVHD. Although MHC class I positive
donor-derived APC are present at that time these cells could not induce GVHD,
showing that host APC are responsible for initiating GVHD20. Auffermann-Gretzinger
et al. showed that blood dendritic cells (DC) of host origin are present during a short
period after SCT in humans. The majority of DC (80%) is of donor origin 14 days
after SCT21. However, preterminal host DC present in irradiated mice during a short
period after BMT can efficiently trigger donor T cells before these DC disappear as
shown by induction of GVHD22.
Rats receiving RIC and BMT in our transplantation model, suffered severely of
GVHD and rats that survived GVHD showed conversion of hematopoiesis from
mixed to full host origin. This conversion started coincidently with morbidity and
mortality of GVHD. These observations suggest that strong alloreactivity can occur
during hematopoietic chimerism and may be exerted by both donor and host
lymphocytes. The results of this two-way alloreactivity may be contrary.
Alloreactivity that is dominated by donor-derived T cells may result in death of rats
by GVHD. Alloreactivity that becomes dominated by host-derived T cells may
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eliminate donor cells including alloreactive T cells and thereby overcome GVHD.
Successively, these allogeneic activated host T cells may be responsible for rejection
of labeled donor T cells after infusion.
We demonstrated in our rat model that MHC class I alloreactive host T cells eliminate
donor cells and thereby reduce the success of DLI after BMT. The majority of human
have been transplanted with HLA identical stem cells. However, disparities in minor
histocompatibility antigens (mHag) can also initiate strong alloreactivity23,24. Host
cytotoxic T cells specificly directed against mHag have been isolated from patients
after rejection of HLA-identical stem cell-grafts23,24. Moreover, Vogt et al. have
shown that sensitization of female recipients prior to SCT by blood transfusion of
male donors increases the number of specific T cells directed against the H-Y mHag.
The presence of H-Y antigen specific T cells resulted in an enhanced frequency of
graft rejection25.
In summary, we show in allogeneic rat model that reversion of hematopoiesis from
donor to host after SCT results in alloreactivity against donor cells. Alloreactive host
T cells eliminate infused donor T cells. This mechanism can contribute to failure of
adoptive allogeneic immunotherapy after SCT in humans who show hematopoietic
cell reversion from donor to host origin.
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ABSTRACT
Analysis of changes in recipient and donor hemopoietic cell origin is extremely useful to
monitor the effect of stem cell transplantation (SCT) and sequential adoptive
immunotherapy by donor lymphocyte infusions (DLI). We developed a sensitive and
accurate method to quantify the percentage of recipient and donor cells by real-time
PCR using single nucleotide polymorphisms (SNPs) as markers. Allele specific PCR of
seven SNPs resulted in specific markers for donor or recipient in 97% of HLA-identical
sibling pairs. Both, recipient- and donor-derived hemopoietic cells can be
simultaneously analyzed in 67% sibling pairs. We expect this can be increased to
approximately 99% by developing three additional SNP-PCR. Serial dilution of SNP-
positive DNA into either SNP-negative DNA or water revealed a detection limit of 0.1-
0.01% depending on the amount of input DNA and start Ct of the used SNP-PCR.
Application of our real-time SNP-PCR method for a CML patient treated with
allogeneic SCT and DLI demonstrated its feasibility to follow donor T cell chimerism
and early detection of residual and recurrent autologous hemopoiesis in response to
treatment. This detailed monitoring of the genetic origin of hemopoietic cells, in
particular immune effector cells and target cells after SCT and DLI, may substantially
contribute to understanding of the mechanisms that play a role in the success of
treatment.
INTRODUCTION
RANSPLANTATION WITH HEMATOPOIETIC STEM CELLS from HLA-identical sibling
donors has been successfully used to treat patients with hemopoietic
malignancies. Allogeneic stem cell transplantation (SCT) results in effective
replacement of eradicated recipient stem cells. Moreover, immunereactivity of donor
effector cells against residual malignant cells contributes significantly to the success
of treatment. This immunoreactivity of donor T cells also limits the success rate of the
therapy by transplantation-related mortality because of severe graft-versus-host-
disease (GVHD)1. T cell depletion of the stem cell graft reduces the incidence and
severity of GVHD but results in an increase of relapse rate, which confirms the
contribution of donor derived immunocompetent T cells in eliminating residual
malignant cells2. In addition, the significantly higher relapse rates in patients who
received stem cells of genetically identical twins compared to patients who received
stem cells of HLA-identical siblings strongly supports the hypothesis that minor
alloantigens significantly contribute to the induction of immunereactivity of donor
lymphocytes against malignant cells3. Attempts are made to further exploit the
immunereactivity of donor cells against recipient hemopoietic cells, including
T
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leukemia and lymphoma cells using a nonmyeloablative conditioning regime prior
transplantation, followed by donor lymphocyte infusion (DLI)4,5. Interestingly, this
treatment regime has also been applied to treat solid tumors and revealed that
achievement of full T cell chimerism was a prerequisite for response to treatment6-9.
DLI can be very effective in preventing and curing relapse of leukemia but harbors
the risk of inducing fatal GVHD10-13. Although the response rate of patients, treated
for CML, to DLI is quite high, the majority of patients with acute myeloid or
lymphoid leukemia (AML and ALL) do not respond to DLI14. Success of DLI may be
improved when dose and timing of given donor T cell infusion can be adapted to each
individual patient, thereby minimizing the risk of GVHD and maximizing the
reactivity against malignant cells15. Mackinnon et al.16 have shown that repetitive
administration of increasing numbers of donor lymphocytes resulted in complete
remission in patients with CML who did not respond to low-dose DLI. Moreover,
infusions of escalating numbers of donor T cells induced less GVHD compared to
DLI given as bulk dose17. In addition, in vitro activation of donor cells can improve
DLI. Slavin et al. showed18 that recurrent leukemia cells in patients not responding to
DLI could be effectively eliminated by donor T cells activated by IL-2 ex vivo.
Furthermore, early detection of relapse may enhance the success rate of DLI by
treatment before the onset of overt clinical relapse19. Increasing numbers of BCR-
ABL-expressing cells can indicate early relapse of CML10-22. Other fusion transcripts
can be indicative for relapse of acute leukemia patients23,24. It has also been suggested
that monitoring of chimerism in lymphoid and myeloid subsets, isolated from
peripheral blood of patients after SCT, allows detection of residual or recurrent
leukemia cells25-27. Imminent relapse of leukemia lacking a genetic marker may be
prevented by adoptive cellular immunotherapy given early after an increase of
percentage of recipient cells26.
The mechanisms responsible for failure of immunotherapy after SCT are not clear. A
high percentage of autologous T cells coincided with reduced alloreactivity of infused
donor T cells, which may suggest rejection of infused T cells or induced T cell
tolerance28,29. Donor-derived regulatory T cells may also suppress reactivity of infused
donor lymphocytes30. Frequent analysis of chimerism in lymphoid and myeloid
subsets after SCT may be of great value to identify patients with high risk for relapse
or graft rejection24,25,27,31. Several techniques have been used in these studies to
monitor chimerism after SCT. PCR of DNA sequences with tandem repeats (VNTR,
STR) or satellite DNA has applied frequently25-27. FISH analysis to discriminate male
and female cells have been utilized in sex-mismatched sibling pairs.
We have developed a real-time PCR method based on the detection of biallelic single
nucleotide polymorphisms (SNPs). Biallelic SNPs exist with a very high frequency in
the human genome32. We show that the method is applicable for almost all
recipient/donor pairs and can accurately quantify at least 0.1% recipient cells among
donor cells and vice versa. Detailed monitoring of the genetic origin of hemopoietic
cells after SCT and DLI can substantially contribute to understanding of the
mechanisms involved in response to therapy and guide adoptive immunotherapy
strategies.
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MATERIAL AND METHODS
Patient and cell samples
Chimerism of hemopoietic cells was studied in patients who received T cell-depleted
SCT with stem cells from a HLA-identical sibling donor. CML patient (UPN 480)
with Philadelphia chromosome positive (Ph+) CML cells was conditioned with 120
mg cyclophosphamide per kg body weight and total body irradiation (9 Gy).
Cyclosporin A was given until two months after SCT to prevent GVHD. PBMC from
peripheral blood collected before and following SCT and DLI were isolated by Ficoll
density gradient centrifugation. T cells and myeloid cells were isolated by flow
cytometry (Epics Elite, Beckman Coulter, Fullerton, CA, USA) after staining with
CD3-FITC-conjugated mAb (UCHT1 Beckman Coulter) or CD13/CD33-PE-
conjugated mAb (WM-54, WM 47, respectively, Dako, Glostrup, Denmark). Purity of
both cell populations was > 99.5%.
DNA preparation and SNP-typing by RLFP analysis
Genomic DNA was isolated with QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) from sorted cell populations, PBMC of donors and recipients collected
before SCT, and from EBV-transformed B cells generated from PBMC of recipients
collected prior SCT and donors (see the Appendix for detailed information). DNA
fragments containing SNPs in PECAM1, ICAM1, HA1, MLH1, SUR1, and the
sequence-tagged sites (STSs) G42863, and G42888, were amplified as described
before33-41. Genotype of SNPs was determined after digestion with restriction enzyme
PvuII (PECAM1 and MLH1) and PstI (SUR1) by agarose gel electrophoresis33,34,41.
Genotype of SNPs in ICAM1, HA1, G42863 and G42888 was determined by DNA
sequencing of PCR products.
Specific amplification of SNPs by real-time PCR
DNA isolated from EBV-transformed cell lines bearing homozygously the identified
SNP was used to develop and optimize Taqman-based real-time PCR for each of the
SNPs (Perkin Elmer Applied Biosystems, ABI Prism 7700)42-44. In addition to allele-
specific real-time PCR, we developed an SMCY-gene (accession number: AF273841)
real-time PCR to quantify male cells (see the Appendix for detailed information).
Quantification of the percentage of cells containing allele-specific sequences
Calibration functions were generated from Ct obtained by real-time PCR of serially
diluted DNA, isolated from cell samples harboring each of the SNPs homozygously,
heterozygously, or hemizygously. These calibration curves were used to calculate the
percentages of recipient and donor cells in the blood samples collected after SCT (see
the Appendix for detailed information). The amount of input DNA was acurately
defined by real-time PCR using a DNA fragment encoding albumin.
Calculation of the discriminating capacity of biallelic SNPs
Genotype frequencies obtained by SNP-PCR from of 80 SCT recipients and their
HLA-identical sibling donors were compared with SNP frequencies described
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earlier33-41. The genotype frequencies we obtained by real-time PCR of SNPs were
used to analyze the discriminative capacity of the seven SNPs. Calculation of
probability that siblings have different genotypes with alleles A and B that are located
on autosomes revealed the following formula: [(Freq AA + 5/8 Freq AB + Freq BB) ×
Freq AB]. The probability that siblings have different genotypes of SNPs located on
the X chromosome was calculated by the formula: [5/8 Freq AB + 1/2 Freq A × Freq
BB + 1/2 Freq B Freq AA].
RESULTS
Development of SNP-specific real-time PCR for identification of recipient and
donor cells
Seven SNPs of which high frequency in human populations have been described,
were selected for the identification of recipient- and donor-derived cells after SCT
(Table 1). SNPs located on chromosome 6, which contain the MHC complex
encoding the HLA molecules, were excluded. RFLP analysis and DNA sequencing of
amplified fragments were used to define cells bearing the selected SNPs,
homozygously, heterozygously, or hemizygously. Using DNA isolated from these
cells, we developed real-time PCR with SNP-allele-specific primers and gene-specific
probes.
Gene Chromosome SNP Location Frequency (%)a
AA/AB/BB
Reference
PECAM1 17 C
G
bp 514
codon 125
28/42/30 33, 34
ICAM1 19 G
A
bp 1462
codon 214
20/47/33 35, 36
HA1 19 C-A
T-G
bp 500-504 17/49/34 37, 38
MLH1 3 G
A
promoter
bp –93
26/55/19 39
SUR1 11 C
T
exon 16
bp –3
32/47/20 40
STSb Chromosome SNP Frequency (%)c
A/B
Reference
G42863 Xq28 A
C
68
32
41
G42888 Xq25 T
C
60
40
41
a
 Genotype frequencies given by the literature.
b
 Sequence-tagged site.
c
 Allele frequencies given by the literature.
Table 1. Characteristics of SNPs used as specific markers for recipient and donor cells
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To hinder amplification of noncomplementary alleles, we synthesized SNP-allele-
specific primers containing one extra mismatch in one of the two adjacent nucleotides
of the polymorphic nucleotides. We replaced these nucleotides for one of the three
alternative nucleotides and determined which of these mismatched primers resulted in
highest specific amplification and lowest background amplification. We observed
significant differences in amplification efficiency and target specificity of allele-
specific primers as shown for the A allele of MLH1 (Fig. 1). High fluorescence signal
early after amplification of the positive allele (MLH1-A, C t 24.5), and low
fluorescence during amplification of the negative allele (MLH1-G, Ct 35.9), was
observed using the allele-specific primer ending with ATT (primer set 1 in Figure 1).
In contrast, allele-specific primer ending with TAT (primer set 2 in Figure 1) showed
lower sensitivity for MLH1-A (Ct 28.2), and allele-specific primer ending with CTT
(primer set 3 in Figure 1) showed high background amplification of the negative allele
MLH1-G (Ct 29.1).
Figure 1. Amplification curves of the MLH1 SNP-alleles by real-time PCR. Amplification
plots of PCR using three reverse primers specific for the A allele and a common forward
primer are shown. Primer set 1, with reverse primer 5'-TCGTGCTCACGTTCTTCCATT-3'
reached threshold after 24.5 cycles for the A allele () and after 35.9 cycles for the G allele
() (∆Ct =11.4). Primer set 2, with reverse primer 5'-TCGTGCTCACGTTCTTCCTAT-3'
reached threshold after 28.2 cycles for the A allele () and after 41.8 cycles for the G allele
(∆) (∆Ct =13.6). Primer set 3, with reverse primer 5'-TCGTGCTCACGTTCTTCCCTT-3'
reached threshold after 24.4 cycles for the A allele () and after 29.1 cycles for the G allele
() (∆Ct =4.7). Primer set 1 gave the best results for the MLH1-A allele.
Using this approach we developed primer sets that reached the detection threshold
before 25 cycles of amplification, and showed background amplification of the non-
complementary allele after 35 cycles, using 500 ng of genomic DNA. Table 2 shows
the developed primer sets, the optimum annealing temperature, and the amplification
efficiency (Ct, and ∆Rn after 45 cycles of amplification), obtained by real-time PCR
for seven SNPs. Cycle threshold of amplification of repeated experiments ranged
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within 0.5 cycle, starting with the same amount of target DNA. Log dilutions of target
DNA resulted in Ct differences of approximately 3 cycles. Theoretically, differences
of more than 10 cycles in reaching the threshold between the positive and negative
allele allowed quantification of at least 0.1% target DNA. Fixed anealing/elongation
temperature of 60°C to screen 100 ng DNA for all seven SNPs in one real-time PCR
run resulted in Ct < 30, using allele-specific primers for ICAM1, HA1, MLH1, and
SUR1. Allele-specific primers for PECAM1 and G42863; G42888 were shortened to
reach Ct < 30 after amplification of 100 ng DNA.
The results shown here demonstrate that real-time PCR of target sequences with SNPs
can be used to identify the genetic origin of cells. Moreover, this method is highly
reproducible and applicable for the detection of very small percentages of cells with
specific SNP-markers.
Gene/STR SNP Alle-specific primer (5’ to 3’)a Amplification ∆Ctc
pos. allele neg. allele
∆Ct ∆Rnb Ct ∆Rnb
PECAM1 C
G
AGGACTCACCTTCCACCAACCCG (R)
AGGACTCACCTTCCACCAACCTC (R)
22.9
25.0
1.1
1.1
44.8
41.4
0.1
0.1
21.9
16.4
ICAM1 G
A
AGAGCACATTCACGGTCACCCAC (R)
AGAGCACATTCACGGTCACCATT (R)
25.5
24.9
1.1
1.1
38.1
36.1
0.3
0.8
12.6
11.2
HA1 C-A
T-G
GCTCTCACCGTCACGCAA (R)
GCTCTCACCGTCATGCCG (R)
24.9
24.1
1.4
1.3
39.9
40.2
0.1
0.2
15.0
26.1
MLH1 G
A
TCGTGCTCACGTTCTTCCTCC (R)
TCGTGCTCACGTTCTTCCATT (R)
23.9
24.5
1.2
1.2
38.5
35.9
0.3
0.8
14.6
11.4
SUR1 C
T
TGCCACCCTCCCTCCCTAC (F)
TGCCACCCTCCCTCCCTAT (F)
23.9
24.5
1.1
1.1
38.5
35.9
0.5
0.8
14.6
11.4
G42863 A
C
GGCTTGTGGATGAAGGAGAA (F)
GGCTTGTGGATGAAGGAGTC (F)
22.0
22.5
1.1
1.1
34.9
34.8
0.8
0.8
12.9
12.3
G42888 T
C
GGGGAGGGGAGGAAGAGACT (F)
GGGGAGGGGAGGAAGAGAGC (F)
21.4
20.9
1.1
1.1
35.1
35.1
0.3
0.7
13.7
14.2
a
 Polymorphic nucleotides are given in bold, and introduced mismatched nucleotides to
decrease background amplification are underlined; (F) = forward primer, (R) = reverse
primer.
b
 Normalized reporter signal minus baseline signal.
c
 Ct of negative allele minus Ct of positive allele
Typing of allelic differences in recipient and donor cells by SNPs
To determine the capacity to discriminate between siblings using real-time PCR for
SNPs, 80 SCT recipients and their HLA-identical donors were screened for presence
of the seven SNPs. First, the genotype frequency of SNPs in 160 paired siblings was
defined (Table 3). This analysis showed that genotype frequency of SNPs in either
donors or recipients was similar (data not shown). Moreover, all SNP genotype
frequencies that we determined correlated with those published, except one (Table 3).
The frequency of the SNP in the MLH1 gene, we found, differs significantly from that
determined in the Japanese population by Ito et al.40. As expected, frequencies of
Table 2. Amplification characteristics of developed SNP allele-specific primers for real-time PCR
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heterozygous genotypes for both SNPs located on the X chromosome were low
because of single alleles in males (Table 3).
  PECAM 1      ICAM1           HA1                MLH1         SUR1          G42863             G42888
GG CG CC  GG AA CA  CA CATG TG  GG GA AA  CC CT TT  C/CC CA A/AA  C/CC CT T/TT
n
Analyzed
by PCR
24   46  30   22 42  36   23   42    35   68  25  7    29  48 23   11    34   55      24   47   29
                                                                                                24           76      49          51
                                                                                                29a          71a     49a         51a
75 F
85 M
160c
Literatureb 28   42  30   20 47  33   17   49    34   26  55  19  32  47 21   32a          68a     40a         60a
a
 Allele frequencies.
b
 References are given in Table 1.
c
 Total
Next, we analyzed the contribution of each SNP regarding their capacity to reveal
specific molecular markers in sibling-pairs. Exclusive appearance of one of the two
polymorphic alleles in either recipient or donor was determined. The seven SNPs
revealed a specific marker for either recipient or donor in 24-50% of the pairs (Table
4). The SNP in MLH1 showed the lowest capacity (24%) to genetically identify cells,
because of high frequency of homozygous MLH1-G in the analyzed population. SNPs
located on the X chromosome contributed as effective in specific recipient or donor
marking as SNPs located on autosomes (Table 4). A significant number of sibling
pairs (28%) allowed recipient- and donor-specific discrimination by both biallelic
variants of one SNP. Hemizygous appearance of allelic SNP-variants on the X
chromosome contributed dominantly to this phenomenon (Table 4). Furthermore, the
probability of the seven biallelic SNP PCRs to reveal specific markers for recipient
and donor was calculated using the genotype frequencies that we had determined in
80 sibling pairs. The analyzed frequencies of SNPs as genomic marker correlated
highly with those calculated, suggesting that all SNP-markers segregate in a Medelian
fashion that is not influenced by the close relationship of siblings (Table 4).
Table 3. Genotype frequencies of SNPs
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Number of
markers for
PECAM1 ICAM1 HA1 MLH1 SUR1 G42863 G42888
Recipient or
donora
Analyzed by
PCR
41 45 30 23 44 35 42
Recipient and
donorb
Analyzed by
PCR
3 2 2 1 2 10 8
Total Analyzed by
PCR
44 47 32 24 46 45 50
Total Calculatedc 38 35 35 23 39 32 43
Cumulative
number of
markers for
PECAM1 ICAM1 HA1 MLH1 SUR1 G42863 G42888
Recipient or
donor
Analyzed by
PCR
44 66 76 83 89 94 97
Recipient or
donor
Calculated 38 60 74 80 88 92 97
Recipient and
donord
Analyzed by
PCR
3 12 24 32 41 55 67
a
 Either recipient or donor DNA contains exclusively one of the allelic variants of SNPs
b
 Both recipient and donor DNA contain different variants of one SNP
c
 Both recipient and donor DNA contain exclusively one of the allelic variants of SNPs.
d
 Probability that recipient or donor DNA exclusively contain one allele of the SNPs;
Calculations were performed using genotype frequencies as analyzed (Table 2).
The high percentages that each SNP could discriminate between siblings resulted in
specific markers for either recipient or donor in 97% of these pairs (Table 4). The
probability calculations based on genotype frequencies revealed the same
discrimination capacity of the seven SNP-markers (Table 4). Each dimorphic SNP
increased the percentage of pairs with a specific marker for both recipient and donor
significantly (8-14%). Location of two SNPs on the same chromosome (19 and X) did
not affect the accumulation of the percentage of sibling pairs with specific SNP-
markers (Table 4). The seven SNPs we utilized revealed a specific genomic marker
for both recipient and donor in 67% of the 80 analyzed sibling pairs (Table 4). The
PCR specific for SMCY located on the Y chromosome discriminated recipient and
donor cells in al sex mismatched sibling pairs and increased the percentage of pairs
that have a specific marker for both recipients and donors with 12% (data not shown).
These results demonstrate that a restricted number of SNPs in the human genome can
be used to genotype the vast majority of sibling pairs. Each SNP with a high
heterozygous frequency has the ability to discriminate 30-50% of sibling pairs either
with a recipient- or donor-specific marker. More importantly, all SNPs used for this
analysis act as additional markers specific for either donor or recipient, which results
in specific markers for 67% of both members of sibling pairs. Addition of three
biallelic SNP-markers that appear to be highly discriminative will lead to specific
markers for both recipient and donor in ≥ 99% of sibling pairs.
Table 4. Recipients and donors (%) that can be discriminated based on SNP markers
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Quantification of recipient and donor cell ratios
We developed a quantitative assay to measure the percentage of recipient or donor
cells by allele-specific real-time PCR in peripheral blood (subsets). Calibration curves
for each SNP were performed. Homozygous and heterozygous DNA for all targeted
alleles were diluted either in DNA, homozygous for the alternative (negative) alleles,
or in water. Amplification-cycle threshold signals (Ct) were plotted against amount of
input DNA. Real-time PCR of DNA encoding the albumin gene was simultaneously
performed to normalize the amount of input DNA of test samples to the calibration
samples. Figure 2 shows calibration curves of amplified SNP-positive DNA
(PECAM1-GG and PECAM1-GC) diluted in negative DNA (PECAM1-CC) (Figure
2a) and amplified SNP-positive DNA diluted in water (Figure 2b). All calibration
curves of DNA amplified by SNP-specific primer sets reached slopes of -3.3 (± 0.2).
Calibration curves for samples diluted in both negative DNA and water gave similar
results for all seven SNP-PCR (data not shown). Deviation in Ct was stable and
average of two-fold standard error of repeated samples did not exceed 0.4 cycle. The
deviation of Ct obtained by real-time PCR is independent of the concentration target
DNA in the samples that reached the threshold between 20 and 35 cycles of
amplification. Therefore within this range, accuracy was directly related to the
concentration and calculated confidential intervals were approximately +30% and -
25% for all measured values. As shown in Table 2, all SNP-PCR showed low
amplification of DNA containing the allele that was not complementary with the
specific SNP-primers (Ct >35). Therefore, specific amplification of 500 ng DNA
results in detection up to 0.1% SNP-positive cells in SNP-negative cells. Specific
amplification of DNA with SNPs that reached the threshold prior to 22 cycles of
amplification (∆Ct > 13) can be quantified up to 0.01%.
Figure 2. Calibration curves of DNA. Serial dilutions of DNA containing the G allele of
PECAM1 homozygously () or heterozygously () (PECAM1-GG and PECAM1-GC,
respectively). Standard errors of Ct are ± 0.25 cycle and presented by sizes of the boxes. (a)
SNP target sequence-positive DNA diluted in target sequence-negative DNA (PECAM1-CC).
(b) SNP target sequence-positive DNA diluted in water.
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The results show that real-time PCR of SNPs can be used to quantify chimerism in
cell samples taken after SCT. Quantification of low percentage target-SNP positive
cells in mixed samples is very accurate but standard errors are high for samples with
high percentage target-SNP positive cells. Analysis of hemopoietic cell populations of
patients after SCT by both recipient and donor specific SNP-markers may result in
significant information about chimerism present in these patients.
Analysis of recipient-derived hemopoietic cells following SCT and adoptive
immunotherapy
To apply our SNP method for the determination of the origin of lymphocytes and
myeloid cells after allogeneic transplantation, we studied in detail chimerism of one
patient treated for CML, who relapsed and was subsequently treated with DLI (Figure
3). The patient relapsed at 9 months after SCT and received 0.7 × 108 T cells/kg body
weight 2 weeks later. Acute GVHD was not observed, but the patient developed
extensive chronic GVHD 3 months after DLI. The percentages of recipient-derived T
cells and myeloid cells in blood were determined by real-time PCR of the ICAM1-G
allele. Remarkably, a high percentage of T cells of recipient origin were detected in
this patient at 1, 3 and 6 months after SCT. After DLI the percentage of recipient
derived T cells decreased rapidly to below the detection limit before the development
of chronic GVHD (Figure 3).
Figure 3. Analysis of cells of recipient origin after SCT. T cells and
myeloid cells are purified by flow cytometry after staining PBMC
with cell lineage-specific mAb. The percentage recipient derived T
cells (◊) and myeloid cells () are detected by real-time PCR with
allele-specific primers for polymorphic DNA of the ICAM1 gene.
Gray bars represent the confidential interval of real-time PCR of
SNP.
QUANTIFICATION OF THE GENETIC ORIGIN OF HEMOPOIETIC CELLS
                                                                                                                                                      
98
A small percentage of autologous cells could be detected in purified myeloid cells at 1
and 3 months after SCT (0.3 and 0.6%, respectively). However, myeloid cell samples
were 99.5% pure, thus contaminating T cells may have contributed to this signal. The
percentage of myeloid cells of recipient origin was significantly increased at 7 months
after SCT. Shortly after DLI, the percentage of recipient-derived myeloid cells still
increased (Figure 3). At two months after DLI the myeloid cells of recipient origin
dropped very fast to below 0.05% (Figure 3). A high percentage (50%) Ph+ cells was
observed in bone marrow by FISH analysis of at 6 months after SCT. The percentage
of Ph+ cells in bone marrow increased up to 90% prior DLI and did not decrease until
1.5 months after DLI. All Ph+ cells disappeared within 5 month after DLI (data not
shown).
The data show persistence of high percentage of recipient-derived T cells in this
patient after SCT. The percentage of these T cells decreased immediately after DLI
before the onset of clinical GVHD symptoms, which suggests that alloreactivity of
infused donor cells can be detected early by this method. Moreover, kinetics of
myeloid cells of recipient origin in blood after SCT and DLI parallel that of Ph+ cells
in BM as analyzed by FISH. This indicates that monitoring of chimerism in myeloid
cells may be informative regarding relapse and response to treatment for those
myeloid leukemia patients whose leukemia cells do not bear a specific malignancy-
marker.
DISCUSSION
The aim of the present study was to develop an accurate, sensitive, and fast method to
quantify the percentage of recipient and donor hemopoietic cells after transplantation
of HLA-identical stem cells. Following SCT, the majority of transplanted patients
have hemopoietic cells of both recipient and donor origin (mixed chimerism) at least
for a short period of time. Hemopoietic cells of some of these patients remain of
mixed origin for a long period of time or revert to autologous hemopoiesis46. The
influence of mixed chimerism on leukemic relapse, graft rejection, and treatment
failure after SCT has been studied extensively8,47,48. It has become clear that the
hemopoietic cell lineage in which mixed chimerism occurs contributes to the choice
for adoptive immunotherapy after SCT49,50. T cell mixed chimerism contributes
clearly to graft tolerance and resistance against GVHD29,30,51. Mixed myeloid cell
chimerism in acute and chronic myeloid leukemia patients may reflect residual
disease and may indicate imminent relapse of disease24,25,27. Particularly, the kinetics
of recipient and donor ratios in these cell lineages could be very informative about
immunereactivity and course of disease, and useful in determining strategies of
additional treatment26,27.
We developed a real-time PCR method using seven genomic SNPs as markers that are
capable to discriminate either recipient or donor cells in 95% of HLA-identical sibling
pairs. Logarithmic diluted concentrations of input target DNA are proportionally
linear with Ct. Deviation in Ct is independent of the concentration DNA ranging
between 500 ng and 0.05 ng. Therefore, the sensitivity is very high for low
concentrations of target DNA but low for high concentrations of target DNA.
However, to reach high sensitivity in both directions, two discriminative SNPs can be
used with two calibration curves: one calibration curve to quantify a range from 0.1 to
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50% recipient cells in donor cells using one SNP-PCR, and one calibration curve to
quantify a range from 0.1 to 50% donor cells in recipient cells by another SNP-PCR.
One recipient-specific and one donor-specific SNP-PCR can be utilized for sensitive
monitoring after SCT and DLI. By this approach seven biallelic SNP-markers resulted
in very sensitive monitoring of chimerism in 67% of our patients. Additional real-time
PCR analysis with three SNPs allows a screening that can routinely applied to
determine specific markers for 99% of both recipients and donors. In addition to SNP-
PCR, we developed an SMCY-gene-specific real-time PCR to quantify male cells in
sex-mismatched recipient/donor pairs. A similar approach has been described for the
DFRY gene by Fehse et al.52. Male-specific PCR are markers in 50% of in randomly
selected recipient and donor pairs and can be utilized as biallelic marker for either
recipient or donor. Dimorphic SNPs revealed to be specific markers for either
recipient or donor of sibling pairs comparable to male specific markers.
As mentioned earlier, very small percentages of recipient cells in donor cells and vice
versa can be detected by real-time PCR. A detection limit of 0.01% can be reached
using SNP-specific primers that efficiently amplify the positive allele (Ct ≤ 22) and
show low amplification (Ct > 35) of the negative alleles. Standard errors in repeated
PCR are small (± 0.2 cycle) which results in confidence interval of roughly +30% and
-25% of the measured values. However, quantification of SNP-specific DNA by real-
time PCR is more accurate than quantification of products by conventional PCRs that
amplify DNA samples to a fixed number of cycles. PCR products that differs in
length by the number of tandem repeats sequences (STR/VNTR) utilize
electrophoresis to quantify both recipient- and donor-specific products amplified in
the same PCR. Analysis of recipient cells and donor cells by separate real-time PCR
of SNPs excludes interference with nonspecific signals. Moreover, real-time PCR
excludes spectral overlap of recipient- and donor-specific fluorescence signals or
stutter peaks of amplified recipient DNA, that comigrates with donor specific peaks or
vice versa, as sometimes observed by amplification of STR53,54. In addition, real-time
PCR of SNPs is less hampered by competition for reagents that may occur by
amplification of PCR products that significantly differ in length. Moreover, the use of
reference gene amplified by real-time PCR may better define the amount of input
DNA compared to conventional PCR. However, sensitive quantification of recipient-
and donor-derived cells in leukocyte subsets may be limited by efficiency of
purification.
The percentage recipient and donor pairs that have an SNP-marker is significantly
higher than the number of patients and donors that have markers applicable for FISH
analysis and can compete with STR markers55-57. Use of specific PCR primers for
about ten SNPs with high heterozygous frequencies will result in a discriminative
marker for both recipient and donor in approximately 99% of all sibling pairs. The
reproducibility of our SNP-marker analysis is very high and the method is
significantly less laborious compared to marker analysis by FISH. High percentage of
recipient and donor cells can be quantified more exactly using FISH analysis58.
Sensitive detection of low percentages of cells can be done more accurately by real-
time PCR than by FISH analysis, because of the restricting number of cells that is
used for FISH analysis. Specific target sequences in recipient and donor DNA can be
separately utilized for quantification by real-time PCR and thus result in sensitive
quantification of both recipient and donor DNA present in one-cell samples.
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In summary, monitoring of hemopoietic chimerism after SCT may indicate imminent
graft rejection or relapse. Moreover, it gives significant information about the
immunological response after SCT and DLI. We show that real-time PCR of SNPs is
a sensitive and very reliable method to analyze chimerism. The method is less
laborious compared to FISH analysis and quantification is more accurate than that
performed after gel electrophoresis and conventional PCR.
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APPENDIX: METHOD IN FOCUS
Leukemia 2003; 17: 630-633
Assay characteristics
The quantitatification method is based on a real-time PCR (Perkin-Elmer Applied
Biosystems, ABI Prism 7700), with allele-specific primers for DNA sequences
containing single nucleotide polymorphisms (SNPs) and target DNA-specific
probes1,2. The nonextendible hybridization probes are labeled with a reporter
fluorescent dye at the 5' end and a quencher at the 3' end, which results in a
fluorescence signal after cleavage by 5'-3' nuclease activity of Taq polymerase. A
charge-coupled device camera attached to ABI Prism 7700 detects target-specific
signals at a threshold of 10 standard deviations above the baseline fluorescence.
Normalized signals minus baseline signals of the reporter dyes (∆Rn) are plotted
against PCR cycle numbers, which results in a logarithmic amplification function.
The cycle number of DNA amplification that generates the first specific fluorescence
signal (∆Rn) above the threshold is called cycle threshold (C t). Therefore, Ct
represents directly the relative amount of target DNA in the analyzed samples.
Allele-specific amplification revealed that each biallelic SNP acts as a specific marker
in 24-50% of 80 sibling pairs. The discriminative capacity of each SNP marker
depends on the frequency of the SNPs in the human population. Calculation of the of
percentage donor and recipient cells is based on the relation of specific amplification
signals from both recipient and donor DNA to specific amplification signals obtained
by calibration curves for both recipient and donor markers. The amount of input DNA
is simultaneously calibrated by amplifying a DNA fragment of the albumin gene.
Protocol
DNA preparation
Genomic DNA is isolated from PBMC, purified hemopoietic cell populations, and
EBV-transformed B cells with QIAamp DNA Blood Mini Kit (Qiagen, Hilden,
Germany) following the protocol of the kit. Samples >50 000 cells are eluted with 200
µl and DNA concentrations are determined by spectrophotometry. Samples ≤50 000
cells are eluted with 2 × 25 µl. DNA and the amount of input DNA is only determined
by real-time PCR of the albumin gene3.
DNA from 4 EBV-transformed B cell lines that contain all 14 SNP alleles are used as
calibrators. Aliquots (20 µl) of DNA dilutions, containing 100, 30, 10, 3, 1, 0.3, 0.1
and 0.03 ng/µl, are stored at –80 oC. In total, 5 µl of these dilutions are amplified by
allele-specific real-time SNP-PCR and by the albumin gene-specific real-time PCR to
construct calibration curves.
PCR
Taqman-based real-time PCR for each of the SNPs, SMCY and albumin has been
performed in a total volume of 50 µl with 1 × PE sample buffer, 1.25 U of DNA
polymerase (AmpliTaq Gold, Perkin-Elmer), 250 µM dNTP, primers at 300 nM, and
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TET-labeled probes at 100 nM. Hot start Taq polymerase is activated for 10 min at
95°C. DNA is amplified for 45 cycles. Screening of recipient and donor DNA with all
SNP-specific PCR occurs in one run at annealing/extension temperature of 60°C.
Allele-specific primers for PECAM1 and G42863; G42888 are used for this
application (Table 1). Annealing and extension of quantitative PCR (calibration
curves and test samples) takes place for 60 seconds at a temperature optimum
dependent on the primer sets used (Table 1). Annealing and extension is followed by
denaturation for 15 s at 95°C.
Analysis of PCR products
Amplification curves are constructed by plotting PCR cycle number versus target-
specific fluorescence signals of the reporter dye (∆Rn). The cycle number that
generates the first fluorescence signal (∆Rn) above the threshold is called cycle
threshold (Ct) and represents the relative amount of input target DNA.
Quantification of donor chimerism
Quantitative analysis is performed by generating calibration functions from Ct
obtained by real-time PCR of DNA serially diluted in water (500-0.05 ng) isolated
from cell samples bearing SNPs. Simultaneously, allele-specific target DNA (SNP)
and DNA encoding the non-polymorphic albumin sequence are amplified. The
calibration functions are
y = a10 log x + b
in which a is the slope of the curve and b is the intercept with the y-axis.
The percentage of recipient or donor target cells, is calculated by the following
formula:
SNP positive DNA (%) = 10(y1-b1)/a1-(y2-b2)/a2 × 100%
where
y1 is the Ct sample, amplified by allele-specific SNP-PCR,
y2 is the Ct sample, amplified by albumin PCR, b1 is the intercept with the y-axis of
allele-specific SNP-PCR calibration curve,
b2 is the intercept with the y-axis of albumin PCR calibration curve, a1 is the slope
of the curve of allele-specific SNP-PCR calibration curve, and
a2 is the slope of the curve of albumin PCR calibration curve.
The slope of all calibration curves is -3.3 (±0.2). The detection limit for each
individual sample is dependent on the Ct of albumin PCR (y2) and the intercept with y-
axis of allele-specific SNP-PCR (b1) and the amount of template DNA: the intercept
with y-axis of albumin PCR (b2). Table 1 shows the detection limits for al SNP-PCR
using a cut-off level at Ct >35 cycles.
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Time requirement
Screening test to discriminate recipient from donor DNA
Total time: 3.5 h; hands-on time: 1.5 h. The time indicated represents total time
required for DNA isolation and PCR preparation, assuming 30 min hands-on time for
DNA isolation of cell samples of one recipient/donor pair. We use ready-to-use PCR
master mix in optical tubes that are stored at -20°C for all allele-specific SNP-PCR.
Preparing master mix for 8 recipient/donor pairs takes about 3 h. One real-time PCR
run (45 cycles) takes 2 h. Analysis of the data of the screenings assay of 8
recipient/donor pair takes 1 h. Combining a number of recipient/donor pair in one
assay reduces the time considerably.
Quantitative chimerism analysis of sorted cell samples
Cell sorting
Total time: 2 h per sample (two subpopulations). T cells and myeloid cells are isolated
by flow cytometry (Epics Elite, Beckman Coulter, Fullerton, CA, USA) from liquid
nitrogen stored PBMC. Both T cells and myeloid cells are sorted from one sample.
DNA-handling and real-time PCR
Total time: 5 h; hands-on time: 3 h. Again, 30 min hands-on time for isolating DNA
of each sample (both lymphoid and myeloid) is assumed. We use ready-to-use
calibration curve samples that are stored at -20°C for all allele-specific SNP-PCR.
About 1.5 h is required to prepare the DNA samples for quantitative PCR, in general
28 tubes (eight tubes SNP-PCR calibration curve, eight tubes albumin-PCR
calibration curve, six tubes per purified cell sample; two tubes positive SNP-PCR,
two tubes negative SNP-PCR and two tubes albumin PCR). One real-time PCR run
(45 cycles) takes 2 h. In addition, 1h is required to analyze the results.
Sensitivity
We include a cut-off level at Ct 35 since we observed that calibration curves are not
always linear when very low amounts of target DNA are amplified. This results in a
sensitivity of ≥0.01% when the signal of SNP-positive DNA (100%) reaches the
threshold ≤23 cycles and background amplification of the negative allele reaches
threshold after 35 cycles (∆Ct = 12). This is reached by an input of about 500 ng
DNA. Roughly, ∆Ct of three cycles represents a 10-fold quantitative difference,
fulfilling the condition that the slope of the calibration function closely fits -3.3.
Therefore, using smaller amounts of input DNA, for example 50 ng, will decrease the
sensitivity to ≥0.1%. In contrast, higher amounts of input DNA will result in higher
sensitivity for all SNP-PCR that show low background amplification.
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Specificity/informativeness
Aspecific amplification with the developed real-time PCR to specific amplify SNP is
not observed. Amplification of DNA containing the negative SNP-alleles is below the
cut-off level (Ct > 35 cycles).
The capacity of biallelic polymorphic markers to discriminate siblings is calculated
from published SNP frequencies. We selected SNP markers that allowed
discrimination between recipient and donor in >30% of sibling pairs. The DNA of 80
sibling pairs is analyzed for all 7 SNP markers by real-time PCR. The SNP marker in
G42888 is most efficient and identifies recipient or donor cells in 50% of sibling
pairs. SNP markers in ICAM1, SUR1, PECAM1, G42863, and HA1 identify donor or
recipient cells in 47, 44, 46, 45 and 32% of sibling pairs, respectively. However, the
SNP marker in MLH1 is significantly less efficient than calculated from published
genotype frequencies (24 vs 44%) due to discrepancy in genotype frequencies in the
analyzed populations. Combining all seven biallelic SNPs results in genotype-specific
markers for recipient or donor in 97% of sibling pairs. Two-way discrimination
(recipient and donor) is feasible in 67% of sibling pairs by use of two SNP markers.
The determination of both the percentage recipient and donor cells improves
significantly the sensitivity and accuracy of the method.
Reproducibility/accuracy
Reproducibility is high; the variability of independent analyses in general does not
exceed the deviation of these samples. To exclude trivial errors, all sample analyses
are performed in duplicated wells. Standard errors of calibration curves (∆y) obtained
from Ct of at least eight dilutions do not exceed 0.2 cycle. The deviation of Ct
obtained by real-time PCR is independent of the concentration target DNA at least for
20≤Ct≤35. Therefore, accuracy (∆x) is directly related to the concentration and can be
calculated by the regression curve (y = a10logx + b) by the formula: ∆x/x = +10∆y/a-1
and -10∆y/a-1. DNA amplification by the developed SNP-PCR are stable logarithmic
processes and slopes (a) of calibration curves are -3.3 (±0.2).
Using a maximal ∆y (∆y calibration curve + ∆y sample = 0.4) and slopes of -3.1, the
maximal deviation can be calculated and reveals that ∆x = -0.26x and +0.30x. Table 2
shows the calculated confidential intervals for percentages between 100 and 0.1.
In summary, due to the logarithmic amplification by PCR, small percentages of target
DNA can be accurately defined. Absolute confidential intervals between 0.25% (-
0.065 and +0.075) and 0.5% (-0.13 and +0.15) will be statistically significant.
However, high percentages of target DNA have high absolute confidential intervals
(for example, measured value of 25% is at least between 18.5% and 32.5% target
DNA, and a measured value of 75% is at least between 55.5% and 100% target
DNA).
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Cost of the assay
The overall cost per analysis is dependent on the total number of analysis performed.
The numbers indicated are based on one blood sample, of which both myeloid and
lymphoid cell are analyzed. Normally, more samples are combined in one assay,
which reduces assay cost considerably.
(1) DNA isolation (Qiagen): 3 euros per sample
(2) Taqman consumables: 17 euros per sample
Trouble shooting
Real-time PCR by allele-specific primers is extremely reproducible and is only
affected by inhibitory factors in DNA. Most problems are related to the use of the
ABI Prism 7700 PCR technique. For detailed information about troubleshooting see
user's manual ‘ABI Prism 7700 Sequence Detection System’, (Perkin-Elmer Applied
Biosystems).
(1) Low signal after amplification of reference DNA
DNA concentration too low  Increase the amount of input DNA
(2) Slope calibration curves not between -3.1 and -3.5 or standard error >0.2 cycles
Bad quality of input DNA  Use another DNA batch for the generation of
calibration curves
(3) Differences between Ct of two-fold repeated samples >0.2 cycles
Always due to trivial errors (polluted tube, no DNA input in one tube, etc) 
Repeat PCR
(4) Ct of negative DNA (DNA that only contains the negative allele) < 33
Input of too high a concentration of DNA as shown by low Ct of albumin PCR
 Decrease the amount of input DNA
PCR conditions not optimal as shown by normal Ct of albumin PCR 
Change PCR conditions
Materials
Hardware
(1) Waterbath. (2) Microtube centrifuge. (3) Spectrophotometer. (4) PE Applied
Biosystems PRISM 7700.
Reagents and solutions
(1) Genomic DNA. (2) Taqman kit 1000 reactions with buffer A. (3) Primers
(Eurogentec, Seraing, Belgium). (4) Probes (PE Applied Biosystems, Cheshire, UK).
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ABSTRACT
We studied the clinical implications of intensification of the conditioning regimen in
patients with chronic myeloid leukemia in first chronic phase (CML-CP1) transplanted
with partially T cell-depleted stem cell grafts from HLA-identical siblings. In addition,
we studied the influence of intensification of the conditioning regimen on the kinetics of
hematopoietic conversion from patient to donor in lymphoid and myeloid subsets.
Nineteen patients received conditioning with cyclophosphamide and total body
irradiation (TBI), and 70 patients received a conditioning regimen intensified by the
addition of idarubicine.
Addition of the chemotherapeutic drug idarubicine resulted in a significant reduction of
the 5-year probability of relapse from 69 to 40% (p = 0.002). The 5-year probability of
leukemia-free survival (LFS) was significantly higher for patients who received the
intensified conditioning. However, the 5-year probability of current LFS, defined as
survival in first or second remission, was identical for both conditioning regimens. This
was mainly caused by a favourable response of patients with CML to therapeutic donor
leukocyte infusion (DLI). The addition of idarubicine correlated with an increase in the
incidence and severity of acute graft-versus-host disease (GVHD), albeit clinically mild.
Addition of idarubicine did not influence transplant-related mortality.
We monitored hematopoietic chimerism after stem cell transplantation (SCT) in
lymphoid and myeloid subsets using a recently developed real-time quantitative PCR for
the detection of recipient/donor-specific single nucleotide polymorphisms. The increase
in acute GVHD and LFS after intensification of the conditioning regimen with
idarubicine coincided with a faster increase in chimerism in both CD4+ and CD8+ T cell
subsets. The addition of idarubicine to the conditioning had no differential effect on the
time to reach full chimerism in non-T cell subsets. These chimerism dynamics may
confirm the importance of the genotype of immune mediators in the development of
allogeneic responses. Furthermore, they imply the importance of T cells in the
development of allogeneic reactivity. This observation may have consequences for the
conditioning regimens before T cell-depleted SCT of patients with hematological
malignancies that do not respond well to therapeutic DLI.
INTRODUCTION
LLOGENEIC STEM CELL TRANSPLANTATION (SCT) is the only curative treatment
option for patients with chronic myeloid leukemia (CML)1,2. Transplantation of
stem cells from a donor results in the effective replacement of recipient stem cells that
are eradicated after total body irradiation (TBI) and chemotherapy. Immunoreactivity
of donor-derived T cells against residual malignant cells, referred to as graft-versus-
A
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leukemia (GVL) reactivity, contributes to the success of this form of therapy.
However, donor T cells may recognize minor histocompatibility antigens that are not
exclusively expressed by the leukemic clone, resulting in immunoreactivity towards
normal host tissues. This broad alloreactivity can result in the development of graft-
versus-host disease (GVHD). GVHD remains one of the major causes of morbidity
and mortality after non-T cell-depleted SCT. Moderate to severe acute GVHD (grade
2-4) occurs in about 45% of recipients of HLA-identical marrow grafts and
contributes to death in 20-70% of those affected3-5. Approximately 30-50% of the
patients develop chronic GVHD which is also associated with significant morbidity
and mortality (50%) as a result of long term immunosuppression and consequently
severe immune dysfunction6. One of the most effective methods to reduce GVHD
after allogeneic SCT is depletion of T cells from the donor graft. However, the
removal of immunocompetent T lymphocytes is associated with an increase of graft
rejection and relapse of leukemia2,7-13. A strategy to prevent relapse after T cell-
depleted SCT is the intensification of the conditioning regimen. We demonstrated a
favourable outcome after intensification of the conditioning regimen with the addition
of idarubicine in standard risk leukemia patients14. Furthermore, we hypothesized that
the addition of idarubicine may exert an immunomodulatory effect14.
In this study we present the outcome of allogeneic SCT with or without an intensified
conditioning regimen in a large cohort of 89 patients transplanted for chronic myeloid
leukemia in first chronic phase (CML-CP1). Moreover, chimerism was monitored
sequentially in highly purified subsets of peripheral blood mononuclear cells
(PBMCs) and granulocytes of 10 patients randomized between recipients of
allogeneic SCT with or without intensification of the conditioning regimen, using a
newly developed real-time PCR for the quantification of hematopoietic chimerism15,16.
The results reaffirm that the addition of the chemotherapeutic drug idarubicine results
in a favourable outcome, demonstrated by a significant reduction of the 5-year
probability of relapse, and a significantly higher 5-year probability of leukemia-free
survival (LFS). Increase in incidence and severity of acute GVHD is clinically mild,
and did not influence transplant-related mortality.
Several mechanisms may contribute to the increased occurrence of GVHD and
probability of LFS. Intensification of the conditioning regimen may cause more
extensive injury to the mucosal barrier resulting in higher levels of pro-inflammatory
cytokines, and subsequent increase in GVH reactivity17,18. The addition of idarubicine
may directly increase the cytoreduction of leukemic cells. Finally, idarubicine-
mediated cytoreduction of autologous T cells may enhance the engraftment of donor
T cells, and therefore indirectly result in an increase of GVH reactivity.
In this study we demonstrated that intensification of the conditioning regimen with
idarubicine results in a faster increase in chimerism in T cell subsets. Several studies
have demonstrated the correlation of a reduced incidence of GVHD and increased
occurrence of relapse with mixed chimerism19-21. The ability to enhance conversion to
full hematopoietic chimerism with a cytoreductive drug may have important
consequences especially for patients with hematological malignancies that do not
respond well to immune mediated cellular therapy, such as SCT and (pre-emptive)
donor leukocyte infusion (DLI).
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PATIENTS AND METHODS
Patients and donors
Between March 1984 and December 2000, eighty-nine consecutive patients received
allogeneic stem cell transplantation for CML-CP1. Donors were HLA-A, -B, -DRB, -
DQB identical siblings. The median age of the recipients (48 males and 41 females)
and donors (54 males and 35 females) was 40 years (range 16-61 and 13-71,
respectively) (Table 1). All recipients and donors or their guardians gave their
informed consent. The ethics committee of the University Medical Center St
Radboud, Nijmegen, approved all protocols and consent forms.
Chemotherapy before SCT
Before SCT all 89 patients were treated with hydroxyurea. Nine patients received
additional interferon alpha (Table 1). Interferon was stopped three months before
SCT.
Conditioning regimen
Nineteen patients received conditioning consisting of cyclophosphamide (Cy)
administered intravenously (60 mg/kg body weight) on each of two consecutive days
(day –6 and –5), followed by fractionated total body irradiation (TBI) in two equal
fractions on day –2 and –1 to a total dose of 9 Gy or 12 Gy. Seventy patients received
an intensification of the conditioning regimen with the intravenous infusion of
demethoxy-daunorubicine (idarubicine) to a total dose of 42 mg/m2 body surface on
days –12 and –11, followed by Cy (60 mg/kg body weight) on days –6 and –5 and
fractionated TBI to a total dose of 9 Gy on day –2 and –1. Donor marrow was
partially depleted of T lymphocytes by density gradient centrifugation followed by
counterflow centrifugation as previously described22,23 and infused 24 hours after
completion of TBI. The median number of T cells in the marrow grafts was 0.7 (range
0.4-1.9) × 106 CD3+ cells/kg body weight. Patients received prophylactic antibiotics
according to institutional guidelines. All patients were managed in single rooms with
filtered air under positive pressure during their hospital stay.
GVHD prophylaxis
Immunoprophylaxis after transplantation consisted of cyclosporine A (CsA) 3
mg/kg/day by continuous intravenous administration from day -1 to +14. Thereafter
CsA dose was reduced to 2 mg/kg/day and continued until day 21. Beyond day 21,
CsA was administered orally at a dose of 6 mg/kg/day until 8 to 10 weeks after SCT.
In the absence of GVHD CsA was gradually tapered and eventually discontinued at
12 weeks post grafting.
CHAPTER 6
                                                                                                                                                      
115
Table 1. Patient and donor characteristics and treatment-related variables.
Conditioned with idarubicine Conditioned without idarubicine
No of patients evaluated 70 19
No of male/female recipients
No of male/female donors
36/34
41/29
12/7
13/6
Donor/recipient gender (No)
male to male
male to female
female to female
female to male
17
16
12
25
10
2
4
3
Median age patients (years)
Median age donors
40
42
40
37
No pre-treated with IFN-α 6 3
Conditioning regimen
Cy (60 mg/kg)
TBI (9 Gy)
TBI (12Gy)
70
70
0
19
13
6
No of T cells in the graft 0.7 × 106/kg 0.7 × 106/kg
Follow-up July 1986-January 2002 March 1984-January 2002
IFN-α, interferon-α; Cy, cyclophosphamide; TBI, total body irradiation.
Assessment of hematopoietic chimerism
Hematopoietic chimerism was determined using cytogenetic analysis, red blood cell
phenotyping (RCP), and real-time PCR.
Cytogenetic analysis was performed on unstimulated bone marrow cells (myelo-
monocytic and erythrocytic progenitor cells) and PHA-stimulated T cells of all 89
recipients. Additional differentiation was performed by fluorescent in situ
hybridization: (FISH) on heterosome interphases (400) of sex-mismatched recipient-
donor couples. In patients with a discriminating marker (n = 72) analysis was
performed routinely before SCT, 6 and 12 months after BMT and annually thereafter
as described previously24. The median number of bone marrow metaphases analysed
was 31 (range 14-34) and the median number of metaphases of lymphocytes was 32
(range 8-32), allowing a sensitivity level of 10-12%25.
RCP was performed using a flow cytometric and/or fluorescent microscopic
microsphere method as described previously26-28. All patients had a discriminating
patient and/or donor marker. Patients were evaluated 1, 2, 3, 6, and 12 months after
SCT and annually thereafter.
Real-time PCR for single nucleotide polymorphisms (SNPs) and/or the SMCY
gene15,16 was performed on granulocytes and purified peripheral blood mononuclear
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cell (PBMC) subsets of 10 patients that were randomized between the groups that
received the intensified or non-intensified conditioning regimen. Chimerism was
analyzed 1, 3, 6, 12 months after SCT and annually thereafter.
Isolation of PBMC subsets and granulocytes
Granulocytes were separated from mononuclear cells by Ficoll-Hypaque density
gradient centrifugation. Mononuclear cells were purified using a magnetic cell
separation technique (MiniMacs, Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer's instructions. Mononuclear subsets were defined as
follows: CD3+/CD4+ (Th lymphocytes), CD3+/CD8+ (Tc lymphocytes), CD45+/CD19+
(B lymphocytes), CD45+/CD14+ (monocytes), CD45+/CD15+ (granulocytes), and
CD3-/CD56+ (NK cells). After direct labelling with anti-CD4, -CD8, -CD19 and -
CD14 Microbeads (Miltenyi Biotec), subsets were magnetically isolated on MiniMacs
columns, to a purity of 93-97%. Magnetic sorted subsets were re-incubated with
fluorescent antibodies specific for each cell population and resorted on the flow
cytometer to obtain a purity of more than 98%. Granulocytes were isolated after lysis
of the red blood cells and subsequent incubation with anti-CD45-FITC and anti-
CD15-PE, using flow cytometric sorting (Coulter-Elite, Miami Fl, USA). CD56-PE-
positive NK cells were sorted excluding CD3-FITC-positive staining cells.
Definitions
The first day of engraftment was defined as the first of 3 consecutive days with
peripheral white blood cell (WBC) counts ≥  109/l. Graft failure was defined as
primary when the WBC count remained < 109/l, and secondary when WBC count was
≥ 109/l on 3 or more consecutive days and subsequently dropped to < 109/l during
follow-up.
Relapse in this study was defined as the occurrence of either, or the combination of,
hematological, cytogenetic, and molecular relapse. Hematological relapse was defined
as the reappearance of clinical features and laboratory characteristics of CML.
Cytogenetic relapse was defined as recurrence of metaphases of interphases
containing the Philadelphia chromosome. Molecular relapse was defined as a positive
PCR at two or more consecutive points with a tenfold increase of the Bcr-Abl fusion
transcript measured by real-time RT-PCR29.
Survival was defined as alive at the end of follow-up. Leukemia-free survival was
defined as survival in first hematological, cytogenetic, and, if available, molecular
remission. Current leukemia-free survival was defined as remission in first or second
hematological, cytogenetic and molecular remission, and remaining in that remission
until the end of follow-up. For these patients the follow-up was also defined as from
SCT onwards.
Follow-up
Follow-up was until January 1st 2002 or prior death. Survival and relapse were
followed to the time of last contact with the patient. The median survival of the
patients alive at end of follow-up (n = 58) was 100 months (range 10-187).
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Statistics
Fisher’s exact test and Chi square test were used for comparison of two proportions.
The probability of relapse, leukemia-free survival, current leukemia-free survival and
survival were calculated using the Kaplan-Meier product limit method. Differences in
probabilities were calculated using the Wilcoxon’s log rank test. Differences in
percentages of the sequentially evaluated autologous CD4+ and CD8+ cells between
the patients conditioned with and without intensification with idarubicine were tested
using ANOVA univariate analysis.
RESULTS
Engraftment
Graft failure occurred in 3/89 patients. One patient showed no signs of engraftment
(primary graft failure), while 2 patients rejected their grafts (secondary graft failure).
All of these patients received idarubicine in the conditioning regimen. Patients were
retransplanted with an unmanipulated graft after fractionated total lymphoid
irradiation (total 12 Gy). One patient died of fungal infection before he was evaluable
for engraftment. Another patient died of severe grade 4 acute GVHD 3 months after
retransplantation. One patient remained in molecular remission 110 months after the
first SCT and 108 months after retransplantation.
Development of GVHD
The incidence and severity of acute and chronic GVHD after allogeneic SCT are
summarized in Table 2. Ninety-three percent (83/89) of patients were evaluable for
acute GVHD. The incidence of acute GVHD was significantly higher in patients
conditioned with idarubicine than in patients that received no intensification of the
conditioning regimen (70 and 37%, respectively; p = 0.015, chi square). Severity of
acute GVHD, however, was clinically mild (grade 1 and 2). Severe acute GVHD
(grade 3 and 4) occurred in only 1 out of 67 patients conditioned with the intensified
regimen and in 1 out of 16 patients who were given no intensification of the
conditioning regimen (p > 0.05).
There was a trend for a higher incidence of chronic GVHD after intensification of the
conditioning regimen (48 over 33%; p = 0.3). Extensive chronic GVHD occurred
more frequently after intensification of the conditioning regimen (p = 0.16). However,
the incidence of extensive chronic GVHD was low in both groups (12% and 0%,
respectively). Twenty-eight patients received therapeutic DLI after relapse. After DLI
8/28 patients developed ≥ grade 2 acute GVHD, 6/28 developed chronic limited
GVHD and 2/28 patients developed extensive chronic GVHD.
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Table 2. Incidence of GVHDa in evaluable patients conditioned with or without the addition
of idarubicin.
Percentage of patients (n)
Conditioned with idarubicine
(n = 67)
Conditioned without idarubicine
(n = 19)
Acute GVHD
Grade 1 49   (33) 31     (5)
Grade 2 20   (13) 0       (0)
Grade 3 0       (0) 0       (0)
Grade 4 1       (1) 6       (1)
Chronic GVHD
Limited 36    (21) 33     (5)
Extensive 12      (7) 0       (0)
aThe clinical manifestations of acute GVHD were classified from grade 1 to 4, according to
the criteria described by Glucksberg, et al46. Chronic GVHD was graded as limited or
extensive as described by Shulman et al47.
Mortality after allogeneic SCT
Thirty-one of 89 patients (35%) died after SCT. Principal causes of death were relapse
(n = 10), GVHD-related causes (n = 6), infection (n = 6), acute respiratory distress
syndrome (n = 2), veno-occlusive disease (n = 2), secondary malignancy (n = 2),
failure of engraftment (n =1), miscellaneous (n = 2). Nine out of 19 patients (47%)
conditioned without idarubicine died. Overall mortality in the patients conditioned
with idarubicine was 22 out of 70 (31%). Non-relapse mortality was 32% in the
patients conditioned without idarubicine and 21% in the patients conditioned with
idarubicine. The day-100 mortality after SCT was lower in the patients conditioned
with idarubicine although this difference was not significant (21% versus 6%, p =
0.06).
Intensification of the conditioning regimen with idarubicine reduces the probability
of relapse of CML-CP1 after allogeneic SCT
Figure 1a shows the probability of relapse in patients after allogeneic SCT with and
without intensification of the conditioning regimen. Patients conditioned with the
intensified conditioning regimen had a significantly lower probability of relapse (p =
0.002) compared with the patients conditioned without idarubicin.
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Figure 1. Probability of relapse (a), leukemia-free-survival (b), and
current leukemia-free-survival (c), after SCT for CML-CP1 patients
conditioned with or without intensification of the conditioning regimen
with idarubicine
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The 5-year probability of relapse for the patients conditioned with and without
idarubicine was 40 and 69%, respectively (Table 3).
Table 3. Five-year probability of relapse, leukemia-free survival, survival and current
leukemia-free survival and P values for patients conditioned with and without the addition of
idarubicine.
5-year probability of Percentage (95% Confidence Interval) p-valuea
With idarubicine Without idarubicine
Relapse 40 (26-54) 69 (45-93) p = 0.002*
Survival 72 (61-83) 68 (47-89) p = 0.14
LFS 47 (31-63) 24 (4-44) p = 0.006*
Current LFS 69 (57-81) 62 (41-83) p = 0.17
ap-value of differences in treatment outcome of patients conditioned with idarubicine versus
no idarubicine, using two-tailed Log Rank test. *P < 0.05.
Intensification of the conditioning regimen with idarubicine increases the
probability of leukemia-free survival after allogeneic SCT
The 5-year probability of survival for the patients conditioned with the intensified
regimen was not different from the 5-year probability of survival in the patients
conditioned without idarubicine (72 and 68%, respectively; p = 0.14) (Table 3).
However, 5-year probability of leukemia-free survival (LFS) for the patients
conditioned with the intensified conditioning was significantly higher compared with
the probability of LFS obtained in the patients conditioned without idarubicine (47
and 24%, respectively; p = 0.006) (Table 3). The probabilities of LFS for the two
different conditioning regimens are depicted in figure 1b.
Patients who remained in complete remission or who responded to therapeutic donor
leukocyte infusions (DLI)30 with a second complete hematological, cytogenetic and
molecular remission, were considered ‘current’ leukemia-free survivors. Twenty-eight
patients received DLI with a median number of 0.7 (range 0.1–2.8) × 108 CD3+
lymphocytes/kg body weight. Nine were from the group without idarubicine (i.e. 47%
of this group) and 19 patients received the intensified conditioning (i.e. 27% of this
group). Both groups responded equally well (70 (7/9) and 72% (13/19), respectively)
to DLI, causing the current LFS to be equal (p = 0.17).
Analysis of hematopoietic chimerism using RCP provides a good marker for relapse
Hematopoietic chimerism was assessed at 6 and 12 months after SCT using red blood
cell phenotyping (RCP) and/or cytogenetic analysis. There was a good correlation
between the increasing number of autologous red blood cells (as part of the CML-
clone), the reappearance of Philadelphia chromosome positive metaphases, FISH-
positivity for the Philadelphia translocation, and the quantitative amount of Bcr-Abl
fusion transcripts measured by quantitative real-time RT-PCR (data not shown).
Figure 2a shows the correlation of different relapse markers with autologous red
blood cell hematopoiesis as determined by RCP for UPN 480.
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Figure 2. Percentage of autologous cells in hematopoietic subsets of
UPN 480 after allogeneic SCT. (a) Percentage recipient red blood cells
combined with the amount of the Bcr-Abl fusion transcript real-time
quantitative RT-PCR in blood and bone marrow, relative to expression in
K562 cell line. (b) Percentage of recipient granulocytes and monocytes in
the peripheral blood. (c) Percentage of recipient peripheral blood NK
and CD4+ and CD8+ T cells. DLI was given at day 292 after SCT.
Using RCP and cytogenetics no difference was observed in the number of patients
with mixed chimerism after SCT who were conditioned with or without idarubicine
(data not shown).
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Quantitative analysis of chimerism in purified subsets of PBMC and granulocytes
Several studies have demonstrated the role of hematopoietic chimerism in the
development of alloimmune responses21,25,31,32. We found an increase in the incidence
and severity of GVHD and an increase in LFS in patients treated with an idarubicine-
intensified conditioning regimen. GVHD is a direct reflection of increased
alloreactivity, whereas LFS may at least in part reflect an increase in GVH reactivity.
We studied whether altered alloreactivity between patients treated either with or
without an idarubicine-intensified conditioning regimen correlated with altered
dynamics in the development of chimerism. Therefore, we randomised ten patients
between recipients of allogeneic SCT that either received no intensification of the
conditioning regimen, or that received intensification of the conditioning regimen
with idarubicin. We increased the frequency of monitoring of chimerism, compared to
the cytogenetic analysis that was performed, to 1, 3, 6, and 12 months, and annually
thereafter. Moreover, we used a recently developed real-time PCR to sensitively
quantify chimerism in purified subsets of PBMCs and granulocytes. The use of
lineage-specific analyses further increases the sensitivity of quantitative assessment of
chimerism33. Six patients (2 patients conditioned with idarubicine and 4 patients
conditioned without idarubicine) in this group relapsed from CML. Five out of six
patients responded to therapeutic DLI with a second complete remission. One patient
conditioned with the intensified regimen relapsed in accelerated phase/blast crises and
did not respond to DLI and died of progressive disease.
At a median of 1 month (range 1-3 months) after SCT all granulocytes and monocytes
were donor derived. In the six patients who relapsed, the recipient granulocytes and
monocytes started to increase at time of relapse suggesting they are part of the
malignant CML clone. Recipient myeloid cells decreased in patients that responded to
therapeutic DLI and became undetectable at time of second complete remission until
end of follow-up. Figure 2b shows the percentages of autologous granulocytes and
monocytes after SCT in UPN 480. Dynamics of persistence of autologous
granulocytes and monocytes paralleled real-time RT-PCR data for Bcr-Abl and RCP
as shown in Figure 2a.
Recipient NK cells defined as CD3-/CD56+ cells had completely disappeared at a
median of 6 months (range 3-12) in all 10 patients. The percentage of autologous cells
did not increase during relapse of CML, except in one patient (UPN 480, Figure 2c).
In this patient CD3-/CD56+ recipient cells increased simultaneously with the red cells,
monocytes and granulocytes during relapse of CML.
During density gradient and counterflow centrifugation not only the T cells but also B
lymphocytes are depleted from the stem cell graft. This B cell-depletion results in a
delayed B cell reconstitution after SCT. The first six months after SCT the number of
B cells isolated by MACS and flow cytometric techniques were too small to obtain
sufficient amounts of DNA for a reliable quantification by real-time PCR. Therefore,
the isolation of CD45+/CD19+ cells from the peripheral blood was stopped after the
fifth randomised patient.
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In summary, we observed no differences in time to reach complete donor chimerism
in granulocytes, monocytes and NK cells, between patients conditioned with or
without idarubicine. Conversion to donor hematopoiesis was fast (within 1 month) for
granulocytes and monocytes. NK conversion was complete after median 6 months.
The addition of idarubicine enhances the conversion of T lymphocytes to donor
origin
T cells are important mediators and effectors of allogeneic immunoresponses. T cell
chimerism was monitored in CD3+/CD4+ (Th) and CD3+/CD8+ (Tc/s) subsets (Figure
3a and b). In both groups the percentage of autologous T cells decreased after SCT
and full chimerism developed in all randomised patients. In patients that received no
idarubicine complete T cell chimerism developed at a median of 12 months (range 3-
24) after SCT. In contrast, patients conditioned with the intensified conditioning
regimen developed full T cell chimerism at a median of 3 months (range 1-12) after
SCT. One month after SCT the median percentages of autologous Th and Tc cells
were relatively high (median 95 and 30%, respectively) in patients conditioned
without idarubicine, whereas Th and Tc cells were already lower in patients who
received intensification of the conditioning regimen (median 10 and 20%). Univariate
analysis showed that the addition of idarubicine contributed significantly to a lower
percentage Th and Tc cells at 1 and 3 months after SCT (p = 0.02).
In the six patients who relapsed with CML the percentage of Th and Tc recipient cells
showed a continuous decreasing pattern independently of increasing percentages of
autologous myeloid and red blood cells. In figure 2a, b, and c these observations are
shown for UPN 480. Patients who had not received intensification of the conditioning
regimen relapsed when they still had a relatively high number of autologous
lymphocytes (Figure 3a and b). Response to DLI was favourable and coincided with a
rapid decrease of the percentage of autologous T cells.
These results show that intensification of the conditioning regimen with idarubicine
enhances the conversion of T cells to donor origin. This enhanced hematopoietic
conversion of genotype coincides with a favourable clinical outcome that may result,
at least in part, from an increase in graft-versus-host (GVH) reactivity.
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Figure 3. Percentage autologous T lymphocytes after allogeneic SCT
in CML-CP1 patients conditioned with (light bars) or without
idarubicin (dark bars). (a) CD3+/CD4+ Th lymphocytes, and (b)
CD3+/CD8+ Tc lymphocytes. The arrows indicate time of DLI for
UPN 459 and UPN 480.
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DISCUSSION
The development of GVHD limits the success of allogeneic SCT as treatment for
CML. The incidence and severity of GVHD can be reduced by removal of
immunocompetent T lymphocytes from the graft. T cell depletion, however is
associated with increased incidence of graft rejection and recurrent leukemia8,10.
Addition of a fixed number of T cells to the stem cell graft after partial depletion of T
lymphocytes by counterflow centrifugation, results in a low incidence of graft failure
in patients transplanted for standard risk acute and chronic leukemia22,34.
Intensification of the conditioning regimen with idarubicine reduces the incidence of
relapse significantly in patients treated for AML, ALL, and CML with T cell depleted
SCT14. Based on these results we hypothesized that the addition of idarubicine may
exert an immunomodulatory effect.
In the current study we evaluated the clinical significance of an intensification of the
conditioning regimen with idarubicine before allogeneic SCT in a large population of
patients with Philadelphia chromosome positive CML in first chronic phase, who
were either conditioned with (n = 70) or without (n = 19) idarubicine. In order to
identify cellular immune mechanisms that may play a role in a differential outcome of
SCT after an idarubicine intensified conditioning regimen we randomized 10 patients
to receive a conditioning regimen with or without intensification with idarubicine.
The choice to randomize only patients with CML was based on the knowledge that if
patients would relapse, CML responds relatively well to cellular immunotherapy with
donor lymphocytes.
Intensification of the conditioning resulted in a significantly lower incidence of
relapse and increased LFS, concordant with earlier observations14. Graft failure and
acute transplant-related-mortality were low. The introduction of highly sensitive
molecular techniques that quantitatively detect minimal residual disease in early phase
after SCT increased the amount of identified relapses. Therefore, relapse rates in this
study might appear relatively high compared to studies that defined relapsed CML
only as cytogenetic and/or hematological relapse. Therapeutic DLI induced complete
secondary missions in the majority of relapsed patients. Therefore, the 5-year
probability of current LFS was similar between both groups. Early detection of
relapse may have contributed to the high number of DLI-induced secondary
remissions35. The conditioning received before SCT did not influence response to
therapeutic DLI. However, therapeutic DLI to treat relapse was administered median
25 months after SCT. This may be significantly late in relation to possible
immunomodulatory effects caused by the addition of idarubicine.
The patients in this study treated with the intensified conditioning developed
significantly more acute GVHD compared to the patients who received no
intensification of the conditioning regimen, although clinically mild. There was a
trend for more chronic GVHD in the patients conditioned with the intensified
regimen. These observations are congruent with the data obtained from our previous
study14.
We considered several different mechanisms underlying the increased incidence and
severity of GVHD and the lower relapse rates in patients treated with an intensified
conditioning. An important factor affecting the development and severity of GVHD
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may be the direct toxicity of idarubicine on tissues like gastro-intestinal mucosa, liver
and skin resulting in an increased release of cytokines from these tissues with
additional activation of donor T lymphocytes18,36. Idarubicine may directly contribute
to an increased eradication of residual leukemic cells, resulting in decreased relapse
rates after SCT. Furthermore, idarubicine may eliminate immunocompetent
autologous T lymphocytes before SCT. In this way the potential of autologous T cells
to abrogate donor T cell mediated allo-reactivity may be reduced32,37. Moreover,
reduced HVG T cell reactivity may enhance donor T cell engraftment, and their
subsequent potential to exert GVH alloreactivity.
We investigated the effect of idarubicine on the dynamics of hematopoietic chimerism
as a reflection of enhanced immunoreactivity of donor derived immunocompetent
cells against cells of recipient origin including the leukemic cells. Chimerism in
lymphoid and myeloid subsets of 10 randomized recipients was investigated with a
recently developed real-time quantitative PCR for the detection and quantification
single nucleotide polymorphic alleles. The sensitivity of this technique combined with
subset-specific analysis allowed accurate quantitative monitoring of hematopoietic
chimerism15,16,33. After SCT the genotype of hematopoietic cells was frequently
monitored over a period of 12 months and annually thereafter. Six patients relapsed
from CML and recurrence of leukemia identified by specific detection with markers
(Bcr-Abl) coincided with an increase of host hematopoiesis in myeloid subsets. In the
absence of relapse we found no difference in the time to conversion to complete donor
chimerism of myeloid subsets in patients with or without intensification of the
conditioning regimen.
Several studies attribute important anti-leukemic activity to activated NK cells38-41.
We did not observe a difference in hematopoietic conversion kinetics of NK cells in
the patients treated with and without an intensified conditioning regimen. Six months
after SCT all NK cells were donor derived. One patient (UPN 480) showed an
increase in the percentage of CD3-/CD56+ (defined as NK cells) autologous cells
simultaneously with the autologous red cells, monocytes and granulocytes during
relapse (fig 2c). This unexpected finding may be explained by the aberrant expression
of the CD56+ antigen on subsets of granulocytes belonging to the CML-clone.
Autologous dendritic cells (DCs) are critical in the induction of GVHD and GVL
reactivity42,43. We do not know whether the addition of idarubicine increased the
reduction of autologous DCs. Theoretically this may result in abrogation of GVL
reactivity. Host DCs, however, can prime donor T cells within 24 hours, prior to their
decay as a result of the conditioning regimen43. Moreover, the incidence and severity
of GVHD was increased after additon of idarubicine, as is the LFS, suggesting that
potential enhanced reduction of autologous DC does not negatively influence the
development of GVL reactivity.
A significant difference in the hematopoietic conversion from recipient to donor
origin was observed in T lymphocytes. After addition of idarubicine in the
conditioning regimen, both CD4- and CD8-positive subsets were almost completely
donor-derived within one month after SCT. Conversion of T cells to donor origin was
much slower in 3 out of 5 patients that received no intensification of the conditioning
regimen. In this group 2 out of 3 patients relapsed.
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These observations may confirm the hypothesis of an immunomodulatory effect
mediated by idarubicine on the development of GVH reactivity after conditioning
with an intensified regimen. Addition of idarubicine enhances the conversion of T
cells to donor origin. Several mechanisms may contribute to enhanced conversion,
including idarubicine-induced increase of ‘danger’ and cytoreduction of autologous T
cells, resulting in enhanced engraftment of donor T cells in an environment that
increases immune effector function.
Salvage therapy with DLI compensates for higher relapse rates in CML patients
associated with partially T cell-depleted SCT, resulting in 5-year survival rates up to
80%11,12,44. We found no differences in current LFS in patients that did not receive
intensification of the conditioning regimen, due to the excellent responses to DLI.
DLI did largely compensate for the higher relapse rates observed in this group.
However, for patients who relapse from ALL and AML the success rate of therapeutic
DLI is low30,35. The introduction of idarubicine decreases the probability of relapse,
and increases LFS, in patients transplanted for CML as well as in patients transplanted
for ALL and AML14. Enhanced development of alloreactive responses after SCT and
DLI is associated with the extent of T cell chimerism. Mixed T cell chimerism is
correlated with a reduction of the development of GVH related alloreactivity,
compared to full chimerism. We found a more rapid conversion of T cells to donor
origin after the addition of idarubicine in the conditioning. These rapid kinetics may
also explain the favourable outcome of pre-emptive DLI for patients with acute
leukemia who do not suffer from significant GVHD after SCT45, since these patients
usually relapse early after SCT. Pre-emptive DLI in the context of complete donor T
cell chimerism may be more immune effective compared to infusion of donor
leukocytes in a situation of mixed T cell chimerism. Taken together, intensification of
the conditioning regimen to prevent relapse after T cell depleted SCT of recipients
that usually do not respond well to therapeutic DLI to treat relapsed leukemia, may
enhance the development of GVL reactivity associated with pre-emptive DLI,
because of enhanced conversion to full T cell chimerism before DLI.
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Allogeneic hematopoietic stem cell transplantation (SCT) following high-dose
systemic chemo- or chemoradiotherapy is the most effective curative treatment for
patients with leukemia. The therapeutic effect of this form of therapy is based on a
steep dose-response reaction of leukemic cells to alkylating agents and/or irradiation.
Unfortunately, normal tissues are also damaged, including healthy hematopoietic stem
cells of the recipient. Stem cells from a donor are infused to reconstitute the
hematopoietic and immune system of the recipient. Interestingly, this transplantation
of donor hematopoietic stem cells provides an additional therapeutic component.
Donor graft-derived T cells can mediate an immunological elimination of residual
leukemic cells, called graft-versus-leukemia (GVL) reactivity. A major complication
associated with donor T cell reactivity is the development of alloreactive responses
towards normal host tissues, called graft-versus-host-disease (GVHD).
The conditioning treatment before allogeneic SCT suppresses the recipient’s immune
system and allows the engraftment and outgrowth of hematopoietic cell populations
of donor origin. T cells in the graft contribute to the establishment of chimerism, that
is, the engraftment and outgrowth of donor hematopoetic cells, by a graft-versus-host
response towards hematopoietic cells. Patients undergoing unmanipulated allogeneic
SCT usually develop full donor hematopoiesis. When the graft is T cell depleted, or
when the conditioning regimen is reduced in intensity, mixed chimerism develops
more frequently.
Relapse of leukemia after allogeneic SCT can be successfully treated by adoptive
cellular therapy with donor lymphocyte infusions (DLI)1-3. Here, donor T cells are the
primary therapeutic modality. However, a significant percentage of patients fails to
respond to this form of therapy. In non-myeloablative allogeneic SCT,
immunosuppressive conditioning is administered merely to allow donor cell
engraftment, and not to eradicate the malignancy. In this way a graft-versus-host
response can be generated towards a broad range of malignancies, including solid
tumors. Patients treated for solid tumors with SCT after non-myeloablative
conditioning or reduced intensity conditioning (RIC) only show tumor remission after
full hematopoietic conversion to donor origin. Apparently, the genotype of the bone
marrow, or, the extent of hematopoietic chimerism, at the time of relapse, may
influence the inititation and magnitude of T cell mediated graft-versus-malignancy
reactivity. Previously, we observed that a high percentage of T cells of host origin in
the peripheral blood of relapsed patients at the time of DLI significantly correlates
with non-responsiveness4. Absence of GVHD in these patients suggests that infused
donor lymphocytes were reactive neither to leukemia cells nor to normal tissues. Host
T cells can inhibit the development of GVHD induced by DLI in a murine bone
marrow transplantation (BMT) model5. However, donor-derived regulatory T cells
developing post-BMT may also be involved in suppression of GVHD after DLI,
probably by induction of tolerance6. The mechanisms by which either donor-derived
or recipient-derived T cells contribute to tolerance or non-responsiveness of infused
donor lymphocytes have not been clearly demonstrated yet.
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The research described in this thesis focusses on the role of the T cell genotype in the
development of alloreactive immune responses. The first part of the thesis describes
the development of a methodology to study the fate of infused T cells, and its
implementation in in vivo mouse and rat transplantation models.
Monitoring of T cell survival, distribution and function
Survival and migration of T cells used for cellular immunotherapy are important
parameters influencing treatment results. To study these parameters we chose to
genetically mark T cells with a Moloney Murine Leukemia virus (MoMLV)-based
vector (Chapter 2) before infusion. Real-time PCR primers and probes were designed
for the detection of a MoMLV provirus-specific DNA sequence, enabling the
detection and sensitive quantification of cells marked with any MoMLV-based vector.
Furthermore, marked cells can be accurately quantified long-term even after in vivo
proliferation, without loss of signal, because of stable integration of retroviral genetic
sequences into the host genome. Finally, detection of cells via non-expressed genetic
retroviral sequences ensures the absence of immunogenicity that may be induced by
expressed marked gene sequences. This is of particular importance when studying the
fate of immune effector cells in an allogeneic setting.
A prerequisite for successful retroviral transduction is that cells divide. During mitosis
the nuclear membrane breaks down, allowing the reverse transcribed provirus to
stably integrate into the host genome. Therefore, cells have to be stimulated in vitro.
Ex vivo manipulation of cells may potentially affect their in vivo survival, migration
patterns, and function. This could be of importance for several immunotherapeutic
approaches that involve the use of in vitro activated T cells. CTLs used in adoptive
cellular immunotherapy for EBV-induced post-transplant lymphoma and relapsed
Hodgkin’s disease, for example, are activated and cultured for several days to weeks
to generate sufficient amounts of specific T cells. Another example is the use of T
cells that have been retrovirally transduced with the HSV-Tk suicide gene, to induce
GVL-activity with control of GVHD.
In Chapter 2 we showed that the period of in vitro stimulation and expansion of
syngeneic murine splenic T cells before infusion strongly influences their survival and
trafficking patterns. Cells were cultured for 3 days as the shortest culture period
possible to ensure stable proviral integration and rule out discrepancies in viral DNA
content per cell. After infusion a significantly higher percentage of labeled cells
persisted in all tissues tested when cells had been cultured for 3 days after ConA/IL-2
stimulation in comparison to cells that had been cultured for 8 days. In addition,
shortly after infusion high percentages of cells cultured for 3 days were found in lungs
and liver. Thereafter, increasing percentages are found in lymph nodes and spleen.
Cells cultured for 8 days preferentially migrated to liver and could hardly be detected
in lymph nodes. This altered persistence and distribution of cultured cells, may reduce
the alloreactive potential of these cells. Contassot et al., and Weijtens et al., described
a reduced capacity of allogeneic T cells that had been cultured before infusion to
induce GVHD7,8. Culture conditions can be adapted to restore the allogeneic effector
capacity of cultured T cells in mice7, and transduced T cells and rats8. Using the
optimized culture and gene transduction protocol, described by Weijtens et al.8, we
studied the capacity of HSV-Tk transduced donor T cells to evoke GVHD in a rat
model after a Class I mismatched allogeneic BMT, supplemented with retrovirally
transduced T cells (Chapter 3). The in vivo distribution and quantity of the added
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transduced T cells were related to the development of GVHD. In the peripheral blood
of allogeneic transplanted rats HSV-Tk+ T cells increased simultaneously with the
onset and progression of GVH reactivity, and closely preceded clinical symptoms of
GVHD. The percentage of allogeneic HSV-Tk+ T cells was significantly higher in all
tissues examined, compared to HSV-Tk+ T cells in syngeneic transplanted rats, 18
days after BMT. T cells showed specific localization patterns in subepithelial regions
of skin, intestines, and tongue, indicating specific homing to target sites. Also, typical
GVH-induced loss of tissue architecture was observed. Notably, in GVHD target
organs most T cells were HSV-Tk positive. Taken together, we showed the
involvement of transduced T cells in in vivo alloreactivity. Furthermore, we showed
that the persistence and distribution of these cells can accurately be monitored.
Reccurent T cells of recipient origin may contribute to failure of adoptive cellular
immunotherapy by rejection of infused donor lymphocytes
The mechanisms by which either donor-derived or recipient-derived T cells contribute
to tolerance or non-responsiveness of infused donor lymphocytes are not clearly
clarified yet. In Chapter 4 we identified a mechanism that may contribute to
unresponsiveness to DLI in relapsed patients. We studied the fate of infused donor T
cells after DLI in recipients with hematopoiesis that reverted to host origin after
allogeneic SCT. Therefore, retrovirally marked donor T cells were infused in rats
repopulated with either recurrent host or persistent donor WBCs. Significant numbers
of retrovirally marked donor T cells persisted after infusion in recipients that
developed stable donor hematopoiesis after BMT. In contrast, infused T cells were
rejected within 3 days in rats with recurrent host hematopoiesis after BMT. The rapid
elimination of transferred donor T cells suggests that this clearance is an active
process mediated by recipient T cells, likely sensitized in vivo. Recurrent T cells of
recipient origin, present at the time of DLI, may therefore inhibit alloreactivity of
infused donor lymphocytes by eliminating these cells. This mechanism can contribute
to failure of adoptive allogeneic immunotherapy after SCT in humans who show
hematopoietic cell reversion from donor to host origin.
The presence of recurrent or persisting host immunocompetent T cells after allogeneic
SCT may reduce the success of subsequent adoptive immunotherapy with donor T
cells. From this perspective recipient T cell immunereactivity should be suppressed to
prevent abrogation of donor T cell reactivity. Moreover, T cell suppression should be
confined to host T cells, which may be difficult with systemic approaches. Non
recipient T cell specific immunosuppression should preferably be mild and transient.
T cell immunosuppression can be achieved via several approaches. The
administration of pharmacological agents, usually used in combination (typically
cyclosporin A and methotrexate), have been widely used as prophylaxis for acute
GVHD (reviewed in9). Newer pharmacological agents, such as rapamycin10,
mycophenolate mofetil11, trimetrexate12, GLAT13, and PG2714, are under investigation.
More aggressive approaches are used for the treatment of acute GVHD, such as
steroids15, and mAbs towards CD316 and interleukin-2 receptor17,18. Unfortunately,
increased risk of serious infections is a major complication after high doses of
steroids. Successful blocking of costimulatory molecule interactions has been
achieved via systemic administration of the CTLA4-Ig fusion protein or antibodies19,
or antibodies against CD40L20. Van Oosterhout et al.21 described the administration of
immunotoxins (ITs), consisting of anti-CD3 and -CD7 mAbs conjugated to
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deglycosylated ricin A (dgA) for the successful treatment of acute GVHD. T cell
immunosuppression was transient and the presence of the CD3-IT provided instant
immunosuppression independent of dgA-based toxicity. Moreover, treatment
selectivity towards activated cells was suggested.
Increased alloimmune reactivity induced by intensification of the conditioning
regimen coincides with a rapid conversion to full T cell chimerism
In the final part of this thesis we described the development of a method to
quantitatively monitor the genetic origin of hematopoietic cells, and used this
technique in a clinical study to monitor changes in chimerism in relation to altered
alloimmune reactivity.
A major complication associated with allogeneic SCT is the development of GVHD.
The occurence and severity of GVHD can be reduced by the depletion of T cells from
the graft. However, the removal of immunocompetent T cells from the graft is
associated with an increased risk of recurrence of leukemia. A strategy to reduce the
risk of relapse after T cell depleted SCT is the intensification of the conditioning
regimen. Addition of the chemotherapeutic drug idarubicine to the conditioning
regimen of patients treated for CML with allogeneic SCT resulted in an increase in
the occurrence and severity of GVHD and in a higher leukemia free survival (LFS)
(Chapter 6). We developed allele-specific quantitative real-time PCRs for seven
single nucleotide polymorphisms (SNPs), which enabled us to unilaterally
discriminate 97% of HLA-identical sibling pairs. Both recipient- and donor-derived
hematopoietic cells can be quantified in 67% of sibling pairs (Chapter 5). We
monitored hematopoietic chimerism in different subsets after SCT, and found that the
increase in GVHD and LFS after intensification of the conditioning regimen with
idarubicine coincided with a faster increase in chimerism in both CD4 and CD8 T cell
subsets. The addition of idarubicine to the conditioning had no differential effect on
the time to reach full chimerism in non-T cell subsets. These chimerism dynamics
may confirm the importance of the genotype of immune mediators in the development
of allogeneic responses. Furthermore, they imply the importance of T cells in the
development of allogeneic reactivity.
Monitoring of dendritic and T cell chimerism as predictive “read-out” for immune
status
DCs are the most potent antigen presenting cells specialized for the initiation of
primary T cell immunity22,23. Recent evidence in murine allogeneic BMT and DLI
models demonstrated that DCs of host origin are critical in the induction of GVHD
and GVL reactivity24-26. Frequent monitoring of chimerism, both in DCs and T cells,
would provide valuable information on the immune status of the recipient before, at
the time of, and after adoptive cellular immunotherapy. The assessment of DC and T
cell chimerism could be used as a reliable indicator of the probable outcome of this
form of therapy, and provide a platform for choosing approaches to manage adoptive
immunotherapy on an individual patient basis, guiding it to a successful outcome.
We have shown that the feasibility to accurately quantify chimerism of T cells and
other easily obtainable hematopoeitic cells (Chapters 5 and 6). DC chimerism,
however, is difficult to monitor, since tissue DCs are difficult to obtain. The
peripheral blood could provide a readily accessible source for DCs. The identification
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of several DC-specific markers27,28 has made it easier to obtain these cells from the
peripheral blood, despite their scarcity.
The interrelationship, however, between the different DC subsets found in the
peripheral blood that have been identified thus far, and their relation with tissue DCs,
is still obscure and needs further investigation27,28. More importantly, little is known
about their functional antigen-presenting activity, and whether this activity accurately
reflects the tissue-DC function. Klangsinsirikul et al.29 showed a rapid in vivo
pretransplant reduction of circulating host myeloid (CD11c+) and plasmacytoid DCs
(CD11c-) by the Campath-1G MoAb (anti-CD52). This may in part explain the lack of
severe acute GVHD in patients after pretransplant Campath treatment30-32, and suggest
a role for circulating DCs in the overall antigen presenting-activity. However, CD52
is differentially expressed on resident DC subsets33 and it is unclear whether in this
way tissue DCs are depleted as efficiently as BDCs. In addition, donor T cell
depletion at the time of marrow infusion by persistent high plasma levels of Campath-
1G may also contribute to the suppression of acute GVHD34. Thus, it is impossible to
separate the effect of T cell depletion of the graft from pretransplant host DC
depletion on the development of GVHD.
Host DCs can prime naïve donor CD8+ T cells within 24 hours24,35, prior to their decay
and disappearance as a result of the conditioning regime. Activated T cells can
undergo as many as 7 divisions, by the time that <1% of residual host DC are
detectable24. Thus, DCs can inititate the induction of allogeneic immune reactivity
within a narrow kinetic window, and subsequently disappear, while T cells
consequently expand.
In summary, both DC and T cell chimerism provide valuable information on the
immunological state of ‘co-existing allogeneic cells’, and consequently contribute to
the success of adoptive cellular immunotherapy. DC chimerism may be the most
accurate prerequisite for predicting alloimmune responsiveness after cellular
immunotherapy. However, tissue DCs are hard to obtain, while DCs from the
peripheral blood, which are easier to obtain, may not reflect tissue DC antigen-
presenting function. Ongoing research may provide answers to these questions. The
role of T cell chimerism in the development of alloimmune responses is extensively
studied and demonstrated. In terms of availability and quantity, T cells provide an
easier, and therefore more reliable ‘read-out’, allowing frequent monitoring of cells
with defined specificity within a dynamic process.
The adoptive transfer of allogeneic immune effector cells constitutes an exceptional
setting that can be exploited therapeutically to induce responses that otherwise would
be difficult to create. Better understanding of the mechanisms involved contributes to
the development of means to exploit this setting.
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Leukemie en maligne lymfomen zijn kwaadaardige aandoeningen (kanker) van het
beenmerg, en organen die bloedcellen gebruiken voor hun functioneren, zoals
lymfeklieren, milt, thymus, en lymfoïd weefsel in de ademhalingswegen en darmen.
Bloed ontstaat uit stamcellen, die zich vermenigvuldigen en ontwikkelen tot
volwassen bloedcellen, zoals witte bloedcellen (leukocyten), rode bloedcellen
(erythrocyten), en bloedplaatjes (thrombocyten). Stamcellen bevinden zich in het
beenmerg. Stamceltransplantatie is een effectieve manier om leukemie te behandelen.
Hierbij worden kwaadaardige cellen vernietigd door middel van chemotherapie,
eventueel in combinatie met bestraling van het hele lichaam. Helaas worden bij hoge
behandelingdoses ook niet-kwaadaardige beenmergcellen ernstig beschadigd. De
patiënt verliest daardoor zijn/haar weerstand (immuunsysteem). Infusie van
stamcellen (de feitelijke stamceltransplantatie) stelt de patiënt in staat opnieuw een
goed functionerend immuunsysteem op te bouwen. De in dit proefschrift beschreven
stamceltransplantaties betreft transplantaties met stamcellen van een donor, de
zogenaamde ‘allogene’ stamceltransplantie. Hierbij krijgt de patiënt als het ware het
immuunsysteem van de donor (meestal een broer of zus). Dit allogene
immuunsysteem blijkt in staat overgebleven (residuale) leukemische cellen, die niet
door middel van chemo-/bestralingstherapie gedood konden worden, als ‘gevaarlijk’
te ‘zien’ en immuunreactiviteit te ontwikkelen tegen deze cellen. Dit noemt men
graft-versus-leukemia reactiviteit. Het therapeutisch succes van allogene
stamceltransplantaties is dus gebaseerd op enerzijds chemo- en radiotherapie, en
anderzijds een immuunreactiviteit van het getransplanteerde immuunsysteem van de
donor tegen leukemiecellen. Helaas beperkt het nieuwe immuunsysteem zijn
reactiviteit meestal niet tot leukemische cellen, maar kan het ook een respons tegen
gezonde organen van de patiënt ontwikkelen. Dit fenomeen, de zogenaamde graft-
versus-host ziekte, is één van de grootste complicaties van allogene
stamceltransplantaties.
Bij een ‘standaard’ allogene stamceltransplantatie worden alle bloedcellen van de
patiënt vervangen door bloedcellen van donororigine. Deze patiënten zijn ‘complete
hematopoietische chimeren’ (full hematopoietic chimeras). Immuunreactiviteit van
donorcellen tegen residuale bloedcellen van de patiënt speelt een rol in het ‘aanslaan’
en uitgroeien van deze cellen. Als van het ‘standaard’ protocol wordt afgeweken, kan
een situatie ontstaan waarbij immuunsystemen van donor en ontvanger origine naast
elkaar bestaan. Dit noemt men ‘gemengd chimerisme’ (mixed hematopoietic
chimerism). Denk hierbij bijvoorbeeld aan een voorbehandeling van de patiënt met
lagere doses chemotherapie, waardoor het immuunsysteem van de patiënt minder
verzwakt is, en het als het ware weerstand kan bieden aan de immuunreactiviteit van
het transplantaat. Het naast elkaar bestaan van twee immuunsystemen, die in principe
in staat zijn om een respons tegen elkaar te ontwikkelen, betekent dat er sprake is van
regulatie van immuunreactiviteit. De manier waarop immuunresponsen worden
gereguleerd is zeer complex.
T cellen zijn witte bloedcellen die een belangrijke rol spelen bij de ontwikkeling en,
met name, de uitvoering van allogene responsen. Zij kunnen er echter ook voor
zorgen dat er juist geen immuunrespons optreedt, de zogenaamde tolerantie-inductie.
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T cellen kunnen als zogenaamde ‘effectorcellen’ gebruikt worden als therapie. Dit
gebeurt met name ná allogene stamceltransplantatie, wanneer de leukemie
‘terugkomt’ (recidiveert). Meestal gaat het hierbij om residuale leukemiecellen die
chemotherapie, radiotherapie, én donor immuunreactiviteit hebben overleefd, en weer
gaan woekeren. Infusie van donor T cellen van dezelfde donor als van de
stamceltransplantatie, kan leukemiecellen opruimen, door graft-versus-leukemia
reactiviteit. Met name gerecidiveerde chronische myeloïde leukemie is op deze
manier goed te behandelen.
De ontwikkeling van immuunresponsen is een complex proces, dat door een groot
aantal factoren wordt beïnvloed. In dit proefschrift wordt de rol van T cel chimerisme
in de ontwikkeling van graft-versus-leukemia en graft-versus-host reactiviteit
beschreven, en één van de mechanismen die mogelijk een rol spelen in verminderde
immuunreactiviteit na therapie met donor T cellen. Om dit te kunnen onderzoeken
hebben we een techniek ontwikkeld om T cellen na infusie in het lichaam te kunnen
vervolgen (Hoofdstuk 2). Bij sommige vormen van immuuntherapie met T cellen is
het noodzakelijk om deze cellen tot grotere hoeveelheden op te kweken vóórdat ze
getransplanteerd worden. In Hoofdstuk 2 is tevens beschreven dat dit een nadelig
gevolg kan hebben voor de therapeutische werking van deze cellen, omdat ze eerder
uit het lichaam van de ontvanger kunnen verdwijnen. Het opkweken van deze cellen
kan op een zodanige manier worden aangepast dat ze niet meer sneller verdwijnen
dan geïnfundeerde ‘verse’ T cellen.
Hoofdstuk 3 laat zien dat het vermeerderen van T cellen in het laboratorium vóór
transplantatie geen invloed heeft op het functioneren van deze cellen, en dat ze een
immuunrespons kunnen bewerkstelligen vergelijkbaar met ‘verse’ T cellen. In het
onderzoek dat in dit hoofdstuk is beschreven hebben ratten een
beenmergtransplantatie gekregen met gekweekte T cellen daaraan toegevoegd.
Gebruik makend van, onder andere, de techniek die in Hoofdstuk 2 is beschreven,
laten we zien dat de ratten ernstige graft-versus-host ziekte krijgen, en dat de
gekweekte T cellen daar mede voor verantwoordelijk zijn. Dit blijkt onder andere uit
het feit dat de T cellen zich sterk vermenigvuldigden rond de tijd dat de ratten ziek
werden. Daarnaast bevonden de T cellen zich met name in organen die sterk
aangedaan waren door de graft-versus-host ziekte.
In Hoofdstuk 4 hebben we in ratten een situatie nagebootst die zich voordoet bij
patiënten waarbij de leukemie terugkomt: patiënten worden behandeld met een
stamceltransplantatie, waarna hun bloedcellen worden vervangen door bloedcellen
afkomstig van de donor. Als de residuale leukemische cellen gaan uitgroeien kan dit
gepaard gaan met een terugkeer van bloedcellen van patiënt origine. Wanneer men
deze patiënten vervolgens behandelt met donor T cellen kan het ontwikkelen van
graft-versus-leukemia activiteit uitblijven. Ook graft-versus-host ziekte komt minder
voor. Blijkbaar kunnen de geïnfundeerde donor T cellen hun werk in deze patiënten
minder goed uitvoeren. In ons rattenmodel hebben we laten zien dat dit komt, doordat
donor T cellen na infusie sneller verdwijnen in ratten die hun eigen bloedcellen
hebben teruggekregen, dan in ratten die bloedcellen van de donor hebben.
Waarschijnlijk komt dit doordat ‘patiënt’ T cellen de donor T cellen opruimen.
Bij een allogene transplantatie is de donor vaak een broer of zus van de patiënt. Dat
betekent dat ze genetisch gezien erg op elkaar lijken. Dat is voordelig, want het
bepaalt mede de geschiktheid van de stamcellen voor transplantatie. Het maakt het
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echter voor onderzoekers moeilijker om een onderscheid te kunnen maken tussen
bloedcellen van de patiënt en donor na een allogene stamceltransplantatie. In
Hoofdstuk 5 is een techniek beschreven waarmee onderscheid gemaakt kan worden
tussen donor- en patiënt-cellen op basis van minieme genetische verschillen, de
zogenaamde single nucleotide polymorphisms. Hiermee kan de mate van chimerisme
in een patiënt na transplantatie worden bepaald. Dit is belangrijk omdat hierdoor,
bijvoorbeeld, transplantaatafstoting voorspeld kan worden of het gaan uitgroeien van
residuale leukemische cellen. Daarnaast kan het belangrijke informatie geven over het
al dan niet ontwikkelen van imuunresponsen van donor cellen tegen de ontvanger.
Hoofdstuk 6 beschrijft een klinisch onderzoek, waarin een groot aantal patiënten
voorafgaand aan allogene stamceltransplantatie is behandeld met het
chemotherapeutisch medicijn idarubicine. Deze groep is vergeleken met patiënten die
de ‘standaard’ behandeling voor stamceltransplantatie hadden ontvangen. Patiënten
behandeld met idarubicine bleken een lagere kans op een terugkeer van de leukemie
te hebben, mogelijk als gevolg van een hogere graft-versus-leukemia reactiviteit.
Daarnaast ontwikkelden zij een hogere, zij het klinisch milde, mate van acute graft-
versus-host ziekte. Gebruik makend van de techniek beschreven in Hoofdstuk 5
hebben we laten zien dat in patiënten behandeld met idarubicine de T cellen van
patiënt origine sneller werden vervangen door T cellen van donor origine, dan in de
patiënten die niet met idarubicine waren behandeld. Hierdoor is de relatie anti-patiënt-
immuunreactiviteit met donor T cellen, na manipulatie met idarubicine, aangetoond.
Samenvattend kunnen we stellen dat de aanwezigheid van T cellen van patient origine
de activiteit van donor T cellen, dus ook de therapeutisch gunstige graft-versus-
leukemia reactiviteit, kan verminderen. De negatieve werking van autologe T cellen
zou op een zodanige manier gemanipuleerd kunnen worden dat er een optimaal
rendement uit therapie met donor T cellen gehaald wordt. Dit kan bijvoorbeeld door
de reactiviteit van patient T cellen (tijdelijk) te onderdrukken. Het is hiervoor
belangrijk om het genotype van T cellen na stamceltransplantatie, en in aanloop van,
en na immuuntherapie met donor T cellen, te (kunnen) volgen.
De infusie van donor T cellen biedt een uitzonderlijke basis die kan worden benut
voor therapeutische doeleinden die op een andere manier moeilijk te realiseren
zouden zijn. Beter begrip van de mechanismen die hierbij betrokken zijn draagt bij
aan de ontwikkeling van methoden om deze vorm van therapie uit te buiten.
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De schrijver van dit proefschrift werd geboren op 16 april 1970, te Eindhoven. In
1988 behaalde hij het Atheneum-B diploma aan het Lorentz Lyceum te Eindhoven,
waarna hij begon met de studie Biologie aan de Katholieke Universiteit Nijmegen. In
het kader van deze studie werden stages gelopen op de afdeling Hematologie (Prof.
Dr. T. de Witte) van het UMC St Radboud en de afdeling Moleculaire
Plantenfysiologie (Prof. Dr. G. Wullems) van de Katholieke Universiteit Nijmegen. In
augustus 1994 behaalde hij het doctoraal diploma Biologie met als specialisatie
‘Medische Biologie’. Vanaf begin 1995 heeft hij als vrijwilliger onderzoek verricht op
het laboratorium voor Biochemie (Dr. W. de Grip). In april 1996 is hij als assistent in
opleiding aan een promotieonderzoek op de afdeling Hematologie van het
Universitair Medisch Centrum (UMC) Utrecht (Prof. Dr. J. Sixma, Prof. Dr. H.
Clevers) begonnen. In mei 1998 is dit project beëindigd, waarna in juni 1998 is
begonnen aan een promotieonderzoek op de afdeling Hematologie van het UMC St
Radboud te Nijmegen (promotor: Prof Dr. T. de Witte, en co-promotores: Dr. E. van
de Wiel-van Kemenade en Dr. H. Dolstra). De resultaten van dit onderzoek zijn in dit
proefschrift beschreven.
De schrijver woont samen met Birgit Vullinghs en is de trotse vader van Iris.
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‘I wish I was as fortunate,
as fortunate as me’
    - Eddie Vedder, Wishlist, Yield (1997)
Erratum
Some of the primer sequences have not been correctly displayed in Table 2 (page 93) and Table 1 (appendix; page 107) of Chapter 5. The following
Table shows the correct primer and probe sequences for all PCRs described in the chapter.
Gene/STS SNP Allele-specific primer (5’-3’)a Common primer (5’-3’) Probe (TET-5’-3’-TAMRA)
PECAM1 C AGGACTCACCTTCCACCAACCG (R) GGATCTATGACTCAGGGACATATAAATG (F) TGTGAACAACAAAGAGAAAACCACTGCAGAGT
G AGGACTCACCTTCCACCAACTC (R)
ICAM1 G AGAGCACATTCACGGTCACCAC (R) GCACTTTCCCACTGCCCAT (F) CAGTGACTGTCACTCGAGATCTTGAGGGC
A AGAGCACATTCACGGTCACATT (R)
HA1 G-T GCTCTCACCGTCACGCAA (R) TGCTGGCGGACGTGG (F) CCGCTTCGCTGAGGGCCTTGA
A-C GGCTCTCACCGTCATGCCG (R)
MLH1 G TCGTGCTCACGTTCTTCCTCC (R) GAGACCCAGCAACCCACAGA (F) ATTCAAGCTGTCCAATCAATAGCTGCCG
A TCGTGCTCACGTTCTTCCATT (R)
SUR1 C TGCCACCCTCCCTCCCTAC (F) GACAGCCCCTGAGACCTTCTG (R) CAGGTGGGCTGCGGCAAGTCC
T TGCCACCCTCCCTCCCTAT (F)
G42863b C GGCTTGTGGATGAAGGAGTC (F) TGGCACATCTGGCAAAATCTC (R) ACAGGGAGAGTGATGTTGGAGCTGGGT
A GGCTTGTGGATGAAGGAGAA (F)
G42888b C GGGGAGGGGAGGAAGAGAGC (F) TTGTGCTGCTGTAATCACTTTTCAT (R) TTCTCTCTCGGGATTTTCTGGGAATCAAAA
T GGGGAGGGGAGGAAGAGACT (F)
SMCYc n.a. TCTTGCGTCCTCAGCGTTTA (F) AGTGTGGTACGAGCCGTCTCA (R) CTCAGGTGCGGAAGGTCTCACAGGTT
a Polymorphic nucleotides are given in bold, and introduced mismatched nucleotides to decrease background amplification are
underlined.
b Sequence-tagged site.
c Male specific PCR.
TET, tetrachloro-6-carboxy-fluorescin; TAMRA, 6-carboxy-tetramethyl-rhodamine; F, forward primer; R, reverse primer; n.a., not applicable.
